text stringlengths 65 123k | url stringlengths 25 420 | crawl_date timestamp[us, tz=UTC]date 2022-04-01 01:00:57 2022-09-19 04:34:04 |
|---|---|---|
LOS ANGELES, Aug. 15, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tupperware Brands Corporation ("Tupperware" or "the Company") (NYSE: TUP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between November 3, 2021 and May 3, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before August 15, 2022.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Tupperware suffered from business challenges making it difficult to maintain revenues and profitability. These problems left the Company's full year 2022 guidance as unrealistic. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Tupperware, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:
SOURCE The Schall Law Firm | https://www.whsv.com/prnewswire/2022/08/15/deadline-today-schall-law-firm-encourages-investors-tupperware-brands-corporation-with-losses-contact-firm/ | 2022-08-15T12:47:59Z |
LOS ANGELES, Aug. 15, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unilever PLC ("Unilever" or "the Company") (NYSE: UL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between September 2, 2020 and July 21, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before August 15, 2022.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Unilever failed to disclose the fact that in July 2020, the board of Ben & Jerry's, a Unilever subsidiary, passed a resolution to end the sales of its ice cream in what it labeled "Occupied Palestinian Territory." The Company also failed to disclose the risks associated with this decision to investors. The Company claimed to comply with all applicable laws and regulations, but failed to discuss the Ben & Jerry's decision, which risked violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states ("Anti-BDS Legislation"). Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Unilever, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:
SOURCE The Schall Law Firm | https://www.whsv.com/prnewswire/2022/08/15/deadline-today-schall-law-firm-encourages-investors-unilever-plc-with-losses-contact-firm/ | 2022-08-15T12:48:06Z |
AUSTIN, Texas, Aug. 15, 2022 /PRNewswire/ -- Digital Brands Group, Inc. ("DBG") (NASDAQ: DBGI), a curated collection of luxury lifestyle, digital-first brands, today reported financial results for its second quarter ended June 30, 2022.
Second Quarter 2022 Highlight Compared to Second Quarter 2021
- Net revenues of $3.7 million, an increase of 273% or $2.7 million
- Gross profit margin of 58.1%, an increase of 450%, versus 39.3%
- Net loss per diluted share of $0.27 versus a net loss of $1.97
- Net loss attributable to common stockholders was $9.5 million versus a net loss of $10.7 million
- Net loss, excluding the non-cash expense associated with a change in the fair value of contingent liabilities, was $3.6 million versus $7.7 million
- Net loss per diluted share, excluding the non-cash expense associated with a change in the fair value of contingent liabilities, of $0.10 versus a net loss of $1.41
"We delivered strong top line results, which we expect to meaningfully accelerate in the second half of the year as we enter our peak selling period. In addition, our gross margin of 58% expanded significantly both sequentially and year-over-year, which we also expect to continue throughout the second half of the year," said Hil Davis, Chief Executive Officer of Digital Brands Group.
"The increasing top line combined with our higher gross margins are creating operating leverage on our fixed costs of business. Given these trends, we expect our combined EBITDA for the September through December period of 2022 to be flat to negative $500,000. We believe this shows there is a clear and short path to profitability," said Davis.
"To that point, we are excited to announce that we hired a head of wholesale for dstld, which has never been offered in the wholesale channel. She joins us from another denim brand, where she increased their wholesale revenue from $6 million to $39 million in three years. This additional revenue driver for 2023 is just one more way we will drive top line growth and achieve profitability," concluded Davis.
Second Quarter 2022 Highlights
Net Sales were $3.7 million versus $1.0 million in the year ago quarter, an increase of 273% year over year. Our second quarter is our lowest wholesale revenue quarter across all our wholesale brands as these brands only ship two of the three months due to lower wholesale demand during this period.
Gross profit margin was 58.1% versus 39.3% a year ago, an increase of 450%. Gross profit increased by $1.8 million due to improved gross margins at all our brands. Additionally, this is the first quarter we have reported where we did not incur any inventory write-downs associated with older product, which we believe illustrates the gross margin power of our brands.
General and administrative expenses as a % of revenue decreased 538% to 133.5% of revenues versus 716.7% a year ago. General and administrative expenses were $5.0 million versus $7.2 million in the year ago quarter. Starting in September, all our brands will share one office and one distribution center, which will result in additional cost savings going forward. Also, we do not expect any additional increases in general and administrative expenses in the second half of the year, which should result in significant revenue leverage as we enter our peak revenue season.
Sales and marketing expenses were 45.6% of revenues versus 92.0% a year ago, a decrease of 50.4%. Sales and marketing expenses were $1.7 million versus $923,000 a year ago. We continue to experience meaningful e-commerce revenue growth year-over year associated with our digital marketing programs. This increase in e-commerce revenue is also driving higher gross margins across all our wholesale brands.
Distribution expenses were 5.9% of revenues versus 7.0% a year ago, a decline of 14.7%. Distribution expenses were $222,000 versus $70,000 a year ago, driven by the addition of Harper & Jones and Stateside distribution expenses in this quarter versus approximately one-third of Harper & Jones distribution expenses and no distribution expenses for Stateside a year ago. We expect to benefit from a reduction in our distribution expenses associated with operating one distribution center versus two distribution centers, as we have consolidated into one distribution center.
Change in the fair value of contingent considerations, which is a non-cash expense, was $5.9 million versus $3.1 million a year ago.
Loss from operations excluding the change in fair value of contingent considerations was $4.7 million versus $7.8 million a year ago.
Net loss attributable to common stockholders was $9.5 million, or $0.27 per diluted share, compared to net loss attributable to common stockholders of $10.7 million, or $1.97 per diluted share, a year ago.
Excluding the non-cash charge associated with the change in fair value of contingent considerations, net loss attributable to common stockholders was $3.6 million, or $0.10 per diluted share, compared to net loss attributable to common stockholders of $7.7 million, or $1.41 per diluted share, a year ago.
Conference Call and Webcast Details
The Company will host a conference call and webcast at 8:30 a.m. ET today to discuss results. The live conference call can be accessed by dialing (866) 605-1828 from the U.S. or internationally or via the web by using the following link: https://tinyurl.com/3xp45f9f. The conference I.D. code is 13732332.
Forward-looking Statements
Certain statements included in this release are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting DBG and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates, however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements regarding DBG's plans, objectives, projections and expectations relating to DBG's operations or financial performance, and assumptions related thereto are forward-looking statements. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. DBG undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Potential risks and uncertainties that could cause the actual results of operations or financial condition of DBG to differ materially from those expressed or implied by forward-looking statements include, but are not limited to: risks arising from the widespread outbreak of an illness or any other communicable disease, or any other public health crisis, including the coronavirus (COVID-19) global pandemic; the level of consumer demand for apparel and accessories; disruption to DBGs distribution system; the financial strength of DBG's customers; fluctuations in the price, availability and quality of raw materials and contracted products; disruption and volatility in the global capital and credit markets; DBG's response to changing fashion trends, evolving consumer preferences and changing patterns of consumer behavior; intense competition from online retailers; manufacturing and product innovation; increasing pressure on margins; DBG's ability to implement its business strategy; DBG's ability to grow its wholesale and direct-to-consumer businesses; retail industry changes and challenges; DBG's and its vendors' ability to maintain the strength and security of information technology systems; the risk that DBG's facilities and systems and those of our third-party service providers may be vulnerable to and unable to anticipate or detect data security breaches and data or financial loss; DBG's ability to properly collect, use, manage and secure consumer and employee data; stability of DBG's manufacturing facilities and foreign suppliers; continued use by DBG's suppliers of ethical business practices; DBG's ability to accurately forecast demand for products; continuity of members of DBG's management; DBG's ability to protect trademarks and other intellectual property rights; possible goodwill and other asset impairment; DBG's ability to execute and integrate acquisitions; changes in tax laws and liabilities; legal, regulatory, political and economic risks; adverse or unexpected weather conditions; DBG's indebtedness and its ability to obtain financing on favorable terms, if needed, could prevent DBG from fulfilling its financial obligations; and climate change and increased focus on sustainability issues. More information on potential factors that could affect DBG's financial results is included from time to time in DBG's public reports filed with the SEC, including DBG's Annual Report on Form 10-K, and Quarterly Reports on Form 10-Q, and Forms 8-K filed or furnished with the SEC.
About Digital Brands Group
We offer a wide variety of apparel through numerous brands on a both direct-to-consumer and wholesale basis. We focus on owning the customer's "closet share" by leveraging their data and purchase history to create personalized targeted content and looks for that specific customer cohort.
Digital Brands Group, Inc. Company Contact
Hil Davis, CEO
Email: invest@digitalbrandsgroup.co
Phone: (800) 593-1047
Related Links
View original content:
SOURCE Digital Brands Group, Inc. | https://www.whsv.com/prnewswire/2022/08/15/digital-brands-group-reports-second-quarter-2022-financial-results/ | 2022-08-15T12:48:13Z |
Experienced EdTech and Business Leader to Drive Growth Strategy and Corporate Development
RESTON, Va., Aug. 15, 2022 /PRNewswire/ -- Ellucian, the leading higher education technology solutions provider, today announced Jeff Dinski as Chief Strategy and Corporate Development Officer. Reporting to the CEO, Mr. Dinski will be responsible for driving our growth strategy with a focus on market expansion leading our strategy and insights, analyst relations and Ellucian's broader corporate development efforts.
"With a strong track record in EdTech and market analysis and strategy, Jeff brings deep experience in helping organizations unlock value and prioritize investments in support of their strategic vision and mission," said Laura Ipsen, President and CEO, Ellucian. "I am pleased to welcome Jeff to Ellucian and look forward to working with him to achieve even stronger growth and market engagement as we accelerate our move to SaaS helping the institutions we serve better achieve their goals."
"Having spent the last decade advising many of the most significant companies in the broader EdTech landscape and also as a product and market development executive, I have seen first-hand the impact of Ellucian's leadership in the market in support of the global higher education community," said Jeff Dinski. "I am excited to join a great team of leaders and be part of their mission to deliver digital transformation solutions that create better outcomes for every institution and the students they serve."
Mr. Dinski joins Ellucian from Tyton Partners, where he was a Partner in the strategy consulting practice. He has had an extensive career as an entrepreneur and in executive roles in the education and media sectors. Prior to Tyton, Mr. Dinski spent nearly four years serving as Vice President of Business Development and then as General Manager of Consumer Services at Parchment, a digital credential company for transcripts and diplomas. He was also the co-founder of the ecommerce business GaggleofChicks.com and held a variety of leadership roles at Comcast Interactive Media, and CBS Interactive.
Mr. Dinski began his career in media and television as a researcher and writer for NBC Sports and he later was part of the team that launched ESPN's first live morning show, Cold Pizza, where he served as head writer and producer.
Mr. Dinski holds a Bachelor of Science in Engineering, with a major in Mechanical & Aeropace Engineering from Princeton University and a Masters in Business Administration from Harvard Business School.
Ellucian is charting the digital future of higher education with a portfolio of cloud-ready technology solutions and services. From student recruitment to workforce analytics; from fundraising opportunities to alumni engagement; Ellucian's comprehensive suite of data-rich tools gives colleges and universities the information they need to lead with confidence.
Working with a community of more than 2,700 customers in over 50 countries, Ellucian keeps innovating as higher education keeps evolving. Drawing on its comprehensive higher education business acumen and suite of services, Ellucian guides its customers through manageable, sustainable digital transformation—so that every type of institution and student can thrive in today's fast-changing landscape. To find out what's next in higher education solutions and services, visit Ellucian at www.ellucian.com.
Media Contact
Lindsay Stanley
Lindsay.Stanley@Ellucian.com
View original content to download multimedia:
SOURCE Ellucian | https://www.whsv.com/prnewswire/2022/08/15/ellucian-welcomes-jeff-dinski-chief-strategy-corporate-development-officer/ | 2022-08-15T12:48:20Z |
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Encompass Corporation, the provider of the leading Know Your Customer (KYC) automation platform, today announced that Aite-Novarica Group, a global advisory firm providing mission-critical insights on technology, regulations, strategy and operations to the financial services industry, has recognized Encompass as the winner of the 2022 Fraud & AML Impact Awards' Best Know Your Customer/Business (KYC/KYB) Innovation.
The award recognizes Encompass for its ability to combine unrivaled data sources, technology and expertise to supercharge corporate KYC due diligence with automation. Allowing financial institutions to unwrap and uncover corporate structures and ultimate beneficial ownership in minutes, Encompass transforms Anti-Money Laundering (AML) compliance and gives institutions the ability to enhance customer onboarding and respond to regulatory changes with greater speed and accuracy.
"By automating the KYC process, financial institutions can pursue aggressive growth agendas and scale while avoiding additional compliance costs," said Alex Ford, President, North America at Encompass. "Our platform is used by banks across the globe to significantly improve the onboarding experience of their clients while also future-proofing technology and processes. We're grateful to be recognized by Aite-Novarica Group for our innovative approach, which brings speed, accuracy and control."
With real-time access to global public and premium data sources, Encompass' platform gives financial institutions the ability to search entities and receive a digital KYC profile within minutes. With Encompass, financial institutions can ensure a consistent KYC process every time, including:
- Search based on pre-defined policy using only bank-approved sources;
- Mapping of ultimate beneficial ownership and corporate hierarchy;
- Screening of entities for PEPs, sanctions and adverse media;
- Cross-checking documents, matching and merging data;
- And the automatic creation of a complete audit trail in real time.
According to Aite-Novarica Group, winners were selected by a global panel of both internal and independent experts on fraud and AML.
Encompass will be presented with the AML Impact Award at the fifth annual Financial Crime Forum, taking place Sept. 18-19, 2022 in Charlotte, NC.
Encompass Corporation (Encompass) transforms regulatory compliance and customer onboarding with Know Your Customer (KYC) automation. As a global leader in automated KYC due diligence worldwide, Encompass serves global banks and financial institutions to streamline their KYC process and comply with regulations and requirements. Launched in 2012, Encompass serves customers across the globe and features offices in Amsterdam, Belgrade, Glasgow, London, New York, Singapore and Sydney. To learn more, visit EncompassCorporation.com.
Aite-Novarica Group is an advisory firm providing mission-critical insights on technology, regulations, strategy and operations to hundreds of banks, insurers, payments providers, and investment firms - as well as the technology and service providers that support them. Comprising former senior technology, strategy and operations executives as well as experienced researchers and consultants, our experts provide actionable advice to our client base, leveraging deep insights developed via our extensive network of clients and other industry contacts. Visit us on the web and connect with us on Twitter and LinkedIn.
View original content to download multimedia:
SOURCE Encompass Corporation | https://www.whsv.com/prnewswire/2022/08/15/encompass-wins-aite-novarica-group-aml-impact-award-best-know-your-customerbusiness-kyckyb-innovation/ | 2022-08-15T12:48:26Z |
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Ernst & Young LLP (EY US) announced today that Cambria Solutions (Cambria) will be joining the EY US organization, which will continue to grow EY US capabilities in serving state and local governments with innovative capabilities in technology and transformation services. The transaction is subject to certain closing conditions.
A California-based information technology and management firm, Cambria provides program and project management services, business process modernization, agile transformation, technology systems implementation, and human-centered design focus with deep sector capabilities in state and local governments. Cambria also brings experience in complex Medicaid and public health/human services programs, as well as transportation and toll systems.
"Among state and local government agencies, Cambria has a stellar reputation for their deep knowledge of health and human services, transportation, and government modernization services," said Gerry Dixon, EY US Government and Public Sector Managing Partner. "It's the blend of strong capabilities with a unique 'human' focus that, together with EY capabilities, will help our government clients' solve their complex problems."
Cambria specializes in transformation and innovation consulting that help enable government entities to improve services and client outcomes through people-focused technology and business processes solutions. Enabled by their innovation lab, Kappy, Cambria delivers novel solutions to some of governments' hardest problems. Kappy will be added to the EY wavespaceTM network.
"Cambria helps our clients' transformation and innovation projects succeed with our HumanGenuity® approach – ingenuity with a human touch," says Suzanne Vitale, President, Cambria Solutions. "We're excited to join EY, an organization that shares our values and our commitment to helping governments transform and excel." CEO and Founder Robert Rodriguez added "We believe the career opportunities for our people, and the EY company culture, are the best fit for our people."
This week both teams will be at the Medicaid Enterprise Systems Community event (MESC 2022), a national conference and community for state, federal and private sector individuals to exchange ideas related to Medicaid systems and health policy affected by those systems. Come meet the EY and Cambria teams at booths 300 and 309, respectively.
To learn more about the EY US Government and Public Sector practice, visit https://www.ey.com/en_us/government-public-sector.
Notes to editors
About EY Consulting Services
In Consulting, we are building a better working world by transforming businesses through the power of people, technology and innovation.
It's our ambition to become the world's leading transformation consultants.
The diversity and skills of our 70,000+ people will help EY clients realize transformation by putting humans at the center, delivering technology at speed and leveraging innovation at scale.
These core drivers of "Transformation Realized" will create long-term value for our people, our clients and society.
For more information about our Consulting organization, please visit ey.com/consulting.
About EY
EY exists to build a better working world, helping create long-term value for clients, people and
society and build trust in the capital markets.
Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.
Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.
Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.
Related links
www.ey.com
View original content to download multimedia:
SOURCE EY | https://www.whsv.com/prnewswire/2022/08/15/ernst-amp-young-llp-announces-signing-an-agreement-cambria-solutions-join-ey-us-augmenting-ey-us-health-human-services-transportation-capabilities-state-local-government/ | 2022-08-15T12:48:33Z |
CHICAGO, Aug. 15, 2022 /PRNewswire/ -- First Industrial Realty Trust, Inc. (NYSE: FR), a leading fully integrated owner, operator and developer of industrial real estate, today announced the closing of a new and undrawn $300 million unsecured term loan.
The new and undrawn term loan has an initial maturity date of August 12, 2025 with two one-year extension options at the Company's discretion, subject to certain conditions. The term loan features interest-only payments and bears an interest rate of SOFR plus a credit spread of 85 basis points based on the Company's current consolidated leverage ratio and credit ratings plus a SOFR adjustment of 10 or 15 basis points depending on the tenor of the interest period. The Company may borrow up to the full principal amount on or before August 11, 2023. The Company plans to use the proceeds for general business purposes, including, without limitation, repayment of indebtedness, working capital needs, and the acquisition and development of property.
U.S. Bank National Association, BofA Securities, Inc., PNC Capital Markets LLC and Regions Capital Markets serve as the Joint Lead Arrangers and Joint Book Runners. U.S. Bank National Association serves as the Administrative Agent and the Sustainability Structuring Agent. Bank of America, N.A. serves as the Syndication Agent. PNC Bank, National Association and Regions Bank serve as the Co-Documentation Agents. JPMorgan Chase Bank, N.A. also participated in the term loan.
"With an effective tenor of five years, this new term loan is an attractive source of capital that supports our growth including funding our profitable development pipeline," said Scott Musil, chief financial officer of First Industrial Realty Trust, Inc. "We thank our banking partners for their continued support and capital commitments."
First Industrial Realty Trust, Inc. (NYSE: FR) is a leading fully integrated owner, operator, and developer of industrial real estate with a track record of providing industry-leading customer service to multinational corporations and regional customers. Across major markets in the United States, our local market experts manage, lease, buy, (re)develop, and sell bulk and regional distribution centers, light industrial, and other industrial facility types. In total, we own and have under development approximately 69.8 million square feet of industrial space as of June 30, 2022. For more information, please visit us at www.firstindustrial.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on certain assumptions and describe our future plans, strategies and expectations, and are generally identifiable by use of the words "believe," "expect," "plan," "intend," "anticipate," "estimate," "project," "seek," "target," "potential," "focus," "may," "will," "should" or similar words. Although we believe the expectations reflected in forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be attained or that results will not materially differ. Factors which could have a materially adverse effect on our operations and future prospects include, but are not limited to: changes in national, international, regional and local economic conditions generally and real estate markets specifically; changes in legislation/regulation (including changes to laws governing the taxation of real estate investment trusts) and actions of regulatory authorities; the uncertainty and economic impact of pandemics, epidemics or other public health emergencies or fear of such events, such as the outbreak of coronavirus disease 2019 (COVID-19); our ability to qualify and maintain our status as a real estate investment trust; the availability and attractiveness of financing (including both public and private capital) and changes in interest rates; the availability and attractiveness of terms of additional debt repurchases; our ability to retain our credit agency ratings; our ability to comply with applicable financial covenants; our competitive environment; changes in supply, demand and valuation of industrial properties and land in our current and potential market areas; our ability to identify, acquire, develop and/or manage properties on favorable terms; our ability to dispose of properties on favorable terms; our ability to manage the integration of properties we acquire; potential liability relating to environmental matters; defaults on or non-renewal of leases by our tenants; decreased rental rates or increased vacancy rates; higher-than-expected real estate construction costs and delays in development or lease-up schedules; potential natural disasters and other potentially catastrophic events such as acts of war and/or terrorism; litigation, including costs associated with prosecuting or defending claims and any adverse outcomes; risks associated with our investments in joint ventures, including our lack of sole decision-making authority; and other risks and uncertainties described under the heading "Risk Factors" and elsewhere in our annual report on Form 10-K for the year ended December 31, 2021, as well as those risks and uncertainties discussed from time to time in our other Exchange Act reports and in our other public filings with the SEC. We caution you not to place undue reliance on forward-looking statements, which reflect our outlook only and speak only as of the date of this press release or the dates indicated in the statements. We assume no obligation to update or supplement forward-looking statements. For further information on these and other factors that could impact us and the statements contained herein, reference should be made to our filings with the SEC.
View original content to download multimedia:
SOURCE First Industrial Realty Trust, Inc. | https://www.whsv.com/prnewswire/2022/08/15/first-industrial-realty-trust-closes-new-300-million-unsecured-term-loan/ | 2022-08-15T12:48:39Z |
VANCOUVER, BC, Aug. 15, 2022 /PRNewswire/ - First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) is pleased to provide an update regarding its offer ("Beattie Offer") to acquire all of the issued and outstanding common shares of Beattie Gold Mines Ltd. ("Beattie Gold") as previously announced on July 18, 2022.
Prior to making the Beattie Offer, First Mining had received signed, irrevocable lock-up agreements from shareholders of Beattie Gold holding, in aggregate, 1,358,652 common shares of Beattie Gold (the "Lock Up Shares") representing 72.3% of the outstanding common shares of Beattie Gold (excluding common shares of Beattie Gold already owned by First Mining or its wholly-owned subsidiary, Clifton Star Resources Inc. ("Clifton Star")). All Lock Up Shares have now been tendered and deposited, and together with the common shares of Beattie Gold already owned by First Mining, both directly and indirectly through Clifton Star, First Mining will own 97.6% of the outstanding common shares of Beattie Gold upon acquiring the Lock Up Shares.
The condition in the Beattie Offer that there be deposited under the offer, and not withdrawn, at least 464,643 of the outstanding common shares of Beattie Gold has now been satisfied. In addition, First Mining has also entered into binding share purchase agreements to acquire the issued and outstanding common shares of 2699681 Canada Ltd. ("269 Canada") and 2588111 Manitoba Ltd. (together, the Concurrent Transactions"). As a result, the remaining condition of the Beattie Offer relating to the completion of the acquisition of the outstanding common shares of 269 Canada will be satisfied when the Beattie Offer and the Concurrent Transactions close, which is expected to be September 15, 2022 (the "Closing Date").
First Mining expects the remaining 2.4% of the outstanding common shares of Beattie Gold to be tendered and deposited by September 9, 2022, and accordingly, First Mining expects that it will own 100% of the outstanding common shares of Beattie Gold, in addition to 100% of the outstanding common shares of 269 and 258811 Manitoba Ltd., following completion of the Beattie Offer and the Concurrent Transactions on the Closing Date.
First Mining is a gold developer advancing a portfolio of gold projects in Canada, with our most advanced project being the Springpole Gold Project in northwestern Ontario, which is one of the largest undeveloped gold projects in Canada, and where we have commenced a Feasibility Study and permitting activities are on-going with a draft Environmental Impact Statement ("EIS") for the project submitted in June 2022. First Mining also owns the Cameron, Duparquet, Duquesne and Pitt gold projects, all advanced-stage gold projects in Ontario (in the case of Cameron) and Québec. Our portfolio of gold project interests also includes the Pickle Crow gold project (being advanced in partnership with Auteco Minerals Ltd.), the Hope Brook gold project (being advanced in partnership with Big Ridge Gold Corp.), an equity interest in Treasury Metals Inc., and a portfolio of 21 gold royalties.
First Mining was established in 2015 by Mr. Keith Neumeyer, founding President and CEO of First Majestic Silver Corp.
ON BEHALF OF FIRST MINING GOLD CORP.
Daniel W. Wilton
Chief Executive Officer and Director
This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date of this news release. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "plans", "projects", "intends", "estimates", "envisages", "potential", "possible", "strategy", "goals", "opportunities", "objectives", or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions.
Forward-looking statements in this news release relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events and include, but are not limited to, statements with respect to: (i) the closing date of the Beattie Offer and the Concurrent Transactions; (ii) the remaining 2.4% of the outstanding common shares of Beattie Gold being tendered and deposited by September 9, 2022, and the Company's ownership of 100% of the outstanding common shares of Beattie Gold following completion of the Beattie Offer; (iii) the Company's plans with respect to advancing its portfolio of gold projects; and (iv) Feasibility and permitting activities related to the Springpole Project.. All forward-looking statements are based on First Mining's or its consultants' current beliefs as well as various assumptions made by them and information currently available to them. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Such factors include, without limitation the Company's business, operations and financial condition potentially being materially adversely affected by the outbreak of epidemics, pandemics or other health crises, such as COVID-19, and by reactions by government and private actors to such outbreaks; risks to employee health and safety as a result of the outbreak of epidemics, pandemics or other health crises, such as COVID-19, that may result in a slowdown or temporary suspension of operations at some or all of the Company's mineral properties as well as its head office; fluctuations in the spot and forward price of gold, silver, base metals or certain other commodities; fluctuations in the currency markets (such as the Canadian dollar versus the U.S. dollar); changes in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins and flooding); the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities, indigenous populations and other stakeholders; availability and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development; title to properties.; and the additional risks described in the Company's Annual Information Form for the year ended December 31, 2021 filed with the Canadian securities regulatory authorities under the Company's SEDAR profile at www.sedar.com, and in the Company's Annual Report on Form 40-F filed with the SEC on EDGAR.
First Mining cautions that the foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements to make decisions with respect to First Mining, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. First Mining does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by the Company or on our behalf, except as required by law.
View original content to download multimedia:
SOURCE First Mining Gold Corp. | https://www.whsv.com/prnewswire/2022/08/15/first-mining-provides-update-regarding-acquisition-duparquet-gold-project/ | 2022-08-15T12:48:46Z |
- BMO & 1871's WMNfintech is North America's largest fintech industry program for women-founded and women-led startups
- More than 15 percent of women fintech founders across North America have participated in WMNfintech
CHICAGO, Aug. 15, 2022 /PRNewswire/ - BMO Financial Group and 1871 today named the five companies presenting at its 2022 WMNfintech Program, after an immersive 4-week educational programming known as PYROS and fintech amplified learning workshops delivered by BMO leaders. WMNfintech is North America's largest nonprofit fintech industry program for women-founded and women-led startups. The program is designed to bridge the gender gap in the startup and tech community by giving more women entrepreneurs the opportunity to bring innovative technologies and products forward.
Since launching, women-led fintechs in the program have raised more than $29M in capital and created over 170 jobs. Additionally, over 15 percent of all women fintech founders in North America have come through BMO's doors since 2018 and become a valuable part of our ecosystem. This year, the following five women-led companies were chosen to participate in the 2022 cohort of WMNfintech:
Sign-Speak (New York, NY)
Sign-Speak is a real-time AI Sign Language recognition software that allows for sign language to be translated into English and vice versa, enabling businesses everywhere to communicate with their Deaf and Hard of Hearing clients and employees more effectively.
• Yamillet Payano, CEO and Co-Founder
Xeni (New York, NY)
Xeni solves the massive problem of payments in the travel industry with a Web 3 native accounting system that includes onramp and offramp for payment and settlement to lower payment and settlement costs, reduces fraud and chargebacks, and simplifies accounting and accounts reconciliation.
• Rachel Spektor, President
Debtle (Sheboygan, WI)
Debtle is a cloud-based software that automates, improves, and simplifies the negotiation and settlement of overdue invoices through a safe and consumer-friendly platform.
• Stephanie Hoskins, Co-Founder
Second Keys (Memphis, TN)
Second Keys is a real estate software company built by property managers for property managers. It has all the standard features of a property management platform: accounting; rent collection; maintenance tracking and proprietary AI-powered maintenance; and an expense and ROI predictor.
• Amber Hayes, CEO
Grounded Technologies (New York, NY)
Grounded Technologies helps banks grow. They are a middleware layer that provides regulated balance sheet growth through core deposits and loans as well as low-code, no code customizable banking products.
• Danae Vachata, Founder and CEO
"We're thrilled to join our longtime partner BMO Financial Group in welcoming the members of our third cohort of WMNfintech, who will pitch their impressive technologies and products," said Betsy Ziegler, CEO of 1871. "These five women-led startups are building extraordinary businesses that will shape the future of the financial sector, and we're proud to provide the resources, mentorship, and support they need to thrive."
"The WMNfintech Program is an incredible opportunity for these women-led fintechs to gain well-deserved exposure with our business leaders and ecosystem partners. It's a chance to showcase how their technology and products are solving crucial financial challenges," said Andrew Harrison, Head, U.S. Digital Partnerships, BMO Financial Group. "This year's cohort have all discovered innovative ways to deliver value for our commercial clients and help them run their business easier. BMO is thrilled to support and contribute to the continued success of these exceptional women-founded and women-led startups as we finish the program's third year."
This week's events begin with a Founder's Roundtable today, a dinner with program leadership on Wednesday, August 17, and the opportunity to showcase their insights to BMO executives and ecosystem partners on Thursday, August 18.
WMNfintech strongly aligns with BMO's commitment for an inclusive society and work to eliminate barriers to inclusion. It represents another example of BMO's Digital First strategy, focused on building a digitally-enabled, future-ready bank that drives progress for its customers, unlocks the power of its people and delivers loyalty, growth and efficiency.
BMO is committed to supporting the advancement of women both within the bank and beyond, including through:
- $1.2 million in funding to SheEO – a not-for-profit company which offers financial support to businesses led by women and non-binary people. BMO's financial commitment will allow SheEO to fund all 2021 venture applicant companies.
- BMO Empower – a series of long-term commitments to advance inclusive economic recovery in the United States, pledging $5 billion over the next five years to address key barriers faced by minority businesses, communities and families.
Learn more about BMO's support for women entrepreneurs, its Purpose to Boldly Grow the Good in business and life, and 1871 by visiting bmoforwomen.com.
About 1871
1871 is Chicago's technology hub and the #1 ranked private business incubator in the world. It exists to inspire, equip, and support early stage, growth scalers and innovators in building extraordinary businesses. 1871 is home to ~450 technology startups, ~300 growth stage companies, and ~1,500 members, and is supported by an entire ecosystem focused on accelerating their growth and creating jobs in the Chicagoland area. The member experience includes virtual and in person access to workshops, events, mentorship, and more. The nonprofit organization has 350 mentors available to its members, alongside access to more than 100 partner corporations, universities, education programs, accelerators, venture funds and others. Since its inception in 2012, more than 650 alumni companies are currently still active, have created over 11,000 jobs, and have raised more than $1.65 billion in follow-on capital.
About BMO Financial Group
Serving customers for 200 years and counting, BMO is a highly diversified financial services provider - the 8th largest bank, by assets, in North America. With total assets of $1.04 trillion as of April 30, 2022, and a team of diverse and highly engaged employees, BMO provides a broad range of personal and commercial banking, wealth management and investment banking products and services to more than 12 million customers and conducts business through three operating groups: Personal and Commercial Banking, BMO Wealth Management and BMO Capital Markets.
1 15 percent of all women fintech founders in North America have participated in the WMNfintech Program according to data collected from Crunchbase on women-founded or women-led Fintechs founded from 2017 to 2022
View original content:
SOURCE BMO Financial Group | https://www.whsv.com/prnewswire/2022/08/15/five-innovative-women-led-startups-pitch-new-technologies-amp-products-bmo-amp-1871s-third-annual-wmnfintech-program/ | 2022-08-15T12:48:53Z |
National Biotechnology Company Selects Louisville for New Location
LOUISVILLE, Ky., Aug. 15, 2022 /PRNewswire/ -- The largest independent blood-plasma donation center operator in the world is adding Kentucky to the states where it operates. The new center is in Louisville and will help meet the worldwide demand for blood-plasma. Freedom Plasma operates donation centers in 12 other states and is a subsidiary of ImmunoTek Bio Centers. Louisville marks the 67th center in the U.S. wholly designed, built, and operated by the organization.
The company has accepted more than six million donations from blood-plasma donors since it launched in 2013. Those donations provide much-needed plasma used to make plasma protein therapies and medicines for healthcare patients around the globe. These plasma-derived medicines treat immune disorders, rare diseases, burn victims, cancer patients, and a variety of other illnesses. To treat just one patient annually requires between 130 – 1,200 plasma donations from healthy donors.
"For patients with life-altering medical conditions, receiving donated plasma can mean the difference between life and death," said Jerome Parnell III, CEO of ImmunoTek. "Not only is plasma used to create valuable therapies and vaccines, but recent research also shows promise with plasma-derived therapies reducing or limiting the effects of Alzheimer's Disease and dementia."
Plasma is the golden liquid part of blood and has such a unique biologic make-up, that it cannot be made synthetically. The U.S. provides 2/3 of the plasma used worldwide and is one of the few countries that allow healthcare companies to financially compensate donors for their time donating plasma. Having a plasma donation center in a community also provides a major economic boost by creating jobs.
"We expect the economic impact of an operating center to be around $5 million annually," said Blair McKinney, Chief Operations Officer of ImmunoTek. "The community benefits from the construction of this new center, compensation for its donors, healthcare-oriented jobs, and the creation of a need for services from local small businesses; plus, our donors know they are helping save lives."
To be eligible to donate plasma, a medical screening is conducted by in-house medical professionals, along with a medical history and physical exam. Donating plasma is much like a blood donation. Plasma is removed from the blood through a safe, sterile, self-contained automated process called plasmapheresis. The remaining red blood cells are returned to the donor. Plasma can be donated up to twice a week.
"Once people understand how desperately needed blood-plasma is for millions of people, they are willing to roll up their sleeves and donate," said Center Director Rachel Donlin. "We are excited to be part of the Louisville community."
Freedom Plasma's new location is at 8209 Preston Highway and will operate Tuesday – Saturday. Following the first week of operation, which is by appointment only, walk-in donors are welcome. If you need more information or want to make an appointment, call the center at 502-212-2230 or visit www.FreedomPlasma.com.
ABOUT FREEDOM PLASMA
Freedom Plasma was developed and is operated by ImmunoTek Bio Centers LLC in partnership with a global healthcare company and leading manufacturer of plasma-derived medicines. Freedom Plasma provides donors within the communities it serves the freedom to improve their financial position and help positively impact patients' lives who rely on plasma-based therapies. Each plasma donation is essential and provides patients the freedom to live healthier and happier lives.
ABOUT IMMUNOTEK BIO CENTERS, LLC
ImmunoTek Bio Centers LLC is the largest and fastest-growing independent plasma collection center operator in the world. ImmunoTek is a global leader in developing a reliable plasma supply chain for international biotech companies, as well as partnering with organizations for ancillary projects related to blood-plasma collection. Since its inception in 2013, ImmunoTek has built and operated more than 60 plasma collection centers, most of which have achieved or are in the process of achieving U.S. FDA-licensure and European certification. ImmunoTek currently has centers operating in 12 states, with 31 additional centers in the construction process, and planning underway for more than 63 more sites over the next three years. For more information, visit www.ImmunoTek.com.
View original content to download multimedia:
SOURCE ImmunoTek Bio Centers | https://www.whsv.com/prnewswire/2022/08/15/freedom-plasma-expands-kentucky/ | 2022-08-15T12:49:00Z |
Clean energy veteran brings more than 15 years of financial leadership experience at public and private organizations
BEVERLY, Mass., Aug. 15, 2022 /PRNewswire/ -- Highland Electric Fleets, the leading provider of electrification-as-a-service for government and municipal fleets in North America, has hired Gaurav Dubey as chief financial officer to help scale its finance organization, optimize its capital structure, and develop new financial products.
"Fleet electrification is at an inflection point, and Highland is well-positioned to meet increasing demand for cleaner communities, healthier kids, and more resilient electric grids," said Highland CEO Duncan McIntyre. "Gaurav's proven track record of leading high-value structured financing, capital allocation, and strategic operations initiatives will support Highland's continued growth as we scale our business to bring simple, affordable electrification upgrades to customers across North America."
Dubey has executed over $3B in equity and debt financing from financial institutions, venture capital firms, private equity investors and capital markets across North America, Europe, and Asia. Prior to joining Highland, he was senior vice president of finance at 8minute Solar Energy, where he built out a finance team and raised $350 million in financing in the absence of a CFO. Before that, Dubey was vice president of corporate finance at SunPower Corporation, where he helped spin out and take public the company's modules business; senior director of finance at VECTRA, an Apollo Company; and director of corporate finance at SunEdison, where he led structured financing and corporate acquisitions. Earlier in his career, Dubey co-founded an energy developer in India. He holds an MBA from Harvard Business School, and a Bachelor of Technology in mechanical engineering from the Indian Institute of Technology, Kanpur.
"I'm excited to join Highland at a time of significant expansion for both the company and the industry," said Dubey. "Financial innovation and deploying capital efficiently at scale will help us lower costs for customers and advance our mission to accelerate adoption of zero-emission transportation."
Highland Electric Fleets is the leading provider of fleet electrification-as-a-service in North America. Founded in 2018, Highland's unique suite of products make it simple and affordable for school districts, governments, and fleet operators to upgrade to electric fleets today. Whatever the customer's need, Highland delivers a seamless experience, with all the equipment and services needed to keep a fleet running smoothly. Active in 30 states and Canada, Highland is responsible for the largest electric school bus deployment in the United States and the first commercial vehicle-to-grid deployment in New England. To learn more, visit https://highlandfleets.com.
Media Contact:
Mission Control Communications
highlandelectric@missionc2.com
View original content to download multimedia:
SOURCE Highland Electric Fleets | https://www.whsv.com/prnewswire/2022/08/15/gaurav-dubey-joins-highland-electric-fleets-chief-financial-officer-scale-amp-accelerate-electric-bus-adoption/ | 2022-08-15T12:49:06Z |
Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial
AUSTIN, Texas, Aug. 15, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Safety Review Committee (SRC) has approved continuation of the Acclaim-1 Phase 1/2 clinical trial of REQORSA™ in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC) following a review of the first cohort of patients in the Phase 1 portion of the trial. In 2020, Genprex received U.S. Food and Drug Administration's (FDA) Fast Track Designation for treatment of the Acclaim-1 patient population.
Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company's lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Tagrisso® (osimertinib) in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso.
"The SRC approval to advance Acclaim-1 to the higher dose in the second cohort of patients is an important milestone that further supports REQORSA's safety profile and brings us one step closer to bringing this potentially ground-breaking gene therapy approach to treating NSCLC to the patients who need it most," said Mark Berger, M.D., Chief Medical Officer of Genprex. "Enrollment in Acclaim-1 remains on track to complete the Phase 1 portion of the study by year end."
The Accaim-1 trial includes up to three sequential dose escalation cohorts that will be treated with REQORSA intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet during 21-day treatment cycles until disease progression or unacceptable toxicity. The first group received REQORSA IV infusion at 0.06 mg/kg, the second group will receive 0.09 mg/kg and the third will receive 0.12 mg/kg (if approved by the SRC) in order to identify the recommended Phase 2 dose.
"REQORSA is a pan-kinase inhibitor shown to inhibit both the EGFR and AKT oncogenic kinase pathways. We believe that REQORSA's multimodal activity will block emerging bypass pathways, reducing the probability that drug resistance develops," added Dr. Berger. "Confirmation of the safety in this first cohort of Acclaim-1 patients is particularly important as these relapsed patients represent a very sick and compromised population."
The SRC is comprised of three physicians who are principal investigators in the trial. The SRC may recommend that the trial continues at the same dose or at a lower dose, that it escalates to a higher dose, or it can recommend terminating the study altogether due to safety concerns.
The Acclaim-1 clinical trial is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company's lead drug candidate, REQORSA, in combination with Tagrisso in patients with late-stage NSCLC with activating epidermal growth factor receptor ("EGFR") mutations whose disease progressed after treatment with Tagrisso. Genprex expects the Phase 1 portion of the Acclaim-1 trial to enroll up to 18 patients in a dose escalation study to determine the maximum tolerated dose of the combination. The Phase 2 portion of the study is expected to enroll approximately 74 patients to be randomized 1:1 to receive either REQORSA and Tagrisso combination therapy or Tagrisso monotherapy. The primary endpoint of the Phase 2 portion of the trial is progression-free survival, which is defined as time from randomization to progression or death. An interim analysis will be performed at 25 events.
REQORSA™ Immunogene Therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC) uses Genprex's unique, proprietary ONCOPREX® Nanoparticle Delivery System, which is the first systemic gene therapy delivery platform used for cancer in human clinical trials. The active ingredient in REQORSA is the TUSC2 gene, a tumor suppressor gene. REQORSA consists of the TUSC2 gene encapsulated in a nanoparticle made from lipid molecules with a net positive electrical charge. REQORSA is injected intravenously and is preferentially taken up by cancer cells. Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed, and the TUSC2 protein is capable of restoring certain defective functions arising in the cancer cell. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells.
Tagrisso® is a registered trademark of AstraZeneca plc and its largest selling drug with 2021 sales of over $5 billion.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. In 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca's Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA for NSCLC in combination therapy with Merck & Co's Keytruda® (pembrolizumab) for patients whose disease progressed after treatment with Keytruda.
For more information, please visit the Company's web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2021.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex's clinical trials and regulatory approvals, including the extent and impact of the COVID-19 pandemic; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status; Genprex's commercial and strategic partnerships, including those with its third party manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:
SOURCE Genprex, Inc. | https://www.whsv.com/prnewswire/2022/08/15/genprex-announces-safety-review-committee-approves-dose-escalation-acclaim-1-phase-12-trial-reqorsa-combination-with-tagrisso-non-small-cell-lung-cancer/ | 2022-08-15T12:49:13Z |
Menu-priced pizzas ordered online are half off this week
ANN ARBOR, Mich., Aug. 15, 2022 /PRNewswire/ -- Domino's Pizza Inc. (NYSE: DPZ), the largest pizza company in the world, knows that Americans are feeling the pinch from higher prices everywhere. One great way to stretch your budget this week is with Domino's 50% off deal, with half off all menu-priced pizzas ordered online, today through Aug. 21.
"Domino's has always been focused on value that can feed a family at a reasonable price," said Frank Garrido, Domino's executive vice president of U.S. operations and support. "Domino's stores nationwide are ready to bring pizzas and smiles to customers who are looking to make their money go further this week."
Domino's 50% off deal is available on menu-priced pizzas ordered through the following online ordering channels:
- Domino's website (dominos.com)
- Domino's ordering apps for iPad®, iPhone® and Android™
- Domino's AnyWare ordering platforms, including through Google Home, Alexa, Slack and Facebook Messenger
Customers can order any size pizza and crust, including hand tossed, handmade pan, Brooklyn style, or crunchy thin crust with Domino's 50% off deal. Specialty pizzas, such as the Cali Chicken Bacon Ranch, Memphis BBQ Chicken, Pacific Veggie and more, are also included in the deal.
Founded in 1960, Domino's Pizza is the largest pizza company in the world, with a significant business in both delivery and carryout pizza. It ranks among the world's top public restaurant brands with a global enterprise of more than 19,200 stores in over 90 markets. Domino's had global retail sales of nearly $17.8 billion in 2021, with over $8.6 billion in the U.S. and over $9.1 billion internationally. In the second quarter of 2022, Domino's had global retail sales of over $4.0 billion, with over $2.0 billion in the U.S. and nearly $2.0 billion internationally. Its system is comprised of independent franchise owners who accounted for 98% of Domino's stores as of the end of the second quarter of 2022. Emphasis on technology innovation helped Domino's achieve more than half of all global retail sales in 2021 from digital channels. In the U.S., Domino's generated more than 75% of U.S. retail sales in 2021 via digital channels and has developed several innovative ordering platforms, including those for Google Home, Facebook Messenger, Apple Watch, Amazon Echo, Twitter and more. In 2019, Domino's announced a partnership with Nuro to further its exploration and testing of autonomous pizza delivery. In mid-2020, Domino's launched a new way to order contactless carryout nationwide – via Domino's Carside Delivery®, which customers can choose when placing a prepaid online order.
Order – dominos.com
Company Info – biz.dominos.com
Media Assets – media.dominos.com
###
View original content to download multimedia:
SOURCE Domino's Pizza | https://www.whsv.com/prnewswire/2022/08/15/give-your-wallet-break-with-dominos-50-off-pizza-deal/ | 2022-08-15T12:49:20Z |
Leading window treatment franchise to provide premium window treatments, consultation services to Huntsville residents
HUNTSVILLE, Ala., Aug. 15, 2022 /PRNewswire/ -- Gotcha Covered, a leader in custom window treatment consultation in the U.S. and Canada, has increased its presence in Alabama with the opening of Gotcha Covered of Huntsville. With the opening of the new center, the franchise has two locations in the state.
The new center is owned and operated by Greg and Bethany Smith. With an emphasis on end-to-end consultations, this business will provide the best in soft and hard window treatments to homeowners in Madison County and the surrounding areas while offering a variety of blinds, draperies, smart solutions and much more.
"Quality is what defines our brand at Gotcha Covered," said Paul Linenberg, president of Gotcha Covered. "We pride ourselves in being able to deliver the best customer experience. That's what the residents of Huntsville are getting with this new location. Window treatments can transform the ambiance of a home. Greg and Bethany are a great asset to the community and will provide community with high-quality window treatment solutions."
Greg and Bethany bring diverse backgrounds to the Gotcha Covered brand. With a bachelor's in liberal studies, Greg started his career in the U.S. Navy. He has previously served as a business owner as well. Bethany is a nurse by trade but has also worked in project management and yacht repair.
While searching for business opportunities, Greg came across Gotcha Covered with the help of his entrepreneurial coach. After learning more about the franchise, he knew it was the right one for him and Bethany.
"Gotcha Covered was perfect for our long-term goals," said Smith. "Plus, the leadership team and other franchisees help create a very positive atmosphere. Everyone has been super helpful, professional and responsive. There is always a helping hand available when you need it. That's part of the culture."
In addition to providing premium window treatments to the Huntsville community, Smith said the duo has aspirations of opening multiple storefronts to service northern and central Alabama.
Adding 27 new franchise locations in 2021, Gotcha Covered currently has over 130 total franchises across the U.S. and Canada. The franchise has been operating under the Gotcha Covered name since 2009.
To schedule an appointment with Gotcha Covered of Huntsville, visit https://www.gotchacovered.com/huntsville/.
About Gotcha Covered
Gotcha Covered is a leader in custom soft and hard window treatment consultation in the U.S. and Canada. Flying under their Gotcha Covered flag since 2009, they offer custom window treatments including blinds, draperies, shutters and much more. They offer end-to-end consultation with the customer's specific needs and goals in mind. The company currently has over 130 total franchises across the U.S. and Canada.
MEDIA CONTACT:
Heather Ripley
Ripley PR
865-977-1973
hripley@ripleypr.com
View original content to download multimedia:
SOURCE Gotcha Covered | https://www.whsv.com/prnewswire/2022/08/15/gotcha-covered-opens-second-location-alabama/ | 2022-08-15T12:49:28Z |
VANCOUVER, BC, Aug. 15, 2022 /PRNewswire/ -- GreenPower Motor Company Inc. (NASDAQ: GP) (TSXV: GPV) ("GreenPower" or the "Company"), a leading manufacturer and distributor of zero-emission, electric-powered, medium and heavy-duty vehicles, today announced the results for its quarter ended June 30, 2022.
"We've achieved a number of milestones across various segments of our business including the first deliveries of our EV Star Cab and Chassis (EV Star CC) to Workhorse in July, expansion of the dealer network for our all-electric school buses, the acquisition of Lion Truck Body and entering into a Contract of Lease-Purchase for the facility in West Virginia," said Fraser Atkinson, CEO of GreenPower. "Our investment in inventory supports the deliveries we're making this summer and through this fall of our all-electric school buses, cargo vans and other EV Star models in addition to the build-up for the Workhorse contract."
Financial Highlights for the quarter:
- Recorded revenues of $3,851,105 for the current quarter an increase of 29% over the revenue of $2,980,086 for the same quarter last year,
- Gross profit of 28.8% of revenue,
- Cash including restricted cash of $5.4 million at the end of the period,
- Inventory of $39.7 million including finished goods of $24.6 million, and
- Working capital at the end of the quarter of $28.3 million.
Acquisition of Lion Truck Body:
During the quarter, GreenPower was engaged in the due diligence and negotiation of the acquisition of Lion Truck Body, a truck body manufacturer located near the port of Long Beach in Los Angeles. Lion Truck Body manufactures and instals a complete line of truck bodies including dry-freight aluminum, refrigerated box, aluminum beds, stake bed, flat bed and service body. With the successful closing of the acquisition in July, GreenPower is vertically integrating an important component of its supply chain, as the company is now able to send EV Star CCs to Lion Truck Body for body installation for customers, which captures another revenue stream that is currently being sent to third-party body manufacturers.
"The combination of GreenPower's EV expertise and the advanced body building experience of Lion Truck Body gives GreenPower a competitive advantage with shortened lead time as well as truck bodies that are optimized for EV Trucks. We've collaborated with Lion Truck Body to develop our new EV Star Cargo+ refrigerated truck, which is slated for delivery to our first customer this quarter with more payload, longer range and lower cost factor than any competitive EV refrigerated truck in its class on the market" stated Brendan Riley, President of GreenPower.
Supply Agreement with Workhorse:
GreenPower began manufacturing its first few tranches of EV Star CC's for the 1,500 unit purchase and sale contract with Workhorse. During the quarter, GreenPower coordinated with its suppliers for the delivery of key components and initiated production of 100 vehicle tranches of EV Star CC's. By the end of the quarter the first 100 EV Star CC's were near completion, the next tranche had entered production and key components for additional tranches had been ordered. The first deliveries to Workhorse began in July, with follow-on deliveries made in August. GreenPower's team is working closely with Workhorse to assist with the integration on the EV Star CC's.
Dealer Network Expansion for GreenPower's School Buses:
GreenPower presently has more than 40 Type D BEAST and Type A Nano BEAST school buses in finished goods inventory with substantially all of these expected to be sold and delivered by the end of this calendar year. GreenPower has ongoing discussions with dealers in the Mid-West, North-East and Pacific North West. GreenPower anticipates that initial deliveries across its dealer network will expand this sales channel, and better position the company to leverage significant local, state and federal funding for all-electric school buses.
EV Star Cargo vans:
During the quarter, GreenPower delivered its first five 22' cargo vans. Presently, GreenPower has approximately 40 EV Star Cargos in finished goods inventory and customers that have approved vouchers from the California Air Resource Board HVIP program or the New Jersey ZIP program for substantially all of these.
West Virginia Facility:
During the quarter, GreenPower entered into a lease-purchase agreement with the state for an 80,000 square foot facility on six acres of land to manufacture all-electric school buses for the U.S. market. As part of this partnership the state will provide worker training and hiring support, up to $3.5 million in employment incentive payments in exchange for meeting hiring targets and has agreed to purchase up to $15 million of GreenPower vehicles produced at the facility.
Results for the three months ended June 30, 2022
For the three-month period ended June 30, 2022 the Company recorded revenues of $3,851,105 and cost of sales of $2,743,431 generating a gross profit of $1,107,674 or 28.8% of revenues. Revenue was generated from the sale of 3 BEAST Type D all-electric school buses, 2 EV Star Plus, 1 EV Star Cargo+, 5 EV Star 22-foot cargo, 6 EV Stars and 4 EV Star Cab and Chassis, as well as revenue from finance and operating leases and other sources. Operating costs consisted of administrative fees of $1,754,768 relating to salaries, project management, accounting, and administrative services; transportation costs of $62,035 which relate to the use of trucks, trailers, contractors as well as other operational costs needed to transport company products around North America; travel, accommodation, meals and entertainment costs of $162,605 related to travel for project management, demonstration of company products, and trade shows; product development costs of $245,118; sales and marketing costs of $366,871; insurance expense of $350,534; professional fees of $312,840 consisting of legal and audit fees; and office expense of $144,484 consisting of rent and other office expenses, as well as non-cash expenses including $1,709,175 of share-based compensation expense and depreciation of $195,608, generating a loss from operations before interest, accretion and foreign exchange of $4,225,321. Interest and accretion of $121,936 and a foreign exchange gain of $1,072 resulted in a loss for the period of $4,346,185.
Media and Investor Contacts:
Fraser Atkinson, CEO
(604) 220-8048
Michael Sieffert, CFO
(604) 563-4144
Brendan Riley, President
(510) 910-3377
Mike Cole, IR
(949) 444-1341
Allie Potter
Skyya PR for GreenPower
(218) 766-8856
allie@skyya.com
About GreenPower Motor Company
GreenPower designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis. GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. GreenPower was founded in Vancouver, Canada with primary operational facilities in southern California. Listed on the Toronto exchange since November 2015, GreenPower completed its U.S. IPO and NASDAQ listing in August 2020. For further information go to www.greenpowermotor.com
Forward-Looking Statements
This document contains forward-looking statements relating to, among other things, GreenPower's business and operations and the environment in which it operates, which are based on GreenPower's operations, estimates, forecasts, and projections. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "upon", "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or are beyond GreenPower's control. A number of important factors, including those set forth in other public filings (filed under the Company's profile on www.sedar.com), could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Consequently, readers should not place any undue reliance on such forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. GreenPower disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. All amounts expressed in U.S. dollars © 2022 GreenPower Motor Company Inc. All rights reserved.
View original content to download multimedia:
SOURCE GreenPower Motor Company | https://www.whsv.com/prnewswire/2022/08/15/greenpower-reports-fiscal-first-quarter-2023-results/ | 2022-08-15T12:49:35Z |
The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offering
SAN DIEGO, Aug. 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery and autoinjector devices, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2028 (the "Convertible Notes"). The Convertible Notes are to be offered and sold to "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company also expects to grant a 13-day option to the initial purchasers to purchase up to an additional $75 million aggregate principal amount of Convertible Notes.
The Convertible Notes will be senior, unsecured obligations of the Company and will accrue interest payable semi-annually in arrears. The Convertible Notes will mature on August 15, 2028, unless earlier redeemed, repurchased or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding February 15, 2028, the Convertible Notes will be convertible only upon the satisfaction of certain conditions and during certain periods, and on and after February 15, 2028, at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date, the Convertible Notes will be convertible regardless of these conditions. The Company will settle conversions in cash and, if applicable, shares of the Company's common stock. The initial conversion rate, interest rate and other terms of the Convertible Notes will be determined at the time of pricing in negotiations with the initial purchasers of the Convertible Notes.
In connection with the offering, the Company intends to enter into privately negotiated capped call transactions with option counterparties that may include one or more of the initial purchasers and/or their affiliates and/or other institutions. If the initial purchasers exercise their option to purchase additional notes, the Company may enter into additional capped call transactions with the option counterparties. The capped call transactions are generally expected to reduce potential dilution to the Company's common stock upon conversion of the convertible notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be.
The Company has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties and/or their affiliates (i) expect to purchase shares of the Company's common stock and/or enter into derivative transactions with respect to the Company's common stock concurrently with, or shortly after, the pricing of the Convertible Notes and (ii) may modify their hedge positions by entering into or unwinding derivative transactions with respect to the Company's common stock and/or purchasing or selling the Company's common stock or other securities of the Company in secondary market transactions following the pricing of the Convertible Notes and prior to the maturity of the Convertible Notes. These activities could have the effect of increasing, or preventing a decline in, the market price of the Company's common stock concurrently with, or shortly following, the pricing of the Convertible Notes. The effect, if any, of these activities, including the direction or magnitude, on the market price of the Company's common stock will depend on a variety of factors, including market conditions, and cannot be ascertained at this time. Any of these activities could, however, adversely affect the market price of the Company's common stock.
The Company expects to use a portion of net proceeds of the offering to fund the cost of entering into the capped call transactions. The Company also expects to use a portion of the net proceeds of the offering to enter into privately negotiated agreements with certain holders of its outstanding 1.25% convertible senior notes due 2024 (the "Existing Convertible Notes") to exchange their Existing Convertible Notes for a combination of cash and shares of its common stock through privately negotiated transactions entered into concurrently with or shortly after the pricing of the proposed offering (the "Note Repurchases").
In parallel to this transaction, the Company expects to use a portion of the net proceeds of the offering for the repurchase of shares of its common stock (the "Share Repurchases") up to $200 million, concurrently with, or shortly after, the pricing of the offering in privately negotiated transactions or otherwise, which may be effected through one or more of the initial purchasers or any affiliate thereof.
The Share Repurchases, if consummated in full, would represent an increase of $100 million of the previously planned share repurchases to be made in 2022 under the Company's ongoing three-year $750 million share repurchase program, which was commenced and previously announced in 2021.
Further, the Company expects to use a portion of the net proceeds of the offering to repay all of its outstanding $250 million term loan facility due 2026. The Company intends to use the remainder of the net proceeds from the offering for general corporate purposes, including other repurchases of the Company's common stock from time to time under the existing stock repurchase program, working capital, capital expenditures, potential acquisitions and strategic transactions. If the initial purchasers exercise their option to purchase additional notes, the Company intends to use a portion of the net proceeds from the sale of additional notes to fund the cost of entering into additional capped call transactions.
The Note Repurchases and Share Repurchases could increase (or reduce the size of any decrease in) the market price of Halozyme common stock or the Convertible Notes. We also expect that some existing noteholders may purchase or sell shares of the Company's common stock in the market to hedge their exposure in connection with these transactions. The Note Repurchases, Share Repurchases and any associated hedging by holders could affect the market price of the Company's common stock prior to, concurrently with or shortly after the pricing of the Convertible Notes and could also result in a higher effective conversion price for the Convertible Notes.
This press release is neither an offer to sell nor a solicitation of an offer to buy the Convertible Notes or the shares of the Company's common stock issuable upon conversion of the Convertible Notes, if any, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offer of these securities will be made only by means of a private offering memorandum.
The offer and sale of the Convertible Notes and the shares of the Company's common stock issuable upon conversion of the Convertible Notes, if any, have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Forward-looking Statements:
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the planned offering. Words such as "anticipates," "estimates," "expects," "projects," "forecasts," "intends," "plans," "will," "believes" and words and terms of similar substance used in connection with any discussion identify forward-looking statements. These forward-looking statements are based on management's current expectations and beliefs about future events and are inherently susceptible to uncertainty and changes in circumstances. Except as required by law, the Company is under no obligation to, and expressly disclaims any obligation to, update or alter any forward-looking statements whether as a result of such changes, new information, subsequent events or otherwise. With respect to the planned offering, such uncertainties and circumstances include whether the Company will offer the notes or consummate the offering; and the anticipated terms of the notes and the use of the net proceeds from the offering. Various factors could also adversely affect the Company's operations, business or financial results in the future and cause the Company's actual results to differ materially from those contained in the forward-looking statements, including those factors discussed in detail in the "Risk Factors" sections contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, which are filed with the Securities and Exchange Commission.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 600,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED®, TLANDO™ and NOCDURNA® and partnered commercial products and ongoing product development programs with industry leading pharmaceutical companies including Teva Pharmaceutical, Covis Pharma, Pfizer and Idorsia Pharmaceuticals.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download multimedia:
SOURCE Halozyme Therapeutics, Inc. | https://www.whsv.com/prnewswire/2022/08/15/halozyme-therapeutics-inc-announces-proposed-offering-500-million-convertible-senior-notes-due-2028/ | 2022-08-15T12:49:41Z |
Gross margin of 24%, which is expected to increase with further asset integration, product availability, and operational improvements
Approximately $6.5 million per year in expected cash cost savings from streamlining operations in Canada and closure of Israeli cultivation farm
TORONTO and GLIL YAM, Israel, Aug. 15, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company", "IM Cannabis", or "IMC") (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, provided financial results for its second quarter ended June 30, 2022. All amounts are reported in Canadian dollars unless otherwise stated.
Q2 2022 Highlights
- Revenues increased 114% year-over-year to $23.8 million.
- Gross profit, before fair value adjustments, was $5.6 million.
- Implemented streamlining and restructuring plan in Canada, with expected cash cost savings of approximately $4 million per year, including the sale of SublimeCulture Inc. ("Sublime").
- Completed the closure of the Sde Avraham cultivation farm that Focus Medical Herbs Ltd. ("Focus Medical") owned and operated in Israel, with expected cash cost savings of $2.5 million per year, and further centralized operations of recently acquired assets in the country.
Management Commentary
"We have accelerated along the path to profitability, with increased revenues, operational streamlining, and a focus on cost reduction," said Oren Shuster, Chief Executive Officer of IMC. "Our primary goal is to continue to increase revenue in each of our core markets to build long term shareholder value. By focusing on sustainable revenue growth, while rigorously pursuing cost and margin efficiencies, we believe we can achieve profitability in the short term."
"Our long-term strategy relies on geographic diversification and preparation to target, upon legalization, new adult-use recreational cannabis markets in Germany followed by the rest of Europe. We are preparing to leverage our global cultivation, brand, and commercial expertise to profitably capture substantial market share across Europe. Our strength is in properly positioning our brands in different markets and the introduction of new SKUs to consistently exceed consumer and patient expectations."
"Like in Israel, we have embarked on a thorough restructuring of our operations in Canada as part of our global integration efforts and to reduce costs. To that end, we have finalized the sale of Sublime, which together with our streamlining initiatives in Israel, is expected to yield $6.5 million in annual cash savings. We expect the majority of savings to begin to materialize in the third quarter, with full realization in the fourth quarter of this year," concluded Shuster.
Operational Highlights
- To further streamline operations in Israel, Focus Medical completed the closure of its Sde Avraham cultivation farm. The closure of Sde Avraham farm allows the Company to efficiently leverage its fully licensed import-export supply chain and focus on importing premium and ultra-premium products from its Canadian subsidiaries and other leading Canadian suppliers.
- In Israel, the Company continued to focus on importing premium and ultra-premium indoor-grown dried cannabis from its Canadian licensed cultivation facilities and its world-leading cannabis suppliers and supply partners. The Company successfully introduced its highly popular WAGNERS Canadian brand in Israel and expects to bring to market new medical cannabis products in Q3 and Q4.
- In Canada, the Company launched numerous new products in response to high market demand for its brands, WAGNERS and Highland Grow, which hold top 3 spots in the premium and ultra-premium segments in Ontario, respectively[i]. At the end of Q2, and in the first weeks of Q3, the WAGNERS pre-roll catalog at the Ontario Cannabis Store ("OCS") grew through the launch of Tiki Rain, Blue Lime Pie, and TRPY SLRP pre-rolls. Two new 3.5g dried flower SKUs – Tiki Rain and Purple Clementine – were also launched in addition to an expansion of the concentrate portfolio with the introduction of soft black hash and 3.5g soap bar hash. Highland Grow added new dried flower SKUs to its OCS portfolio – Gas Tank and Diamond Breath as well as White Lightning pre-rolls. New product rollouts continue with the introduction of new strains including Frost Bite, Leviathan, and Space Jagger.
- On August 5, 2022, the Company closed the sale of Sublime, which along with additional streamlining measures taken in Canada is expected to generate annual cash cost savings of approximately $4 million per year. All cultivation, genetics, and logistics have been centralized in the Company's facilities in Kitchener, Ontario which has sufficient cultivation capacity to support the streamlining initiative. The Company sold Sublime to a group of purchasers that included the current and former members of the Sublime management team for aggregate proceeds of $100,000 less adjustments. The transaction constituted a "related party transaction" within the meaning of Multilateral Instrument 61-101 – Take-Over Bids and Special Transactions ("MI 61-101"). Pursuant to Sections 5.5(a) and 5.7(1)(a) of MI 61-101, the transaction is exempt from the formal valuation and minority shareholder approval requirements of such instrument.
- In Germany, May was the strongest sales month to date, and the Company's IMC Hindu Kush strain was the top selling T20 in the market, strengthening Adjupharm GmbH's ("Adjupharm") position as one of the top 10 cannabis companies in Germany. With receipt of the extended EU-GMP license on May 24th, including additional production, testing & release steps, the Company achieved another milestone that supports its strategy of product and brand variety. Adjupharm commenced several new product license applications preparing for the launch of new high-quality and high-THC products in Q4 2022 and Q1 2023.
Q2 2022 Financial Results
- Revenues were $23.8 million in Q2 2022, representing an increase of 114% from Q2 2021. Total dried flower sold for Q2 2022 was 3,210 kilograms at an average selling price of $5.72 per gram, compared to 1,842 kilograms for the same period in 2021 at an average selling price of $3.92 per gram. The increase in revenues is primarily attributed to the increase in the quantity of medical and recreational cannabis products sold, as well as from the higher average selling price per gram the Company realized from its portfolio of premium branded cannabis products in Israel and Canada.
- Gross profit, before fair value adjustments, was $5.6 million in Q2 2022 compared to $0.6 million in Q2 2021.
- General and administrative expenses were $11.1 million in Q2 2022 compared to $7.4 million in Q2 2021. The increase in the general and administrative expense is mainly attributable to the growing corporate activities in Israel and Canada following the Company's acquisitions in 2021.
- Sales and marketing expenses were $5.0 million in Q2 2022 compared to $1.2 million in Q2 2021. The increase in the sales and marketing expenses was due mainly to the Company's increased marketing efforts in Israel, brand launch in Germany, and increased distribution expenses relating to the growth in sales and consolidation of sales and marketing expenses of entities acquired in 2021.
- Adjusted EBITDA loss was $(4.6) million in Q2 2022 compared to $(5.7) million in Q2 2021.
- Net loss was $18.98 million in Q2 2022 compared to net loss of $5.01 million in Q2 2021. Included in the net loss was a non-cash charge of $5.4 million, related to restructuring activities in Canada and Israel, along with associated write-downs in tangible and intangible assets, such as other non-cash impairments of $1.5 million in financial expenses and $3.8 million in general and administrative costs.
- Cash and cash equivalents totaled $5.86 million as at June 30, 2022, compared to $34.05 million as at December 31, 2021.
The complete interim condensed consolidated financial statements of the Company and related management's discussion and analysis for the three months ended June 30, 2022 and 2021, will be available under the Company's SEDAR profile at www.sedar.com.
Q2 2022 Conference Call
The Company will host a zoom web conference today at 9:00 a.m. ET to discuss its Q2 results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.
About IM Cannabis Corp.
IM Cannabis (NASDAQ: IMCC, CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers. IM Cannabis is one of the very few companies with operations in Israel, Germany, and Canada, the three largest federally legal markets. The ecosystem created through its international operations leverages the Company's unique data-driven perspective and product supply chain globally. With its commitment to responsible growth and financial prudence, and the ability to operate within the strictest regulatory environments, the Company has quickly become one of the leading cultivators and distributors of high-quality cannabis globally.
In Israel, the Company imports and sells premium and ultra-premium medical cannabis, operating retail pharmacies, online platforms, distribution centres and logistical hubs through IMC Holdings Ltd. and its subsidiaries and affiliates, which enable safe delivery and quality control throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm, where it also distributes cannabis to pharmacies to medical cannabis patients. In Canada, IM Cannabis operates through Trichome Financial Corp. and its subsidiaries TJAC and MYM, where it cultivates and processes cannabis for the adult-use market at its Ontario, Nova Scotia, under the WAGNERS and Highland Grow brands.
Disclaimer for Forward-Looking Statements
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities laws (collectively, "forward-looking information"). Forward-looking information are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking information in this press release includes, without limitation, statements relating to the Company's business objectives and milestones and the anticipated timing of execution; expected increase in gross margin attributed to acquired Israeli assets, product availability and yield improvement; the expected cost savings from streamlining operations in Canada and Israel; compliance with NASDAQ Listing Rules; the performance of the Company's business, strategies and operations; the intention to expand its product portfolio and potential business activities; the future impact of the Company's acquisitions; the future product portfolios of the Company, its subsidiaries, Focus Medical and High Way Shinua Ltd. ("HW Shinua", and together with the Company, its subsidiaries and Focus Medical, the "Group") and the Company's ability to export its products, strains and genetics from Canada to Israel and Germany; the competitive conditions of the cannabis industry and the growth of medical or adult-use recreational cannabis markets in the jurisdictions in which the Company operates; and the anticipated decriminalization or legalization of adult-use recreational cannabis in Germany and Europe.
Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited, the anticipated increase in demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company's satisfaction of international demand for its products; the Company's ability to implement its growth strategies and leverage synergies of acquisitions; the Company's ability to reach patients through e-commerce and brick and mortar retail operations; the development and introduction of new products; the ability to import and the supply of premium and indoor grown cannabis products from the Company's Canadian subsidiaries and third-party suppliers and partners; the changes and trends in the cannabis industry; the Company's ability to maintain and renew or obtain required licenses; the ability to maintain cost-efficiencies and network of suppliers to maintain purchasing capabilities; the effectiveness of its products for medical cannabis patients and recreational consumers; future cannabis pricing and input costs; cannabis production yields; the Company being able to continue to drive organic growth from Canadian operations; and the Company's ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: general business risk and liability, including claims or complaints in the normal course of business; any failure of the Company to maintain "de facto" control over Focus Medical and/or HW Shinua in accordance with IFRS 10; limitations on stockholdings of the Company in connection with its potential direct engagement in the Israeli medical cannabis market; the ability and/or need to obtain additional financing for continued operations; the lack of control over the Company's investees; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company, its acquisitions to integrate each entity into the Company's operations and realize the anticipated benefits and synergies of each such transaction and the timing thereof and the focus of management on such integration; any potential undisclosed liabilities of entities acquired by the Company that were unidentified during the due diligence process; the interpretation of Company's acquisitions of companies or assets by tax authorities or regulatory bodies, including but not limited to the change of control of licensed entities; the ability of the Group to deliver on their sales commitments or growth objectives; the Group's reliance on third-party supply agreements and its ability to enter into additional supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations; the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses.
Please see the other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated March 31, 2022, which is available on the Company's issuer profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Financial Outlook
The Company and its management believe that the statements regarding increased revenue and adjusted EBITDA contained in this press release are reasonable as of the date hereof, are based on management's current views, strategies, expectations, assumptions and forecasts, and have been calculated using accounting policies that are generally consistent with the Company's current accounting policies. These statements are considered future-oriented financial outlooks and financial information (collectively, "FOFI") under applicable securities laws. These statements and any other FOFI included herein have been approved by management of the Company as of the date hereof. Such FOFI are provided for the purposes of presenting information about management's current expectations and goals relating to the benefits of the streamlining and restructuring plan in Canada and Israel, expansion of the Company's product portfolio in Israel, Canada and Germany, existing sales and supply agreements with Focus Medical and Adjupharm, increased sales in Israel through the fulfilment of Focus Medical's existing supply agreements, increased sales from the resumption of product shipments to Adjupharm and new supply agreements for medical cannabis to be received by Adjupharm in Germany, the inclusion of the Israeli pharmacies, Panaxia, MYM and Trichome operations in the Company's financial results following closing of the respective acquisitions, additional product launches by Trichome under the WAGNERS brand and the future business of the Company. However, because this information is highly subjective and subject to numerous risks, including the risks discussed above under "Disclaimer for Forward Looking Statements", it should not be relied on as necessarily indicative of future results. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the FOFI prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although management of IMC has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company disclaims any intention or obligation to update or revise any FOFI, whether as a result of new information, future events or otherwise, except as required by securities laws.
Non-IFRS Measures
This press release includes references to "EBITDA", "Adjusted EBITDA" and "Gross Margin", which are non-International Financial Reporting Standards ("IFRS") financial measures. Non-IFRS measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS, and are therefore unlikely to be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest, tax, depreciation and amortization. EBITDA has no direct, comparable IFRS financial measure. The Company defines adjusted EBITDA as EBITDA adjusted by removing other non-recurring or noncash items, including the unrealized change in fair value of biological assets, realized fair value adjustments on inventory sold in the period, share-based compensation expenses, depreciation of right-of-use assets, revaluation adjustments of financial assets and liabilities measured on a fair value basis and non-recurring transaction costs included in operating expenses. The Company defines gross margin as the difference between revenue and cost of goods sold divided by revenue (expressed as a percentage), prior to the effect of a fair value adjustment for inventory and biological assets. IMC has used or included these non-IFRS measures solely to provide investors with added insight into IMC's financial performance. Readers are cautioned that such non-IFRS measures may not be appropriate for any other purpose. Non-IFRS measures should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.
Company Contact:
Maya Lustig
Director, Investor & Public Relations
IM Cannabis
+972-54-677-8100
maya.l@imcannabis.com
[i] Depletion and e-commerce sales data from Ontario Cannabis Store - Sale of Data report for period between April 1, 2022 – June 30, 2022 for dried flower product between $7.50 - $9.99/gram and above $12.99/gram, respectively.
The accompanying notes are an integral part of the interim condensed consolidated financial statements.
The accompanying notes are an integral part of the interim condensed consolidated financial statements.
The accompanying notes are an integral part of the interim condensed consolidated financial statements.
The accompanying notes are an integral part of the interim condensed consolidated financial statements.
The accompanying notes are an integral part of the interim condensed consolidated financial statements.
The accompanying notes are an integral part of the interim condensed consolidated financial statements.
View original content:
SOURCE IM Cannabis Corp. | https://www.whsv.com/prnewswire/2022/08/15/im-cannabis-reports-record-second-quarter-2022-financial-results-revenues-increase-114-yoy-238-million/ | 2022-08-15T12:49:50Z |
- The deadline to vote is at 10:00 am (Pacific Time) on Friday, August 26, 2022.
- For any questions, please contact Alexco's proxy solicitation agent and communications advisor, Laurel Hill Advisory Group, toll free at 1-877-452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com.
VANCOUVER, BC, Aug. 15, 2022 /PRNewswire/ - Alexco Resource Corp. (NYSE American: AXU) (TSX: AXU) ("Alexco" or the "Company") is pleased to announce that a leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS") has recommended Alexco shareholders ("Alexco Shareholders") vote "FOR" the proposed acquisition of Alexco by 1080980 B.C. Ltd. ("108"), a subsidiary of Hecla Mining Company ("Hecla") at the upcoming special meeting of securityholders to be held on Tuesday, August 30, 2022, at 10:00 a.m. (Pacific Time) (the "Meeting").
At the Meeting, securityholders will be asked to consider and, if deemed advisable, pass a special resolution (the "Arrangement Resolution") to approve an arrangement (the "Arrangement"), in accordance with the terms of an arrangement agreement entered into by the Company and Hecla on July 4, 2022, as assigned and amended (the "Arrangement Agreement") pursuant to which 108 will acquire all of the issued and outstanding common shares of Alexco (the "Alexco Share") that it does not already own by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia). Under the terms of the Arrangement, shareholders will receive 0.116 common shares in the capital of Hecla for each Alexco Share held.
ISS is a leading independent, third-party proxy advisory firm who, among other services, provides proxy voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.
In their report ISS stated: "The transaction makes strategic sense as shareholders will benefit from jurisdictional and project risk diversification, enhanced financing capacity and access to capital, and the benefits conferred by a consolidation of assets with Hecla."
Alexco's Meeting will be conducted at:
The meeting materials have been filed by the Company on SEDAR and EDGAR and are available under the Company's profile on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. The meeting materials are also available on the Company's website at Alexco - Investors - Special Meeting of Shareholders (https://alexcoresource.com/investors/special-meeting-of-shareholders/).
Due to the essence of time, Alexco securityholders are encouraged to vote online or by telephone.
For any questions or assistance with voting, Alexco securityholders can contact the Company's proxy solicitation agent, Laurel Hill Advisory Group:
North America Toll Free: 1-877-452-7184
Outside North America: 1-416-304-0211
Email: assistance@laurelhill.com
Founded in 1891, Hecla Mining Company (NYSE: HL) is the largest silver producer in the United States. In addition to operating mines in Alaska, Idaho and Quebec, Canada, the Company owns a number of exploration properties and pre-development projects in world-class silver and gold mining districts throughout North America.
Alexco is a Canadian primary silver company that owns and operates the majority of the historic Keno Hill Silver District in Canada's Yukon Territory, one of the highest-grade silver mines in the world.
Website: www.alexcoresource.com
Some statements ("forward-looking statements") in this news release contain forward-looking information concerning Alexco's Meeting, Alexco's anticipated results and developments in Alexco's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future, made as of the date of this news release. Forward-looking statements may include, but are not limited to, statements regarding the Meeting, statements with respect to the consummation and timing of the transaction; approval by securityholders; the satisfaction of the conditions precedent to the transaction; and timing, receipt and anticipated effects of court, regulatory and other consents and approvals. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors, which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Such factors include, among others, the risk that the Arrangement may not close when planned or at all or on the terms and conditions set forth in the Arrangement Agreement; the failure of the Company and Hecla to obtain the necessary regulatory, court, securityholder, and other third-party approvals, or to otherwise satisfy the conditions to the completion of the Arrangement, in a timely manner, or at all, may result in the Arrangement not being completed on the proposed terms, or at all; changes in laws, regulations and government practices; if a third party makes a Superior Proposal (as defined in the Arrangement Agreement), the Arrangement may not be completed and the Company may be required to pay the Termination Fee (as defined in the Arrangement Agreement); if the Arrangement is not completed, and the Company continues as an independent entity, there are risks that the announcement of the Arrangement and the dedication of substantial resources of the Company to the completion of the Arrangement could have an impact on the Company's current business relationships and could have a material adverse effect on the current and future operations, financial condition and prospects of the Company; future prices of silver, gold, lead, zinc and other commodities; market competition; and the geopolitical, economic, permitting and legal climate that we operate in. Forward-looking statements are based on certain assumptions that management believes are reasonable at the time they are made. In making the forward-looking statements included in this news release, Alexco has applied several material assumptions, including, but not limited to, assumptions as to the ability of Alexco and Hecla to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court, securityholder and other third party approvals; the satisfaction of the conditions to closing of the Arrangement in a timely manner and completion of the Arrangement on the expected terms; the expected adherence to the terms of the Arrangement Agreement and agreements related to the Arrangement Agreement; the adequacy of our and Hecla's financial resources; favourable equity and debt capital markets; and stability in financial capital markets. There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Alexco expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.
View original content:
SOURCE Alexco Resource Corp. | https://www.whsv.com/prnewswire/2022/08/15/independent-proxy-advisory-firm-iss-recommends-alexco-shareholders-vote-proposed-transaction-with-hecla/ | 2022-08-15T12:49:57Z |
STOCKHOLM, Aug. 15, 2022 /PRNewswire/ -- Securitas welcomes representatives from the financial market and media to an online Investor update on Wednesday, August 24, 2022, starting at 2.00 p.m. CEST to approximately 4.00 p.m. CEST.
Magnus Ahlqvist, President and CEO and Andreas Lindback, CFO, will make an update on our strategy and announce new financial targets following the acquisition of Stanley Security. Tony Byerly, Global President Securitas Technology, will also participate and answer questions.
2.00 p.m. Presentation followed by a Q&A session
To follow the web cast of the telephone conference via the web, please follow the link www.securitas.com/webcasts
Questions for the management can be placed by phone or through the webcast question form. To ask questions by phone, access to the teleconference register by clicking on the link To the teleconference
After the registration to the teleconference, you will be provided phone numbers and a conference ID to access the conference. If you wish to ask a question, please dial *5 on your telephone keypad to enter the queue.
If you register in beforehand, please note the telephone number and conference ID. Otherwise you need to register again.
A recorded version of the web cast will be available on the same web page after the telephone conference. We value your privacy and want to be transparent with you on the way that we collect and use your personal data when you participate in the telephone conference. Please follow this link to read our privacy policy for telephone conferences/web casts in relation to publication of interim reports and investor presentations: www.securitas.com/privacy-policy-audiocasts.
Further information:
Investors: Micaela Sjökvist, Vice President, Investor Relations; +46 76 116 7443, micaela.sjokvist@securitas.com
Media: Helena Andreas, SVP, Communications & People; +46 10 470 30 20, press@securitas.com
Securitas is a leading intelligent security solutions partner. Our guarding, electronic security, fire and safety, and risk management solutions enable more than 150,000 clients to see a different world. We are present in 47 markets and our innovative, data-driven approach makes us a trusted partner to many of the world's best-known companies. Our 345,000 employees live our values of integrity, vigilance and helpfulness, and our purpose is to help make your world a safer place.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Securitas | https://www.whsv.com/prnewswire/2022/08/15/invitation-securitas-investor-update/ | 2022-08-15T12:50:04Z |
A strong return to action for lottery jackpots drives surge in active customers and lottery revenues
VANCOUVER, BC, Aug. 15, 2022 /PRNewswire/ - Kings Entertainment Group Inc. ("Kings Entertainment" or the "Company"), an international online service provider for lottery, casino, and sportsbook gambling and parent company of global online gaming innovators LottoKings and WinTrillions, shared its corporate results for July today.
With U.S. seeing its first spike in jackpots of the year in July, the month saw a significant uptick in active customers and lottery revenues. Lottery sales jumped 18% over the previous month, with WinTrillions and Lotto Kings pulling in a combined $446,126 in July versus $378,329 in June. Overall revenue rose 9% in July to $555,349 versus $510,440 in June. Total active customers also increased by 9%.
"We're very pleased that July brought such a strong return to action for lottery jackpots," said Steve Budin, CEO of Kings Entertainment. "It's been a challenging year, without a significant lottery jackpot to promote – but we focused on keeping players active through the drought and are now seeing this effort pay off."
In May 2022, Kings Entertainment announced a business combination with Sports Venture Holdings, the parent company of the Bet99 brand, one of Canada's largest online sport and casino betting websites. This combination furthers the vision of Kings to build leadership positions within each of the regulation jurisdictions the Company enters.
Established in 2005, Kings Entertainment (CSE:JKPT) is an international online service provider for lottery, casino, and sportsbook gambling and parent company of global online gaming innovators LottoKings and WinTrillions, These brands leverage their ability to acquire high-potential players through renowned lottery offerings, then engage players in a range of casino and sportsbook offerings. LottoKings and WinTrillions have attracted and retained millions of player sign-ups since their inceptions.
This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that the Company anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements with respect to: listing of the Company's shares on the CSE; the Company's business and business plans; the Company's strategy and current focus on developing brands in the global online gaming market; the anticipated effect of the Company's listing; global market opportunities in the online gaming space, including in respect of anticipated growth, progress of legalization in various jurisdictions and growth in Latin America; and the expected use of the Escrowed Proceeds. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to the Company, including information obtained from third-party industry analysts and other third-party sources, and are based on management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Trading in the securities of the Company should be considered highly speculative.
Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this news release.
View original content to download multimedia:
SOURCE Kings Entertainment Group Inc. | https://www.whsv.com/prnewswire/2022/08/15/kings-entertainment-shares-july-corporate-highlights/ | 2022-08-15T12:50:10Z |
LEWISTON, Maine, Aug. 15, 2022 /PRNewswire/ -- Farmers' Almanac is proving once more that a 206-year-old publication is relevant, informative, entertaining, and popular. The 2023 edition is here and within this compact 8" x 5" package, you will not only find a cold winter outlook, but also an eclectic mix of calendars, charts, tips, and articles that offer valuable answers to life's secrets for happier, healthier, and more harmonious times.
More than a Magazine
"The Farmers' Almanac is a book, a calendar, a reference source, and a guide to great living," shares editor Pete Geiger, Philom., adding "it's a time capsule of important how-to's as well as when to do things." What kind of things? How about brew beer, can tomatoes, go fishing, plant a garden, get married, take a vacation, and watch a meteor shower.
But that's not all. Some of the most popular features in the Farmers' Almanac are life hacks that help you save money and time. (Did you know you could use bubble wrap to keep the cold air out of your home? Or freeze eggs for future use?) It also offers a unique blend of humor and inspirational thoughts called "philosofacts."
Originally named after the people of its time – farmers – the Farmers' Almanac is sometimes mistaken for a farm-only read. But if you pick up this 206th edition, you will see that it contains articles and advice for people with backyard balconies as well as folks with backyard chickens. "An entire year's worth of weather predictions is what make the Farmers' Almanac so famous," states Sandi Duncan, Philom., managing editor, "but the content is much more than weather or farm related. We share everything from the best times to view fall foliage to best days potty train your toddler."
The latest edition of the Farmers' Almanac contains articles on ways to help slow the effects of climate change, shares compelling reasons why pigeons should be appreciated, includes tips on ways to eat rather than rake acorns, doles out weather wisdom and lore, and includes newly designed charts and calendars that help readers glean helpful ideas for planning their gardens and year ahead. The 206th edition goes on sale August 15, and can be purchased at grocery and bookstores and online at FarmersAlmanac.com
Media Contacts:
Peter Geiger, Philom., Editor
pgeiger@farmersalmanac.com, 207-755-2246
Sandi Duncan, Philom., Mg. Editor
sduncan@farmersalmanac.com, 207-755-2349
View original content to download multimedia:
SOURCE Farmers' Almanac | https://www.whsv.com/prnewswire/2022/08/15/lifes-secrets-palm-your-hands/ | 2022-08-15T12:50:18Z |
ST. PETERSBURG, Fla., Aug. 15, 2022 /PRNewswire/ -- Lillian Finance LLC, a Medical Blockchain crypto company had an incredible breakout month despite the Crypto Bear market, seeing nearly a two hundred sixty percent gain.
As the first youth inspired, medically focused cryptocurrency, Lillian Finance is making history by creating an accessible financing vehicle with a charitable bent. Lillian utilizes the ascent and durability of cryptocurrency platforms such as blockchain to democratize the market and create wealth where it did not previously exist.
From the lab bench to billing, from diagnostics to data management, Lillian supports projects that break down the barriers to new knowledge by targeting areas of research and medical practice where real needs have been neglected. The goal is to solve problems in healthcare by employing a next generation financing system aimed at accelerating positive and innovative change.
"Despite the Crypto Bear market Lillian has delivered on everything as promised," explains Lillian Founder Brad Beatty. "Lillian Finance is currently having discussions with a few of the Largest Medical Fin-Tech companies as we continue to develop our Medical Blockchain solutions and Eco system. We are also working on listing Lillian Finance on a few Tier 1 Exchanges in the coming months. Our newest collaboration is with Brew Labs Inc, one of the leading Crypto staking and farming companies in the industry. Lillian had created three staking and farming pools developed to give Lillian holders an option of making a passive income."
In July Lillian launched on Shiba Swap, which is a large cryptocurrency trading platform developed by Shiba Inu. Since Shiba Swap listing Lillian Finance has seen great success in gains and holder count.
Lillian has put a stake in the ground by locking its Liquidity for 5 years and giving its investors peace of mind knowing it's not going anywhere. We use the industry's top liquidity locking Defi security company EverRise to secure our Liquidity.
Lillian went live on August 8, 2022, on a top 10 Globally traded exchange, BitMart. With 9 million users BitMart provides fast, secure, and professional crypto trading services, having $3.6 billion daily volume.
In August 2022 Lillian Bay Foundation was launched; a 501c3 named after founder Brad Beatty's daughter. The foundation is geared to fund and organize children's surgeries. Since launch, Lillian Bay Foundation has already delivered 3 successful surgeries and the website goes live this month.
Inspired by one girl's survival story, Lillian Finance identifies needs, opportunities, and problems in health care, by employing next generation blockchain technology and financing systems to improve the lives of millions of people worldwide. Investors are directly involved in helping children, since Lillian tokeonomics are designed in a way, that a percentage of every transaction goes to the foundation.
To purchase or learn more about the Lillian Finance project.
http://www.Lillianfinance.com | Info@LillianFinance.com
To Donate or learn more about the Lillian Bay Foundation.
http://www.Lillianbayfoundation.org | Info@Lillianbayfoundation.org
View original content to download multimedia:
SOURCE Lilly Finance | https://www.whsv.com/prnewswire/2022/08/15/lillian-finance-first-youth-inspired-medically-focused-cryptocurrency-is-making-history/ | 2022-08-15T12:50:24Z |
Second quarter revenue of $6.3 million, compared to $0.1 million in the prior year period
Georgia facility commenced commercial operations in July 2022
Announces Texas as location of next facility
Reaffirms full year 2022 guidance
HAMILTON, Mont., Aug. 15, 2022 /PRNewswire/ -- Local Bounti Corporation (NYSE: LOCL, LOCL WS) ("Local Bounti" or the "Company"), a breakthrough U.S. indoor agriculture company combining the best aspects of vertical and greenhouse growing technologies, today announced its second quarter 2022 results for the three months ended June 30, 2022 and reaffirmed full year 2022 guidance.
"We produced solid results and made important progress on our commercial facility expansion during the second quarter. The integration of Local Bounti and Pete's is progressing extremely well — we've had great engagement across the organization and I have been very impressed by our team and our expanded set of capabilities," stated Craig Hurlbert, Co-CEO of Local Bounti. "Looking ahead, we are especially excited about the recent opening of our Georgia facility and the commercial benefits it entails as we expand our footprint. We continue to bring fresh thinking and solutions to the industry and are implementing new elements in real-time that accelerate our build-out schedules and drive higher crop turns — the combination of which support our unwavering focus on capital efficiency."
- Sales of $6.3 million in the second quarter 2022, as compared to $108 thousand in the prior year period. Revenue from the Company's Hamilton, MT facility increased by 52% on a sequential basis in second quarter reflecting the pivot from R&D to commercial production, and the Company's California facilities increased revenue by 9% on a similar basis.
- Gross profit was negative $12 thousand in the second quarter of 2022. Adjusted gross margin percentage1 was approximately 38%, excluding depreciation, stock-based compensation, business combination related integration costs, and business combination fair value basis adjustment to inventory. The reduction in reported gross profit reflects temporary supply chain challenges with suppliers that have since been resolved, but impacted second quarter yields in its California facilities, resulting in higher costs to fill orders. In response to realized cost inflation, the Company expects to realize the benefit from price increases during the third or fourth quarter of 2022.
- Net loss of $31.7 million in the second quarter 2022. Adjusted EBITDA1 loss was $7.9 million excluding $11.7 million in stock-based compensation, $5.5 million in interest expense, $1.3 million of depreciation, $2.1 million of amortization, the fair value inventory adjustment mentioned above of $1.0 million, business combination and integration costs of $1.6 million and restructuring costs of $500 thousand. Net loss was $7.6 million in the prior year period and adjusted EBITDA loss was $3.5 million in the prior year period.
1See reconciliation of the non-GAAP measures at the end of this press release.
Next facility to be located in Texas
Local Bounti is currently in site diligence for its next facility to be located in eastern Texas. This location was selected based on customer demand and prospective off-take agreements.
Georgia facility commenced operations in July
As previously announced, the Company completed Phase 1-A construction of its Georgia facility in July 2022 — commencing commercial operations of three acres of the 24-acre plan. In parallel with Phase 1-A's completion, the Company began construction on Phase 1-B in June 2022, which will mirror Phase 1-A in terms of size and capabilities — doubling the capacity of the Georgia facility.
As a component of Phase 1-B's construction, the Company also began construction on the integration of its Stack & Flow Technology™ ("Stack & Flow"). Stack & Flow TechnologyTM will be integrated across both Phase 1-A and 1-B, which is expected to add approximately 40% of incremental revenue generating capacity to the finished Georgia facility. The Phase 1-B construction is expected to be completed in the second quarter of 2023 and commence operations in the third quarter 2023.
The Company continues to expect to achieve initial run-rate revenue of at least $30 million at full production from its California and Georgia (Phase 1-A) facilities, excluding the expected future positive impact from additional capacity due to incorporating Stack & Flow TechnologyTM at all three facilities.
California facility upgrades
The Company's two California facilities in Carpinteria and Oxnard are currently undergoing targeted and phased upgrades to existing infrastructure. The first phase, which is currently planned, will complete necessary infrastructure upgrades and increase near-term yields of select SKUs by an estimated 10%. The second phase, which is under consideration, will provide additional yield increases and create opportunities to grow new products, further expanding the Company's SKU diversity. The last phase will be to complete preparations for Stack & Flow TechnologyTM integration, which is expected to commence in 2023 given coordination and other planning measures with local utilities.
Pasco, Washington facility progress
The future Pasco, Washington facility continues to progress toward construction, which is expected to recommence in September. The site has been redesigned to further optimize operational synergies, to drive best in class unit economics, and to account for synergies with Pete's growing systems to meet demand across the combined product portfolio.
Hamilton, Montana update
The Company continues to advance its growing systems at its Hamilton, Montana facility. Year-to-date ended July 22, 2022, annualized yields from this facility have improved by approximately 20% versus the comparable prior year period. This direct and progressive improvement in yield is an apples-to-apples comparison highlighting the Company's ability to drive higher yields for current and future facilities. Importantly, these improvements do not reflect the impact of existing and future R&D enhancements and innovations that are expected to further accelerate performance at each of our facilities.
Addressing new growth verticals in high-value crop varieties
Beyond advancements to yield, the Company has identified additional opportunities and applications of its Stack & Flow TechnologyTM to reduce costs and increase yields across a variety of crops and growing environments. The Company is in the early trial stages of longer-term projects for high-value crops such as berries, and it continues to believe that its Stack & Flow TechnologyTM has a very important place in the future of agriculture.
Launching tests for new salad kit innovations in third quarter
Complementing the Company's existing product assortment is a new category of product innovation — premium salad kits. The SKUs will launch as tests with retailers in the Northwest through the end of 2022 in anticipation of a broader launch in 2023.
The Company ended the quarter with cash, cash equivalents and restricted cash of $41.3 million and approximately $41.8 million of undrawn capacity on its credit facility with Cargill. It had approximately 94.2 million basic and diluted shares outstanding as of June 30, 2022 and had an additional 11.5 million warrants outstanding and approximately 10.3 million restricted stock units outstanding.
Management is reaffirming its full year 2022 sales guidance of at least $20 million, including partial year contribution from its acquisition of Pete's which closed on April 4, 2022.
The Company will host a conference call with members of the Local Bounti executive management team. The conference call is scheduled to begin at 8:00 a.m. ET on Monday, August 15, 2022. To participate on the live call, listeners in North America may dial (877) 514-3623 and international listeners may dial (201) 689-8768.
In addition, the call will be broadcast live via webcast, hosted at the "Investors" section of the Company's website at localbounti.com and will be archived online.
Local Bounti is redefining indoor farming with an innovative method – its proprietary Stack & Flow Technology™ – that significantly improves crop turns, increases output and improves unit economics. Local Bounti operates advanced indoor growing facilities across the United States, servicing approximately 10,000 retail doors with its two brands: Local Bounti® and Pete's®. We grow healthy food utilizing a hybrid approach that integrates the best attributes of controlled environment agriculture with natural elements. Our sustainable growing methods are better for the planet, using 90% less land and 90% less water than conventional farming methods. With a mission to 'bring our farm to your kitchen in the fewest food miles possible,' Local Bounti's food is fresher, more nutritious, and lasts 3 to 5 times longer than traditional agriculture. To find out more, visit localbounti.com or eatpetes.com, or follow Local Bounti on LinkedIn for the latest news and developments.
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify these forward-looking statements by words such as "anticipate," "approximate," "believe," "commit," "continue," "could," "estimate," "expect," "hope," "intend," "may," "outlook," "plan," "project," "potential," "should," "would," "will" and other similar words or expressions. Forward-looking statements reflect the Company's current expectations or beliefs concerning future events and actual events may differ materially from historical results or current expectations. The reader is cautioned not to place undue reliance on these forward-looking statements, which are not a guarantee of future performance and are subject to a number of uncertainties, risks, assumptions and other factors, many of which are outside the control of the Company. The forward-looking statements in this press release address a variety of subjects including, for example, projected financial information, statements regarding estimates and forecasts of other financial and performance metrics, projected costs of building or acquiring facilities, projections of market opportunity and market share, and the business prospects of the Company following the Pete's transaction. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: Local Bounti's ability to effectively integrate the recently acquired operations of Pete's into its existing operations; the ability of Local Bounti to retain and hire key personnel; the uncertainty of projected financial information; Local Bounti's increased leverage as a result of additional indebtedness incurred in connection with the recent acquisition of Pete's; restrictions contained in Local Bounti's debt facility agreements with Cargill Financial Services International, Inc.; Local Bounti's ability to repay, refinance, restructure and/or extend its indebtedness as it comes due; and unknown liabilities that may be assumed in acquisitions; Local Bounti's ability to generate revenue; the risk that Local Bounti may never achieve or sustain profitability; the risk that Local Bounti could fail to effectively manage its future growth; the risk that Local Bounti will fail to obtain additional necessary capital when needed on acceptable terms, or at all; Local Bounti's ability to build out additional facilities; reliance on third parties for construction, delays relating to material delivery and supply chains, and fluctuating material prices; Local Bounti's ability to maintain its gross margin or decrease its cost of goods sold over time; potential for damage to or problems with Local Bounti's CEA facilities; Local Bounti's ability to attract and retain qualified employees; Local Bounti's ability to develop and maintain its brand or brands it may acquire; Local Bounti's ability to maintain its company culture or focus on its vision as it grows; Local Bounti's ability to execute on its growth strategy; the risks of diseases and pests destroying crops; Local Bounti's ability to compete successfully in the highly competitive natural food market; Local Bounti's ability to defend itself against intellectual property infringement claims; changes in consumer preferences, perception and spending habits in the food industry; seasonality; Local Bounti's ability to achieve its sustainability goals; and other risks and uncertainties indicated from time to time, including those under "Risk Factors" and "Forward-Looking Statements" in Local Bounti's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 30, 2022, as supplemented by subsequent Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K, and other reports and documents Local Bounti files from time to time with the SEC. Local Bounti cautions that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date hereof. Local Bounti does not undertake or accept any obligation or undertaking to update or revise any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
This press release contains references to adjusted EBITDA, adjusted gross profit, adjusted gross margin percentage and adjusted selling, general and administrative, which are adjusted from results based on generally accepted accounting principles in the United States ("GAAP") and exclude certain expenses, gains and losses. The Company defines and calculates adjusted EBITDA as net loss attributable to Local Bounti before the impact of interest expense, depreciation, amortization, and adjusted to exclude stock-based compensation expense, business combination fair value basis adjustment to inventory, business acquisition and strategic transaction due diligence and integration related costs, restructuring and business realignment costs, and certain other non-core items. The Company defines and calculates adjusted gross profit as gross profit excluding depreciation, stock-based compensation, business combination related integration costs, and business combination fair value basis adjustment to inventory. The Company defines and calculates adjusted gross margin percentage as adjusted gross profit as a percent of sales. The Company defines and calculates adjusted selling, general and administrative as selling, general and administrative expense excluding stock-based compensation, depreciation, amortization, business acquisition and strategic transaction due diligence and integration related costs, and restructuring and business realignment costs.
These non-GAAP financial measures are provided to enhance the user's understanding of the Company's prospects for the future and the historical performance for the context of the investor. The Company's management team uses these non-GAAP financial measures in assessing performance, as well as in planning and forecasting future periods. These non-GAAP financial measures are not computed according to GAAP and the methods the Company uses to compute them may differ from the methods used by other companies. Non-GAAP financial measures are supplemental, should not be considered a substitute for, or superior to, financial information presented in accordance with GAAP and should be read only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP.
Refer to the attached financial supplement for a reconciliation of these non-GAAP financial measures to their most directly comparable GAAP measures for the three and six months ended June 30, 2022 and 2021.
View original content to download multimedia:
SOURCE Local Bounti | https://www.whsv.com/prnewswire/2022/08/15/local-bounti-announces-second-quarter-2022-financial-results/ | 2022-08-15T12:50:30Z |
- Interim data from SUNRISE trial in four pediatric patients showed detectable levels of ALB-2A biomarker demonstrating site-specific gene insertion and protein expression
- Two of four patients demonstrated increasing ALB-2A levels over time, indicating expansion of edited hepatocytes carrying the corrective gene
- Proprietary manufacturing process, mAAVRx, has shown 15- to 30-fold yield increase over standard transfection processes
LEXINGTON, Mass., Aug. 15, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage genetic medicine company, today reported financial results for the second quarter ended June 30, 2022, and provided business updates, including early clinical data from its ongoing SUNRISE trial evaluating LB-001 in pediatric patients with severe methylmalonic acidemia (MMA).
"We are excited to continue to see GeneRide® demonstrating its ability to precisely knock in the correct version of a gene with a single intravenous infusion—a significant milestone in the field of genetic medicine," said Fred Chereau, president and chief executive officer of LogicBio. "Additionally, LogicBio's proprietary mAAVRx™ process has continued to show significant improvement in production yields. As quality and cost of goods in genetic medicine manufacturing remain a key priority, we intend to leverage mAAVRx for our development candidates and as a potential source for business development collaborations."
Interim SUNRISE Phase 1/2 Results
SUNRISE is a first-in-human, open-label, multi-center, Phase 1/2 clinical trial designed to assess the safety, tolerability, and preliminary efficacy of a single intravenous infusion of LB-001 in pediatric patients with MMA. LB-001 is designed to non-disruptively knock-in a corrective copy of the methylmalonyl-CoA mutase (MMUT) gene into the albumin locus to drive lifelong therapeutic levels of MMUT expression in the liver. LB-001 is based on the company's proprietary GeneRide technology, which uses homologous recombination, a natural DNA repair process, to enable precise editing of the genome without the need for exogenous nucleases and promoters that have been associated with an increased risk of immune response and cancer. Detection of the technology-related biomarker albumin-2A (ALB-2A) in the serum indicates MMUT gene integration and MUT protein expression. Increasing levels of ALB-2A suggest the expansion of the edited cells over time.
The Phase 1/2 interim results include safety and efficacy data from four patients treated with a single intravenous infusion of LB-001 at dose level 5e13 vg/kg. The first two patients dosed were in the three to 12 years old age group and experienced no drug-related serious adverse events (SAEs). As previously disclosed, the third and fourth patients, who were in the six months to two years old age group, each experienced a drug-related SAE, categorized as thrombotic microangiopathy (TMA). The TMA events have resolved, and both patients remain in the study. Based on dialogue with the U.S. Food and Drug Administration (FDA), the SUNRISE protocol was amended to include enhanced monitoring measures, including frequent testing for complement activation, a characteristic of TMA, as well as the use of a complement inhibitor in the event there are laboratory findings indicating a potential or imminent TMA. Additionally, prior to the TMA event, the fourth patient experienced a grade 1 drug-related SAE that was categorized as cytokine release syndrome and necessitated an additional day in the hospital post-dosing.
In addition to safety and tolerability, SUNRISE is designed to evaluate preliminary efficacy through biomarkers such as ALB-2A, a technology-related biomarker, as well as several others related to the disease itself, including methylmalonic acid, methylcitric acid, fibroblast growth factor 21 (FGF21) and propionate oxidation. ALB-2A has been detected in the serum of all four patients, which indicates site-specific integration of the MMUT gene. In two of the four patients, increasing levels of ALB-2A were seen over time, indicating selective advantage. Selective advantage enables edited hepatocytes carrying the corrective gene to survive and reproduce better than the endogenous mutated hepatocytes and to ultimately repopulate a part or whole of the diseased liver. The disease-related biomarkers, including methylmalonic acid, methylcitric acid, propionate oxidation and FGF-21, were variable and do not show a clear trend to date.
"These early results from the first four pediatric patients treated with LB-001 validate the proof of mechanism for our novel GeneRide genome editing technology," said Dr. Daniel Gruskin, chief medical officer of LogicBio. "The interim data suggest that a single systemic administration of LB-001 can lead to precise insertion of a corrective copy of the MMUT gene in the patient's hepatocytes. While the increase in ALB-2A is a promising sign, based on an analysis of preclinical and clinical data generated to date, we believe that significant additional time would be needed to determine clinical efficacy. I would like to thank the patients, their families, and the investigators who are participating in this ground-breaking trial. We look forward to continuing to better understand the biochemical and clinical effect of our genome editing therapy."
The company plans to continue observing the four patients through the long-term follow-up study to the SUNRISE trial where efficacy parameters will continue to be measured per protocol. As previously disclosed, the company expects to dose the next patient in the SUNRISE trial in the third quarter.
Recent Business Highlights:
- In May, the FDA lifted the clinical hold on LogicBio's Investigational New Drug Application (IND) for LB-001, allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial in pediatric patients with MMA.
- In May, LogicBio presented four abstracts highlighting the company's GeneRide® technology in preclinical hereditary tyrosinemia type 1 (HT1) models and optimized adeno-associated virus (AAV) manufacturing processes at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting in Washington D.C.
- As part of the ASGCT presentations, LogicBio highlighted mAAVRx, its new proprietary manufacturing process. mAAVRx is an improved transient transfection of suspension cells, which has shown a 15- to 30-fold increase in vector yields compared to standard upstream processes.
Second Quarter 2022 Financial Results:
Three Months Ended June 30, 2022 and 2021
- Revenue: Revenue for the quarter ended June 30, 2022 consisted of $3.2 million in collaboration and service revenue recognized under our April 2021 agreements with CANbridge Care Pharma Hong Kong Limited (CANbridge) and Daiichi Sankyo Company, Limited (Daiichi Sankyo). Revenue for the quarter ended June 30, 2021 consisted of $0.8 million in collaboration and service revenue related to our arrangements with CANbridge, Daiichi, and our agreement with Takeda Pharmaceutical Company Limited (Takeda).
- R&D Expenses: Research and development expenses for the quarter ended June 30, 2022 were $4.8 million, compared to $7.3 million for the quarter ended June 30, 2021. The decrease of approximately $2.4 million was primarily due to a decrease of $1.2 million in LB-001 external development and manufacturing costs incurred during second quarter 2021 to start up the LB-001 SUNRISE clinical trial and a $1.0 million decrease in other research and development costs primarily related to one-time intellectual property costs that occurred as a result of entering into the April 2021 collaboration agreement with CANbridge.
- G&A Expenses: General and administrative expenses were $3.3 million for the quarter ended June 30, 2022, compared to $3.8 million for the quarter ended June 30, 2021. The decrease of approximately $0.5 million was primarily driven by a decrease of approximately $0.5 million in professional service fees as we brought more professional work in-house through key hires made during 2021.
- Net Loss: Net loss for the quarter ended June 30, 2022 was $5.0 million or $0.15 per share, compared to a net loss of $10.5 million, or $0.33 per share, for the quarter ended June 30, 2021.
- Cash Position: As of June 30, 2022, we had cash and cash equivalents of $38.8 million as compared to $53.5 million as of December 31, 2021. As of June 30, 2022, we had 32,962,733 shares outstanding.
- Financial Guidance: Based upon our current operating plan, we believe that our $38.8 million in cash and cash equivalents as of June 30, 2022 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023.
About LogicBio Therapeutics
LogicBio® Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide®, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company's proprietary manufacturing process, mAAVRx™, aims to overcome one of the current limitations of AAV manufacturing by improving yields and product quality. The company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.
About LB-001
LB-001 is an investigational, first-in-class, single-administration, genome editing therapy for early intervention in methylmalonic acidemia (MMA) using LogicBio®'s proprietary GeneRide® drug development platform. GeneRide technology utilizes a natural DNA repair process called homologous recombination that enables precise editing of the genome without the need for exogenous nucleases and promoters that have been associated with an increased risk of immune response and cancer. LB-001 is designed to non-disruptively insert a corrective copy of the methylmalonyl-CoA mutase (MMUT) gene into the albumin locus to drive lifelong therapeutic levels of MMUT expression in the liver, the main site of MMUT expression and activity. LB-001 is delivered to hepatocytes intravenously via liver-targeted, engineered recombinant adeno-associated virus vector (rAAV-LK03). Preclinical studies found that LB-001 was safe and demonstrated transduction of hepatocytes, site-specific genomic integration, and transgene expression. LB-001–corrected hepatocytes in a mouse model of MMA demonstrated preferential survival and expansion (selective advantage), thus contributing to a progressive increase in hepatic MMUT expression over time. LB-001 resulted in improved growth, metabolic stability, and survival in MMA mice. The U.S. Food and Drug Administration (FDA) granted fast track designation, rare pediatric disease designation and orphan drug designation for LB-001 for the treatment of MMA. In addition, the European Medicines Agency (EMA) granted orphan drug designation for LB-001 for the treatment of MMA.
About Methylmalonic Acidemia (MMA)
Methylmalonic acidemia (MMA) is a rare and life-threatening genetic disorder affecting approximately 1 in 50,000 newborns in the United States. In the most common form of MMA, a mutation in a gene called methylmalonyl-CoA mutase (MMUT) prevents the body from properly processing certain fats and proteins. As a result, toxic metabolites accumulate in the liver, in muscle tissue and in the brain. Symptoms include vomiting, lethargy, seizures, developmental delays and organ damage. There is no approved medical therapy addressing the underlying cause of the disease. To manage the symptoms, patients go on a severely restrictive, low-protein, high-calorie diet, often through a feeding tube. Even with aggressive management, these patients often experience life-threatening metabolic crises that can require recurrent hospitalizations and cause permanent neurocognitive damage. Because of this risk for irreversible damage, early intervention is critical, and newborns are screened for MMA in every state in the United States.
Forward-Looking Statements
Statements in this press release regarding LogicBio®'s strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, including but not limited to statements the potential of the GeneRide® platform; the potential of LB-001, including its ability to lead to precise insertion; our ability to leverage mAAVRxTM for our development candidates or any potential business development collaborations; the potential expansion of edited cells and timing thereof; the amount of time necessary to demonstrate clinical efficacy; and the anticipated timing of when we expect to dose the next patient. The terms "believe," "look forward," "future," "intend," "designed," "potential," "suggests," "plans," "expects" and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the risk that existing preclinical and/or clinical data may not be predictive of the results of ongoing or later preclinical and/or clinical results; the risk that we may not be successful in efforts to leverage our technologies for business development or otherwise; risks associated with management and key personnel changes and transitional periods; the actual funding required to develop and commercialize product candidates, including for safety, tolerability, enrollment, manufacturing or economic reasons; the timing and content of decisions made by regulatory authorities; the actual time it takes to initiate and complete preclinical and clinical studies, including the actual time it takes to demonstrate clinical efficacy; the competitive landscape; changes in the economic and financial conditions of LogicBio. Other risks and uncertainties include those identified under the heading "Risk Factors" in LogicBio's Annual Report on Form 10-K for the year ended December 31, 2021 and other filings that LogicBio may make with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and LogicBio does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
Media Contacts:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com
View original content:
SOURCE LogicBio Therapeutics, Inc. | https://www.whsv.com/prnewswire/2022/08/15/logicbio-therapeutics-reports-second-quarter-2022-financial-results-provides-corporate-update/ | 2022-08-15T12:50:37Z |
WASHINGTON, Aug. 15, 2022 /PRNewswire/ -- MAG Aerospace has won the Army Program Executive Office Intelligence, Electronic Warfare and Sensors (PEO IEW&S) Project Manager Electronic Warfare & Cyber (PM EW&C) Systems Engineering Technical Assistance (SETA) task order under the Responsive Strategic Sourcing for Services (RS3) multiple award IDIQ contract. This task order has a ceiling value of approximately $258 million with a performance of a 1-year base period and four 1-year option periods. This is MAG's third consecutive win of this contract.
"We take great pride in the confidence PEO IEW&S and PM EW&C has entrusted in MAG to continue to deliver high-quality support on this task order." said Jerry Rippon, Executive Vice President of MAG's Advanced Engineering & Technology (AET) Business Unit. "We look forward to continuing our long-term relationship with PM EW&C, as we support one of the most important initiatives in the Army and the Electronic Warfare and Cyber mission to acquire integrated Intelligence, Electronic and Cyber Warfare capabilities that provide Spectrum and Cyberspace Superiority to enable freedom of maneuver on the Battlefield."
Support under this task order spans across 5 product management offices, (Product Manager Information Warfare (PdM IW), Product Manager Electronic Warfare Integration (PdM EWI), Product Manager Terrestrial Spectrum Warfare (PdM TSW), Product Lead Electronic Attack (PL EA), Product Lead Tactical Space Superiority (PL TSS)) responsible for the development, acquisition, production, fielding, and sustainment of Programs of Record and Quick Reaction Capabilities. This includes support in a diverse range of program/business management services, technical/engineering support services, and logistics support services that span the total life-cycle of PM EW&C systems. All must be planned and executed in coordination with multiple units and organizations, with special consideration for the US Army war-fighting mission and the current Operations Tempo (OPTEMPO) of US Army war-fighting units as they undergo exercises and training events, deployment, operations, redeployment and reset. The PM EW&C mission also supports a series of Army, Joint, and Combined experiments, demonstrations and exercises that will help define the concepts, requirements, doctrine and equipment for the continued modernization and transformation of the Army.
"Ensuring the protection of Electronic and Cyber Warfare capabilities that provide Spectrum and Cyberspace Superiority to the Warfighter is one of the most critical responsibilities in the Army and the Electronic Warfare and Cyber mission," said Joseph Reale, CEO of MAG. "We are proud to partner with PEO IEW&S and Project Manager Electronic Warfare & Cyber in achieving their vision for an Army equipped with upgradable, integrated and networked SIGINT, EW, Cyber and Space Superiority capabilities to overmatch the threat in multi and joint all domain operations."
Distribution Statement A: Approved for Public Release. Distribution is Unlimited. U.S. Army PM EW&C PRAS-830.
View original content to download multimedia:
SOURCE MAG Aerospace | https://www.whsv.com/prnewswire/2022/08/15/mag-aerospace-wins-258m-army-program-executive-office-intelligence-electronic-warfare-sensors-peo-iewamps-project-manager-electronic-warfare-amp-cyber-pm-ewampc-systems-engineering-technical-assistance-contract/ | 2022-08-15T12:50:43Z |
RADNOR, Pa., Aug. 15, 2022 /PRNewswire/ -- Main Line Health today announced that its acute care hospitals have been rated as top national performers in the Centers for Medicare & Medicaid Services' (CMS) latest Overall Hospital Quality Star Ratings, with Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital all ranked in the highest tiers.
The overall ratings show how well each hospital performed on average compared to others in the United States. The ratings range from one to five stars. Results are based on data from 2020 and 2021, highlighting Main Line Health's commitment to quality and safety during the pandemic.
Main Line Health acute care hospitals received the following ratings:
- Lankenau Medical Center — 5 stars
- Bryn Mawr Hospital — 5 stars
- Paoli Hospital — 5 stars
- Riddle Hospital — 4 stars
The Overall Hospital Quality Star Ratings summarize data from a variety of measures across five categories—mortality, safety of care, readmission, patient experience, and timely and effective care. Overall, 13.8% of hospitals received 5 stars.
"This is an incredible achievement but is no surprise," said Jack Lynch, FACHE, President and Chief Executive Officer, Main Line Health. "Every day, our employees, medical staff and volunteers go above and beyond to ensure that patients receive the highest quality of care. Achieving excellence in patient safety and patient experience is not just the responsibility of those at the bedside. It involves a collective commitment by every member of our team because we all have a role in making Main Line Health a great place to give and receive care. Congratulations to all of our employees for their dedication to our patients, visitors and staff."
For more information about the ratings, visit the CMS Care Compare site.
About Main Line Health
Founded in 1985, Main Line Health is a not-for-profit health system serving Philadelphia and its western suburbs. Main Line Health's commitment—to deliver advanced medicine for treating and curing disease, playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to be the region's premier choice for clinical care, research, and education. A team of more than 10,000 employees, 3,000 nurses and 2,000 physicians care for patients throughout the Main Line Health System.
At Main Line Health's core are four of the region's most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation's premier facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region's largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care, and service, including U.S. News & World Report's Best Hospitals, System Magnet® designation; the nation's highest distinction for nursing excellence and the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award. Main Line Health is committed to creating an environment of diversity, respect, equity, and inclusion, has proudly received awards in this area and has embraced the American Hospital Association's #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education, and research to help patients stay healthy and live their best lives.
View original content to download multimedia:
SOURCE Main Line Health | https://www.whsv.com/prnewswire/2022/08/15/main-line-health-hospitals-are-top-performers-new-centers-medicare-amp-medicaid-services-ratings/ | 2022-08-15T12:50:51Z |
MIAMI, Aug. 15, 2022 /PRNewswire/ -- CEO Coaching International, the leading CEO coaching firm for growth-focused CEOs and entrepreneurs globally, is pleased to announce Aakash Shah as its newest Partner and Coach.
Shah is an entrepreneurial executive with rapid business scale-up experience in the industrial value-added distribution and asset light manufacturing space, as well as in specialty chemicals and ingredients. Shah is also a longtime private investor in direct-to-consumer startups, sports technology funds, and emerging technologies, like blockchain.
Some notable highlights from Shah's career include:
- Turning around a struggling family business from declining revenue of $3 million to $100 million in sales at exit.
- Scaling and professionalizing a specialty chemicals/ingredients business and selling it to private equity on two separate occasions, most recently in December 2021 for a nine-figure exit.
- Starting a grassroots asset light manufacturing plant making value-added, higher-than industry-average gross margins.
- Completing multiple acquisitions and successfully integrating them into a platform company.
- Currently involved as a private equity board member active with mergers and acquisitions.
"Aakash is a highly successful entrepreneur who is deeply experienced in helping businesses achieve rapid sales growth and prepare for a BIG exit. He is a proven expert in family business, having taken his own family business from floundering to flourishing at its exit," said Mark Moses, CEO and Founding Partner of CEO Coaching International. "He is an excellent addition to our team and will provide invaluable guidance to other leaders looking to achieve extraordinary growth."
"I'm excited to help fellow entrepreneurs and business owners grow their business beyond their wildest dreams by being a strong resource for them," Shah said.
Shah was recently a featured guest on the CEO Coaching International podcast, where he discussed the "4 Keys to Preparing Your Business for Sale to Private Equity."
Shah has an undergraduate degree in Chemical Engineering from Northwestern University and an MBA in International Business and Marketing from the Kellogg School of Management. He is a guest lecturer at Kellogg and at Columbia Business School (NY) on the topics of Family Business, Private Equity, and Mergers and Acquisitions. In addition, Aakash is an active member of YPO globally and attends many continuing education programs, most recently having completed an executive program at London Business School.
To schedule a complimentary introduction call with Aakash Shah or another one of the CEO Coaching International coaches, visit: CEOCoachingInternational.com/Coach/Aakash-Shah/
CEO Coaching International works with CEOs and their leadership teams to achieve extraordinary results quarter after quarter, year after year. Known globally for its success in coaching growth-focused entrepreneurs to meaningful exits, CEO Coaching International has coached more than 1,000 CEOs and entrepreneurs in more than 60 countries and 45 industries. The coaches at CEO Coaching International are former CEOs, presidents, or executives who have made BIG happen. The firm's coaches have led double-digit sales and profit growth in businesses ranging in size from startups to over $10 billion, and many are founders that have led their companies through successful eight, nine, and ten-figure exits. Companies working with CEO Coaching International for three years or more have experienced an average EBITDA CAGR of 30.4% during their time as a client, more than three times the U.S. average and a revenue CAGR of 18.6%, nearly twice the U.S. average. For more information, please visit: https://www.ceocoachinginternational.com.
View original content to download multimedia:
SOURCE CEO Coaching International | https://www.whsv.com/prnewswire/2022/08/15/mampa-rapid-sales-growth-expert-family-business-entrepreneur-joins-ceo-coaching-international/ | 2022-08-15T12:50:57Z |
HOUSTON, Aug. 15, 2022 /PRNewswire/ -- McDermott International has been awarded a Pre Front-End Engineering Design (Pre-FEED) contract from Woodside Energy for the proposed H2Perth project located in the Kwinana/Rockingham area in Western Australia.
Under the contract scope McDermott will provide pre-FEED services for a proposed export-scale production facility for renewable and lower-carbon hydrogen and ammonia. Hydrogen will be produced using electrolysis technologies and natural gas reforming with carbon emissions abated or offset.
"This award follows the successful completion of the concept study on H2Perth and decades of experience executing both onshore and offshore projects for Woodside Energy," said Tareq Kawash, Senior Vice President, Onshore of McDermott. "We are pleased to continue supporting Woodside's energy transition opportunities and are mutually aligned on the importance of driving lower-carbon energy to advance Australia's vision as a global leader in clean, innovative, safe and competitive hydrogen production."
Work on the project will be executed from McDermott's office in Perth, Australia, and its engineering centre of excellence in The Hague, the Netherlands.
McDermott is a premier, fully-integrated provider of engineering and construction solutions to the energy industry. Our customers trust our technology-driven approach engineered to responsibly harness and transform global energy resources into the products the world needs. From concept to commissioning, McDermott's innovative expertise and capabilities advance the next generation of global energy infrastructure—empowering a brighter, more sustainable future for us all. Operating in over 54 countries, McDermott's locally-focused and globally-integrated resources include more than 30,000 employees, a diversified fleet of specialty marine construction vessels and fabrication facilities around the world. To learn more, visit www.mcdermott.com.
McDermott cautions that statements in this communication which are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties. These forward-looking statements include, among other things, statements about the expected scope and execution of the project discussed in this press release. Although we believe that the expectations reflected in those forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Those statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, among others: adverse changes in the markets in which we operate or credit or capital markets; our inability to successfully execute on contracts in backlog; changes in project design or schedules; the availability of qualified personnel; changes in the terms, scope or timing of contracts, contract cancellations, change orders and other modifications and actions by our customers and other business counterparties; changes in industry norms; actions by lenders, other creditors, customers and other business counterparties of McDermott and adverse outcomes in legal or other dispute resolution proceedings. If one or more of these risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of McDermott's management as of the date hereof. Except to the extent required by applicable law, McDermott undertakes no obligation to update or revise any forward-looking statement.
Contacts:
Global Media Relations
Reba Reid
Senior Director, Global Communications and Marketing
+1 281 588 5636
RReid@McDermott.com
Local Media Relations
Barbara Knight
Senior Director, Business Line Communications and Marketing
+971 56 403 2903
BBKnight@McDermott.com
View original content to download multimedia:
SOURCE McDermott International, Ltd | https://www.whsv.com/prnewswire/2022/08/15/mcdermott-awarded-pre-feed-contract-proposed-h2perth-project-woodside-energy/ | 2022-08-15T12:51:03Z |
TORONTO, Aug. 15, 2022 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2022.
Streamlining and Focusing Operations
- On April 20th, experienced Pharma and Med Tech executive David Pidduck was named Chief Executive Officer and Director of the Company.
- Subsequent to the quarter, entered into a Share Purchase Agreement for the sale of MediPharm Labs Australia PTY for a minimum of AUD$6.9M, which is expected to close in Q3 or Q4 2022. The sale strengthens the balance sheet while enhancing capacity utilization at the Company's Canadian GMP facility. The Company expects to save approximately $4M in expenses annualized following the sale of this facility.
- Implemented a restructuring plan that will reduce Canadian non-manufacturing headcount by approximately 30%, reducing annualized expenses by approximately $3M beginning in Q3 2022.
- Engaged strategic M&A advisors to assess inorganic growth opportunities
Continued Progress Towards Leadership in the Cannabis-Based Pharmaceutical Opportunity
- Subsequent to the quarter, entered into a research support agreement with the Keck School of Medicine of University of Southern California to conduct a Phase 2 trial on the efficacy of THC and CBD to treat hospice-eligible patients diagnosed with dementia and experiencing agitation. The lead investigators have been awarded a total of US$16M in the form of grants from the US National Institute of Health and the National Institute on Aging.
Further Expansion of International Medical Business
- The Company's German partners, such as STADA, generated sequential growth in patient sales during Q2. MediPharm expects inventory replenishment by these partners during H2 2022 to have an incrementally positive impact on wholesale sales.
- Subsequent to the quarter, MediPharm received its first regulatory permits to ship GMP API to Denmark.
- Received its first commercial volume import permits from the Brazilian Health Regulatory Agency (Anvisa). Brazil is a large potential market with rigorous regulatory oversight. MediPharm is a one of only a few manufacturers with approved products for sale under the country's medical access program and has the only authorization for a product produced in Canada. First commercial shipments to Brazil are expected to be delivered in H2 2022.
Innovation and New Product Launches Drive Canadian Distribution Growth
- MediPharm began distributing Shelter Cannabis dried flower products in late Q2, beginning in Ontario, BC, and Alberta, followed by Quebec and Saskatchewan. Initial product feedback and demand has been positive.
- The Company successfully launched its innovative CBN and CBD soft chew, and a novel all-in one rechargeable vape pen and vape cartridge variety pack with three units per package. These products were delivered to the Ontario Cannabis Store warehouse in July and were available to consumers at the beginning of August, with plans to expand nationally in the coming months.
- As the Company continues to expand its portfolio to grow future sales, the MediPharm wellness cannabis oil remains a core product line. In Q2 2022, MediPharm held the number two market share nationally in this subcategory.
Solid balance sheet, materially debt free, outright ownership of key assets
- In July, the company was awarded a favourable summary judgment in the Ontario Court of Justice in connection with a supply agreement dispute in the amount of $9.8M. This summary judgement and subsequent payment, and the conditional sale of the Australian facility, are expected to add over $16M in cash to the balance sheet.
- The Company remains materially debt free and has outright ownership of its assets, including its GMP facility in Ontario.
David Pidduck, CEO, MediPharm Labs commented, "I joined MediPharm in late April, and we immediately increased our focus on improving efficiency, maximizing capacity utilization and re-allocating capital to the core opportunities that will maximize revenue growth potential. I continue to be impressed by the team's focus on being one of the most Pharma focused companies in the global Cannabis market. Our quality processes and GMP approach allow us to participate in the Pharmaceutical cannabis market, while being early entrants into large evolving international Cannabis markets that require GMP licences. The recent signing of a research agreement with the Keck School of Medicine at USC provides further evidence that MediPharm is well-positioned as a strong Pharma cannabinoid partner."
Mr. Pidduck, continued, "We will continue to push on innovation in the Canadian market and this quarter saw eight product launches. July saw the approval of four new products in the German market, which combined with the beginning of commercial shipments to Brazil, should contribute to growing international sales in the second half of the year. While we have more work to do, I am pleased with our progress over the past few months, and I look forward to continuing to update shareholders as we focus on driving efficiency and revenue growth."
Greg Hunter, CFO, MediPharm Labs added, "In Q2 MediPharm made notable progress growing its revenue base, reducing cash burn, and driving toward sustainable growth and profitability. The combination of the sale of our Australian asset and recent Canadian restructuring should result in approximately $7M in annualized savings beginning in Q3. With a strong cash balance of $22 million and no material debt, we are well positioned to take advantage of the growing global cannabis pharmaceutical and wellness markets."
MediPharm will host a conference call and webcast to discuss the Company's financial results and outlook.
Date: August 15, 2022 | Time: 8:30 a.m. ET
Conference ID: 4921762
Participant Dial-in: +1 (888) 330-2454 / International number: +1 (240) 789-2714
(Participants are asked to dial in approximately 15 minutes before the start of the call)
An audio webcast will be available in the Events section of the MediPharm website https://www.medipharmlabs.com/investors or by visiting the following link here.
For those who are unable to participate on the live conference call or webcast, a replay will be available approximately one hour after completion of the call.
Adjusted EBITDA and adjusted Gross Profit are not recognized performance measures under IFRS, do not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers. Adjusted EBITDA and adjusted Gross Profit are included as a supplemental disclosure because Management believes that such measurement provides a better assessment of the Company's operations on a continuing basis by eliminating certain non-cash charges and charges or gains that are non-recurring. Adjusted EBITDA is defined as net loss excluding interest, taxes, depreciation and amortization expense, interest income and expense, finance fees, gain in revaluation of derivative liabilities, taxes, impairment losses on inventory, write down of deposits and share-based compensation. Adjusted EBITDA has limitations as an analytical tool as it does not include depreciation and amortization expense, interest income and expense, taxes, share-based compensation and transaction fees. Because of these limitations, Adjusted EBITDA should not be considered as the sole measure of the Company's performance and should not be considered in isolation from, or as a substitute for, analysis of the Company's results as reported under IFRS. The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is operating income (loss). The above is a reconciliation of the Company's operating loss to Adjusted EBITDA. See "Reconciliation of non-IFRS measures" in the Company's Management's Discussion and Analysis for the period ended December 31, 2021, for additional information. Adjusted gross profit is defined as gross profit/(loss) excluding the adjustments for accelerated depreciation, write down of non-current deposits and write down of inventory. Adjusted gross profit is a useful measure as it represents gross profit for management purposes based on costs to manufacture, package and ship inventory sold, exclusive of any impairments due to changes in internal or external influences.
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment Licence from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing Licence for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: cash savings from the sale of the Australian facility and the corporate restructuring; the collection of the favourable summary judgment; the closing of the sale of the Australian facility; potential for material revenue growth for years to come; and the Company's transition towards pharmaceutical and medical markets reaching new heights. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
View original content to download multimedia:
SOURCE MediPharm Labs Corp. | https://www.whsv.com/prnewswire/2022/08/15/medipharm-labs-reports-second-quarter-results/ | 2022-08-15T12:51:10Z |
Reach Out and Read program provides free books to children birth-5 years of age at well-child visits
DETROIT, Aug. 15, 2022 /PRNewswire/ -- Meridian of Michigan, a leading provider of government-sponsored health plans in the state, and Grace Health in Battle Creek, have partnered to foster the development of early literacy skills among children as part of its pediatric primary care program, Reach Out and Read.
Through the program, Grace Health provides books to children birth to 5 years of age at their well-child visit. During the visit, the provider discusses with the parent or guardian the importance of reading to and with a child.
"Grace Health is committed to serving our community in every possible way, and one of those ongoing initiatives is related to child development," said Diane Craig, coordinator of the Reach Out and Read program at Grace Health.
Research conducted by the national Reach Out and Read program found it is important for a child's development to receive books during the younger years. Children receiving books at a young age are better prepared for school, and it helps with brain development.
"At Meridian, we recognize the value of treating the whole child as part of routine primary care practice," said Dr. Kay Judge, Meridian's Chief Medical Officer. "Research shows that a child's experiences early in life are critical to their ability to achieve their potential and become a productive member of society."
In 2021, Grace Health distributed more than 5,500 books. Earlier this year, Meridian donated $5,000, which will fund four months' worth of books.
"We provide this program because it helps our patients and aids in the development of children – linking healthcare and education, which helps build stronger kids," said Craig.
###
Meridian in Michigan provides government-sponsored managed care services to families, children, seniors, and individuals with complex medical needs primarily through Medicaid (Meridian), Medicare Advantage and Medicare Prescription Drug Plans (Wellcare), Medicare-Medicaid Plans (MeridianComplete), and the Health Insurance Marketplace (Ambetter from Meridian). Meridian is a wholly owned subsidiary of Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives. For more information about Meridian, visit mimeridian.com.
Grace Health, dually designated Federally Qualified Health Center: Community Health Center and Health Care for Homeless provider, began delivering primary health care to Calhoun County, Michigan residents in 1986. Additional services were added to meet community needs. Services include Family Practice, Internal Medicine, OB/GYN, Pediatrics, Behavioral Health, Dental, Optometry/Vision Care, Podiatry, Physical Therapy, and Pharmacy. Grace Health operates from its main site in Battle Creek and 12 additional sites located throughout the County, including public schools. Grace Health's target populations are un(der)served, low/no income and un(der)insured persons. For more information about Grace Health, visit https://www.gracehealthmi.org.
View original content to download multimedia:
SOURCE Meridian of Michigan | https://www.whsv.com/prnewswire/2022/08/15/meridian-michigan-grace-health-prescribe-reading-young-children/ | 2022-08-15T12:51:17Z |
The event features some of the leading influencers in the legal and compliance space with over 30 sessions, including AI integrated product releases
AUSTIN, Texas, Aug. 15, 2022 /PRNewswire/ -- Today, Mitratech, a leading global provider of legal, compliance, and HR software, kicks off its customer conference, Interact, in Nashville TN. The annual event brings over 300 of the best minds in legal and claims, compliance, risk, and HR for two-and-a-half days of exclusive user insights and networking. With more than 30 panels, workshops, keynotes and presentations, the event runs from August 14-17.
This year will feature notable speakers in the legal and GRC space including Ryan O'Leary
Research Director, Privacy and Legal Technology at IDC, Michael Rasmussen, GRC analyst from GRC 20/20, Rohit Gulati from HBR Consulting, Justin Hectus, CIO at KP Labs, and many more.
"We are thrilled to host platform experts, industry voices, and strategic partners at Interact 2022. They will be covering an array of topics that have been carefully tailored to the specific needs of our customer base," said Mike Williams, CEO of Mitratech. "This can't-miss event is a unique chance for our customers to supercharge their organization's platform capabilities, network with their peers and get to know Mitratech's rapidly expanding global network."
Mitratech will also be announcing the release of several product developments at Interact, including TeamConnect InvoiceIQ, a new suite of features within Mitratech's flagship enterprise legal management product that operationalizes the latest machine learning technologies.
Mitratech's enterprise risk product, Alyne, will showcase new cutting edge AI-driven capabilities for document summarization and evidence checking to help companies understand complex documents and streamline audit processes. Additionally, Mitratech's contract management product, EraCLM, will reveal a set of integrations with leading word processing and CRM tools.
Interact 2022 is sponsored by Morae Global Corporation, HBR Consulting LLC, Black Kite Technologies, Kroll LLC, PwC, Consilio LLC, Wisetime (an Anaqua Company), FTI Consulting Inc, Kranium Consulting, KP Labs, Uplevel Ops, and the Clear Law Institute, LLC.
For more information: https://mitratech.com/interact/
Mitratech is a proven global technology partner for corporate legal, risk, compliance, and HR professionals seeking to maximize productivity, control expense, and mitigate risk by deepening organizational alignment, increasing visibility, and spurring collaboration across an enterprise. Mitratech serves over 2,000 organizations worldwide spanning more than 160 countries.
For more info, visit: www.mitratech.com
View original content to download multimedia:
SOURCE Mitratech Holdings Inc | https://www.whsv.com/prnewswire/2022/08/15/mitratech-kicks-off-its-annual-interact-conference-nashville/ | 2022-08-15T12:51:24Z |
- Continued advancement across clinical and preclinical programs; on track with multiple milestones and key data readouts expected through the second half of 2022
- Company has sufficient capital to fund operations beyond mid-2024
HOUSTON, Aug. 15, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended June 30, 2022. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
"The first half of this year has been marked by demonstrated execution resulting in clinical progress, and importantly, continued compelling safety and efficacy data across our development pipeline. As we look to the remainder of the year, we are committed to operational excellence, driving our clinical programs forward and meeting our expected data readout timelines. Based on the progress and positive data demonstrated to date, we believe we are well positioned to continue to execute on our clinical milestones and potentially offer solutions for patients across a number of indications," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin.
Recent Highlights
- Announced the conclusion of the Phase 1b portion of its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (STS lung mets) and opened recruitment for the Phase 2 portion of the trial.
- Received allowance to proceed with Phase 1/2 study of Annamycin in combination with Cytarabine for the treatment of Acute Myeloid Leukemia (AML).
- Commenced dosing in the Phase 1a clinical trial evaluating WP1122 in healthy volunteers in the United Kingdom (UK) for the treatment of COVID-19 and announced the completion of the first and second single ascending dose (SAD) cohorts with preliminary results allowing the Company to proceed to 32 mg/kg dose of WP1122 in the third cohort toward establishing maximum tolerated dose (MTD).
Programs Update
Next Generation Anthracycline – Annamycin
Annamycin is the Company's next-generation anthracycline that has been designed to be non-cardiotoxic and has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin, as well as demonstrating the ability to avoid the multidrug resistance mechanisms that typically limit the efficacy of doxorubicin and other currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases and the Company believes it may have the potential to treat additional indications.
STS Lung Mets
The Company recently announced completion of its Phase 1b portion of the U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of STS lung mets. Preliminary results from the study continue to document clinical activity for Annamycin in the treatment of STS. The safety review committee (SRC) deemed the dose of 390 mg/m2 to be safe after conclusion of the fourth cohort. Consistent with the recommendation of the SRC, the Company determined that the RP2D will be 360 mg/m2 for the first three subjects in the Phase 2 portion of the study, for which screening has begun. For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.
AML
The Company received allowance from the Polish Department of Registration of Medicinal Products (URPL), as well as the requisite Ethics Committee approval, to proceed with its Phase 1/2 clinical trial in Poland of Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) in the treatment of subjects with AML who are refractory to or relapsed after induction therapy. The Phase 1/2 AnnAraC trial (MB-106), an open label trial, builds on the safety and dosage data from the two successfully concluded single agent Annamycin AML Phase 1 trials (MB-104 and MB-105) in the U.S. and Europe, respectively, and the preclinical data from the Company's sponsored research studies.
Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of STS lung metastases, in addition to Orphan Drug and Fast Track Designation for the treatment of relapsed or refractory acute myeloid leukemia.
Upcoming Milestones Expectations
- Q3 2022: Commence enrollment in Phase 1/2 study of Annamycin in combination with Ara-C in Acute Myeloid Leukemia.
- H2 2022: Commencement of an investigator-funded, second Phase 1b/2 clinical trial of Annamycin in sarcoma lung metastases in Europe.
- H2 2022: Report Phase 2 interim data from ongoing Phase 1b/2 study of Annamycin for the treatment of sarcoma lung metastases in the US.
Metabolism/Glycosylation Inhibitor – WP1122 Portfolio
WP1122 was developed as a 2-DG prodrug to provide a more favorable pharmacological profile and was found to have greater potency than 2-DG alone in preclinical models where tumor cells require higher glycolytic activity than normal cells. WP1122 has also been shown to have a greater antiviral effect than 2-DG against SARS-CoV-2 in MRC-5 cells in culture. The improved pharmacokinetic and pharmacodynamic (PK/PD) profile of WP1122 compared to 2-DG was noted in mice following oral dosing at equimolar (i.e., equivalent levels of 2-DG) doses.
COVID-19
The Company is currently evaluating WP1122 in an ongoing Phase 1a, first-in-human, randomized, double-blind, placebo-controlled, overlapping SAD and MAD (Multiple Ascending Dose) clinical trial investigating the effects of WP1122 administered as an oral solution in healthy human volunteers. It is the first step in a planned investigation of WP1122 for the treatment of COVID-19. Dose escalation will take place in sequential SAD cohorts, and MAD will start as soon as SAD has successfully completed at least 3 dosing cohorts. This study in healthy volunteers will explore safety and PK, and subsequent antiviral clinical development is expected to be in patients infected with SARS-CoV-2 to further evaluate safety and establish a favorable risk/benefit profile. The Company expects to enroll approximately 80 subjects in this trial.
The Company's first completed SAD cohort consisted of 9 subjects dosed with 8 mg/kg or placebo in the dose escalation trial. Based on the overall results in Cohort 1, the safety review committee (SRC) deemed the first cohort dose safe and well-tolerated. The Company's second completed SAD cohort consisted of 8 subjects dosed with 16 mg/kg or placebo in the dose escalation trial. Based on the overall results in Cohort 2, the SRC deemed the cohort dose safe and well-tolerated and began its SAD Cohort 3 with a dose escalation to 32 mg/kg.
While the Company is in the process of identifying additional countries where potential future Phase 2 COVID-19 clinical studies might occur, the volatility and unpredictability of COVID-19 incidence in various countries may limit the ability to recruit certain subjects and could make it infeasible to conduct a Phase 2 clinical trial. Importantly, however, the safety and tolerability data from this Phase 1 trial will also enable the initiation of future clinical trials in cancer indications.
Glioblastoma Multiforme
Additionally, Moleculin recently received IND clearance from the FDA to initiate a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM, which the Company expects to commence in 2022.
Upcoming Milestones Expectations
- H2 2022: Topline data from Phase 1a study of WP1122 for the treatment of COVID-19 in the UK.
- H2 2022: Potential to launch Phase 2 study of WP1122 for the treatment of COVID-19 outside of the US.
- 2022: Identify investigators interested in initiating a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM.
- Ongoing preclinical development work, including other molecules in the WP1122 Portfolio in additional anti-viral indications such as HIV, Zika, and hemorrhagic fever viruses. Collaborations targeted for 2022.
Summary of Financial Results for the Second Quarter 2022
Research and development (R&D) expense was $4.2 million and $3.0 million for the three months ended June 30, 2022 and 2021, respectively. The increase of $1.2 million is mainly related to increased clinical trial activity as described above, and costs related to manufacturing of additional drug product.
General and administrative expense was $3.2 million and $2.4 million for the three months ended June 30, 2022 and 2021, respectively. The increase of $0.8 million is mainly related to an increase in regulatory and legal services.
For the six months ended June 30, 2022 and 2021, the Company incurred net losses of $13.6 million and $8.7 million, respectively, and had net cash flows used in operating activities of $12.8 million and $10.4 million, respectively
The Company ended the quarter with $58.0 million of cash. The Company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current R&D rate of expenditures, beyond mid-2024.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company's ability to meet the milestones described in this release under the sections "Upcoming Milestones Expectations", the Company's forecasted cash burn rate (including its estimate of cash sufficient to meet its projected operating requirements), the ability of the US STS lung metastases clinical trial to continue the recruitment of subjects, the ability of the EU STS lung metastases trial to recruit subjects, the ability of Annamycin to eventually be approved by the FDA and the European Medicines Agency, the ability of the WP1122 Phase 1 clinical trial to continue to recruit subjects and demonstrate safety and tolerability, and the ability of the Company to attract collaborators for expanded development of the WP1122 portfolio. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:
SOURCE Moleculin Biotech, Inc. | https://www.whsv.com/prnewswire/2022/08/15/moleculin-reports-second-quarter-2022-financial-results-provides-programs-update/ | 2022-08-15T12:51:30Z |
SINGAPORE, Aug. 15, 2022 /PRNewswire/ -- Multichain, a leading protocol among cross-chain token and NFT transfer service providers released a whitepaper that outlines the details of anyCall - one of the most anticipated cross-chain products of 2022.
anyCall will lay down an infrastructure to be used by blockchains and Dapps to facilitate generic cross-chain communication. Primitive cross-chain technologies are limited to cross-chain token transfers, but anyCall can transfer arbitrary information across supported chains. The messages through anyCall are secured by Multichain's SMPC nodes, which already secure assets worth billions of dollars.
anyCall is the road to a real multi-chain ecosystem
anyCall opens endless possibilities. anyCall enabled multi-chain Dapps can process cross-chain contract calls that will allow users to access its features on all chains within a single transaction, which means a cleaner UI/UX and no need to access multiple bridges with complicated steps.
Curve.fi is one of the first Dapps to deploy anyCall, which streamlines reward distribution with cross-chain gauges that communicate across supported chains in real time to offer fair and accurate rewards to Curve users.
Web3 is amid an evolution in Dapp design. Dapps of the future will support cross-chain messaging natively, which will end primitive issues like Dapp cloning and liquidity fragmentation.
anyCall has already been deployed on eleven prominent blockchains and has been integrated by renowned Dapps like Curve.fi and Hundred finance, and more will soon follow. The multi-chain ecosystem is inevitable, the Dapps that do not adapt to this market shift will soon be replaced by new ones. anyCall is at the forefront of this evolution.
About Multichain
Multichain, born as Anyswap on the 20th of July 2020, is positioned as a fully decentralized Cross-Chain Router Protocol (CRP), an infrastructure supporting a multi-chain ecosystem. Multichain envisions to be the ultimate router for web3. It has taken an absolute leading position in the cross-chain industry in terms of its rapidly expanding ecosystem map (59 supported chains and nearly 3,000 bridges), large DAU number, and great product and technology development.
View original content to download multimedia:
SOURCE Multichain | https://www.whsv.com/prnewswire/2022/08/15/multichain-makes-leaps-development-multi-chain-ecosystem/ | 2022-08-15T12:51:37Z |
Named a 'sample vendor' for Pharma PLM technology along with Oracle, SAP, Siemens, Infor and Dassault Systemes
NEW HAVEN, Conn., Aug. 15, 2022 /PRNewswire/ -- Neo PLM, a leading provider of software solutions for managing pharmaceutical product knowledge and manufacturing, has been named a "sample vendor" in the 2022 Gartner® Hype Cycle™ for Life Sciences Manufacturing, Quality and Supply Chain report.
Neo PLM was mentioned in the Hype Cycle's analysis of the pharmaceutical product life-cycle management space, also known as Pharma PLM. Neo PLM joins Oracle, SAP, Siemens, Infor and Dassault Systemes in being named a sample vendor in this category. It is the fifth consecutive year Neo PLM has been in Gartner's Hype Cycle analysis of Pharma PLM.
"To receive this recognition from Gartner in today's pharmaceutical climate is particularly gratifying," said Cathal Strain, president and founder of Neo PLM. "Digital transformation is becoming increasingly urgent for pharma and biotech manufacturers, and Neo is proud to be at the forefront in providing the technology to power that evolution."
Gartner noted in the Hype Cycle report that uncertainties like COVID-19, war in Ukraine, supply-chain issues, rising inflation and movements toward deglobalization have "reinforced the need for CIOs to work closely with quality, operations and supply-chain leaders to sustain flexible production capabilities and to build in extra resiliency."
Gartner also stated that "today, many pharmaceutical clients use PLM in a very narrow fashion, as they are over-relying on heavily customized ERP environments that are not geared for handling life cycles, like PLM. Shifting capabilities to PLM represents an opportunity to standardize life cycle processes."
For Strain, an industry veteran who started his career pioneering IT solutions at Pfizer, the key to that shift is technology that integrates digital process design with production data analytics, creating a shorter bridge from R&D to commercial scale-up and production.
"The key to bringing high-quality medicines to market faster is to streamline, accelerate and optimize core business processes such as tech transfer and batch analysis," said Strain. "The encouraging thing is we can now help companies address this no matter where they sit on the digitization spectrum. The more that modernization can be implemented across the industry as a whole, the better it can respond to new worldwide challenges when it comes to the development and distribution of medicines."
Gartner clients can access the 2022 Hype Cycle for Life Science Manufacturing, Quality and Supply Chain here: Hype Cycle for Life Science Manufacturing, Quality and Supply Chain, 2022
Neo PLM provides pharmaceutical and biotech manufacturers with a patented digital platform for managing product knowledge and manufacturing processes from late-stage R&D through commercial scale-up and production. As the first software to integrate digital process design with production data analytics, the Neo suite streamlines and optimizes core business processes, empowering manufacturers to deliver high-quality medicines to market faster and ultimately unlock the promise of Pharma 4.0. Initially launched as a custom solution for one of the world's largest pharmaceutical companies, Neo's technology is now deployed in highly complex manufacturing settings worldwide.
GARTNER and HYPE CYCLE are trademark and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
View original content:
SOURCE Neo PLM | https://www.whsv.com/prnewswire/2022/08/15/neo-plm-mentioned-2022-gartner-hype-cycle-report-fifth-consecutive-year/ | 2022-08-15T12:51:43Z |
SAN FRANCISCO, August 15, 2022 /PRNewswire/ -- Newfront, a tech-enabled, full-service brokerage, participated in the William Blair 5th Annual Insurance Technology Conference earlier this month. CEO and Co-Founder Spike Lipkin spoke during a panel discussion focusing on Upgrading Distribution in the industry.
"Technology is rapidly changing the landscape of the insurance industry," said Spike. "Newfront is proud to blaze a trail as we build the modern insurance experience, combining our industry expertise and carrier relationships with technology."
Spike was joined by other industry leaders to discuss where data makes a difference in insurance and making consumer engagement more efficient with tech stacks.
This year's virtual conference experience offered a series of live panel discussions with experts that are shaping the insurance and banking landscape while driving technology adoption in today's highly dynamic global environment. Attendees included a mix of institutional investors and industry executives.
Newfront is transforming the delivery of risk management, employee experience, insurance, and retirement solutions by building the modern insurance platform. Transparent data delivered real-time translates into a lower total cost of risk and greater insights. Newfront makes insurance work for you.
Headquartered in San Francisco, Newfront has offices throughout the country and is home to more than 750 employees who serve clients across the United States and globally. Learn more about building the modern insurance experience here.
William Blair is the premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients' evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.
Chief Marketing Officer
Newfront
View original content to download multimedia:
SOURCE Newfront | https://www.whsv.com/prnewswire/2022/08/15/newfront-featured-5th-annual-william-blair-insurance-technology-conference/ | 2022-08-15T12:51:50Z |
- If authorized, Novavax' vaccine would be the first protein-based COVID-19 booster for adults
- If authorized, the Novavax COVID-19 Vaccine, Adjuvanted could be used as a booster dose for adults aged 18 and older vaccinated with any other currently available COVID-19 vaccine
GAITHERSBURG, Md., Aug. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous and heterologous booster in adults aged 18 and older.
"It's important for people to have a choice as they evaluate how to stay protected against COVID-19, and boosters are an invaluable tool to build upon immunity obtained from previous vaccinations," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Based on the data presented to the FDA's VRBPAC and the CDC ACIP, we believe our vaccine offers a broad, long-lasting immune response against a range of variants."
This application for EUA is supported by data from Novavax' Phase 3 PREVENT-19 trial conducted in the United States and Mexico, and from the UK-sponsored COV-BOOST Phase 2 trial. As part of an open-label booster phase of the PREVENT-19 trial, a single booster dose of the Novavax COVID-19 Vaccine, Adjuvanted was administered to healthy adult participants at least six months after their primary two-dose vaccination series of the Novavax COVID-19 Vaccine, Adjuvanted. The third dose produced robust antibody responses comparable to or exceeding levels associated with the efficacy data in the primary series Phase 3 clinical trials. In the COV-BOOST trial, the Novavax COVID-19 Vaccine, Adjuvanted induced a significant antibody response when used as a heterologous third booster dose.
In the PREVENT-19 trial, following the booster, local and systemic reactions had a median duration of approximately two days. Safety reporting of reactogenicity events showed an increasing incidence across all three doses of the Novavax COVID-19 Vaccine, Adjuvanted, reflecting the increased immunogenicity seen with a third dose. Medically attended adverse events, potentially immune-mediated medical conditions, and severe adverse events occurred infrequently following the booster dose.
In the U.S., the FDA granted EUA, followed by a positive recommendation from the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP), and endorsement from the CDC for a two-dose primary series in adults aged 18 and older in July. Doses of the Novavax COVID-19 Vaccine, Adjuvanted have been available for use in the U.S. since July.
This project has been supported in part with federal funds from the Department of Health and Human Services (HHS); the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), through the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) under contract number MCDC2011-001.
Use of the Novavax COVID-19 Vaccine, Adjuvanted in the U.S.
The Novavax COVID-19 Vaccine, Adjuvanted has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA) to provide a two-dose primary series to individuals 18 years of age and older to prevent Coronavirus Disease 2019 (COVID-19).
The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
Authorized Use
The Novavax COVID-19 Vaccine, Adjuvanted is authorized for use under an Emergency Use Authorization (EUA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.
IMPORTANT SAFETY INFORMATION
Contraindications
Do not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted.
Warnings and Precautions
Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Novavax COVID-19 Vaccine, Adjuvanted. Monitor the Novavax COVID-19 Vaccine, Adjuvanted recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control (CDC) and Prevention guidelines.
Myocarditis and Pericarditis: Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of the Novavax COVID-19 Vaccine, Adjuvanted (see Full EUA Prescribing Information).
Syncope (fainting): May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Novavax COVID-19 Vaccine, Adjuvanted.
Limitations of Vaccine Effectiveness: The Novavax COVID-19 Vaccine, Adjuvanted may not protect all vaccine recipients.
Adverse Reactions
Adverse reactions reported in clinical trials following administration of the Novavax COVID-19 Vaccine, Adjuvanted include injection site pain/tenderness, fatigue/malaise, muscle pain, headache, joint pain, nausea/vomiting, injection site redness, injection site swelling, fever, chills, injection site pruritus, hypersensitivity reactions, lymphadenopathy-related reactions, myocarditis, and pericarditis.
Myocarditis, pericarditis, and anaphylaxis have been reported following administration of the Novavax COVID-19 Vaccine, Adjuvanted outside of clinical trials.
Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Novavax COVID-19 Vaccine, Adjuvanted.
Reporting Adverse Events and Vaccine Administration Errors
The vaccination provider enrolled in the federal COVID-19 Vaccination Program is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS):
- vaccine administration errors whether or not associated with an adverse event,
- serious adverse events (irrespective of attribution to vaccination),
- cases of Multisystem Inflammatory Syndrome (MIS), and
- cases of COVID-19 that results in hospitalization or death.
Complete and submit reports to VAERS online: https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should include the words "Novavax COVID-19 Vaccine, Adjuvanted EUA" in the description section of the report.
To the extent feasible, report adverse events to Novavax, Inc. using the following contact information or by providing a copy of the VAERS form to Novavax, Inc. Website: www.NovavaxMedInfo.com, Fax Number: 1-888-988-8809, Telephone Number: 1-844-NOVAVAX (1-844-668-2829).
Please click to see the Novavax COVID-19 Vaccine, Adjuvanted Fact Sheet for Healthcare Providers Administering Vaccine (Vaccine Providers) and EUA Full Prescribing Information.
About the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373)
The Novavax COVID-19 Vaccine, Adjuvanted is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. The Novavax COVID-19 Vaccine, Adjuvanted contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
The Novavax COVID-19 Vaccine, Adjuvanted is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.
The PREVENT-19 trial is being conducted with support from the U.S. government, including the Department of Defense, BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the HHS, and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health at HHS. BARDA is providing up to $1.75 billion under a Department of Defense agreement (number MCDC2011-001). JPEO-CBRND is also providing funding of up to $45.7 million under a separate agreement. To date, the U.S. government has agreed to order 3.2 million doses of the Novavax COVID-19 Vaccine, Adjuvanted. Novavax and the U.S. government will determine the timing, pricing, and amounts for delivery of any additional doses. Novavax intends to pursue additional U.S. procurement of both the Novavax COVID-19 Vaccine, Adjuvanted doses and other potential formulations.
Novavax has established partnerships for the manufacture, commercialization, and distribution of the Novavax COVID-19 Vaccine, Adjuvanted worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.
About Matrix-M™ Adjuvant
Novavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 Vaccine, Adjuvanted, the company's COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including in the U.S., European Union and with the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines the Novavax COVID-19 Vaccine, Adjuvanted and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on LinkedIn.
*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.
Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the potential for subsequent orders from the U.S. government for additional doses of NVX-CoV2373 and other potential formulations, the timing of clinical trial results, the ongoing development of NVX-CoV2373, NVX-CoV2515, a bivalent vaccine candidate and a COVID-seasonal influenza investigational combination vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including potential recommendations and authorizations from the CDC, Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents, and as a booster, the evolving COVID-19 pandemic, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, the efficacy, safety, intended utilization, and expected administration of NVX-CoV2373 and Novavax' other vaccine candidates are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; unanticipated challenges or delays in conducting clinical trials; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors Erika Schultz | 240-268-2022
ir@novavax.com
Media Ali Chartan or Giovanna Chandler | 202-709-5563
media@novavax.com
View original content to download multimedia:
SOURCE Novavax, Inc. | https://www.whsv.com/prnewswire/2022/08/15/novavax-submits-application-us-fda-emergency-use-authorization-novavax-covid-19-vaccine-adjuvanted-booster-adults-aged-18-older/ | 2022-08-15T12:51:56Z |
NAPPANEE, Ind., Aug. 15, 2022 /PRNewswire/ -- Offsight, the industry-leading manufacturing project management software for the off-site construction and building products industry, recently announced a partnership with ICC NTA, LLC, to accelerate off-site construction growth through digitization. ICC NTA is an accredited third-party agency and part of the International Code Council (ICC) Family of Solutions, which provides plan review and inspection for the off-site construction industry.
ICC NTA inspectors will now leverage Offsight's software to seamlessly track building code conformance and manage regular reporting and auditing in collaboration with their many client factories. Furthermore, Offsight will expedite client onboarding for all ICC NTA clients interested in leveraging Offsight's full software functionality to completely digitize quality, reporting and streamline collaboration with their ICC NTA inspector and other third-party project stakeholders.
"Our partnership with Offsight will be a huge value-add for ICC NTA's residential and commercial off-site clients. Our inspectors can verify building code conformance with real-time collaboration with our clients. It will also help our clients track and resolve issues and completely streamline a lot of the back, and forth that's lost with manual processes." said David Tompos, President of ICC NTA.
In addition to driving value for ICC NTA's clients, the partnership is also geared towards accelerating off-site construction growth. "Over 45% of the construction value chain is expected to be disrupted by off-site construction, and a vast majority of contractors have already made large investments in their off-site businesses and factories", said Offsight CEO Vikas Murali. "Companies who adopt a digital solution like Offsight early on can completely streamline their factory operations as they scale and set themselves up for growth and long-term success."
Both organizations believe that pairing software like Offsight with the industry knowledge and skill set for identifying and tracking building code conformance provided by ICC NTA can be a winning combination in helping factories scale operations. Ultimately, this partnership aims to help prefab, modular, and building product manufacturers invest and acquire more off-site projects each year.
View original content to download multimedia:
SOURCE Offsight | https://www.whsv.com/prnewswire/2022/08/15/offsight-icc-nta-llc-announce-partnership-accelerate-off-site-construction-growth-by-digitizing-third-party-reporting-auditing-building-code-inspections/ | 2022-08-15T12:52:03Z |
More than 520,000 travelers flew into or out of the Southern California gateway in July, beating 2019 levels for the 5th straight month
ONTARIO, Calif., Aug. 15, 2022 /PRNewswire/ -- July marked the fifth straight month in which Ontario International Airport (ONT) recorded passenger volumes higher than the same month in 2019, as the Southern California gateway continues to post one of the most impressive post-pandemic recoveries among airports across the United States.
More than 520,000 airline passengers traveled through ONT last month, an increase of 8.8% over July 2021 and 5% higher than July 2019. The number of domestic and international travelers totaled more than 502,000 and 17,000, respectively, in July. Domestic passenger volume increased by 7.4% compared with July 2019 and 8.7% over July a year ago.
From January through July, ONT welcomed 3.1 million passengers, 3% more than the same period in 2019 and 48.8% higher than last year.
The July totals also represented the third straight month in which ONT has exceeded a half-million travelers, and were the most in a single month since at least 2008 – years before the airport's return to local control.
"Ontario International continues to deliver strong results as demand for air travel in Southern California rebounds. We expect the trend will continue through the summer travel season and into the fall," said Alan D. Wapner, president of the Ontario International Airport Authority (OIAA) Board of Commissioners and Mayor pro Tem of the City of Ontario. "The statistics underscore the high level of confidence our guests have in our facilities and services."
"Since March, ONT passenger volumes have outpaced pre-pandemic levels every month, a very positive trend despite the emergence of COVID-19 variants and generally higher airfares," said OIAA chief executive officer Atif Elkadi. "Our customers in the Inland Empire and beyond have demonstrated their heightened demand for air travel through Ontario International, and our airline partners are responding with more planes to more destinations."
Air cargo shipments which totaled 68,000 tons in July increased nearly 6% compared to 2019. Over the first seven months of the year, the volume freight and mail, more than 476,000 tons, was 11% higher than the same period three years ago.
About Ontario International Airport
Ontario International Airport (ONT) is the fastest growing airport in the United States, according to Global Traveler, a leading publication for frequent fliers. Located in the Inland Empire, ONT is approximately 35 miles east of downtown Los Angeles in the center of Southern California. It is a full-service airport which, before the coronavirus pandemic, offered nonstop commercial jet service to 26 major airports in the U.S., Mexico, Central America and Taiwan. More information is available at www.flyOntario.com. Follow @flyONT on Facebook, Twitter, and Instagram
About the Ontario International Airport Authority (OIAA)
The OIAA was formed in August 2012 by a Joint Powers Agreement between the City of Ontario and the County of San Bernardino to provide overall direction for the management, operations, development and marketing of ONT for the benefit of the Southern California economy and the residents of the airport's four-county catchment area. OIAA Commissioners are Ontario Mayor Pro Tem Alan D. Wapner (President), Retired Riverside Mayor Ronald O. Loveridge (Vice President), Ontario City Council Member Jim W. Bowman (Secretary), San Bernardino County Supervisor Curt Hagman (Commissioner) and retired business executive Julia Gouw (Commissioner).
OIAA Media Contact:
Steve Lambert (909) 841-7527 slambert@flyontario.com
View original content to download multimedia:
SOURCE Ontario International Airport | https://www.whsv.com/prnewswire/2022/08/15/ontario-international-airport-extends-run-topping-pre-pandemic-passenger-volume/ | 2022-08-15T12:52:09Z |
Panacea to offer banking and lending services to eligible GDA members
LITTLE ROCK, Ark., Aug. 15, 2022 /PRNewswire/ -- Panacea Financial (Panacea), which provides financial services for physicians, dentists, and veterinarians through all stages of their training and practice, has partnered with the Georgia Dental Association (GDA), the premier dental association in the state, with over 3,600 members, to provide preferred dental-specific student loan refinancing to GDA members.
Tyler Stafford, CFA, CEO and Co-Founder of Panacea said, "We know that it is extremely difficult to become a dentist and that the cost to train can be burdensome to many. That is why it is vital for us to provide the dental community with options for their student loans that make sense for them. At Panacea we are able to allow dentists and dentists-in-training to refinance their student loans in a way that is both accessible and understanding of the sacrifices dentists make in training and practice."
Panacea is a financial services company created for doctors, by doctors that provides tailored product offerings and service delivery designed specifically for physicians, dentists, and veterinarians throughout their career: from school, through training, and into practice. Panacea's products cover the full suite of banking needs for this unique population, including PRN personal loans, student loan refinancing, and practice loans.
"We are pleased to partner with Panacea Financial to offer dental student loan refinancing options to our members," said GDA President Dr. Zach Powell. GDA Executive Director, Frank J. Capaldo, adds, "The financial cost of becoming a dentist can be daunting, with new dentists today starting their careers owing over $300,000 in educational debt. Offering innovative solutions to our members is critical in addressing the burden of student debt faced by today's dental school graduates."
Panacea President and Co-Founder, Michael Jerkins, MD, added, "As a doctor-founded company, we are on a mission to make financing more accessible to doctors and doctors-in-training across the country. We couldn't be more thrilled to partner with GDA to bring dentists in Georgia unique offerings to potentially make their financial lives a little less stressful."
For more information, please visit www.panaceafinancial.com.
About Panacea Financial
Panacea Financial, a Division of Primis Financial Corp. (NASDAQ: FRST), is a nationwide financial services company offering products in all 50 states as well as Washington, D.C. Panacea offers a full suite of banking solutions specifically built for doctors, by doctors. Follow Panacea Financial on Instagram, Facebook, Twitter, and LinkedIn
About the Georgia Dental Association.
The Georgia Dental Association is the premier professional organization of dentists in the state committed to improving oral health in Georgia and continuously promoting the highest standards of dentistry through education, advocacy, and professionalism.
Media Contact for Panacea Financial:
media@panaceafinancial.com
Media Contact for GDA:
carol@gadental.org
View original content to download multimedia:
SOURCE Panacea Financial | https://www.whsv.com/prnewswire/2022/08/15/panacea-financial-announces-partnership-with-georgia-dental-association-gda/ | 2022-08-15T12:52:16Z |
ELKHART, Ind., Aug. 15, 2022 /PRNewswire/ -- Patrick Industries, Inc. (NASDAQ: PATK) ("Patrick" or the "Company") today announced that on August 11, 2022, the Company amended its credit agreement to expand its existing senior secured credit facility to $925 million from $700 million. The expanded credit facility is comprised of a $775 million revolving credit facility and a $150 million term loan. The maturity date for borrowings under the credit agreement was extended to August 2027 from April 2026. In addition, base interest rates for borrowings under the credit agreement were changed to the Secured Overnight Financing Rate (SOFR) from LIBOR. Other material provisions remained unchanged.
"We are excited to close the expansion and maturity extension of our credit facility, bolstering our already nimble and flexible posture while reinforcing our ability to execute on our business strategy," said Andy Nemeth, Chief Executive Officer of Patrick. "Our credit facility is provided by a world-class group of financial institutions, and we appreciate their support and partnership as we continue to grow and diversify our business and drive shareholder value."
Patrick Industries (NASDAQ: PATK) is a leading component solutions provider for the Leisure Lifestyle and Housing markets. Founded in 1959, Patrick is based in Elkhart, Indiana, with over 12,000 employees across the United States.
This press release contains certain statements related to future results, our intentions, beliefs and expectations or predictions for the future, which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any projections of financial performance or statements concerning expectations as to future developments should not be construed in any manner as a guarantee that such results or developments will, in fact, occur. There can be no assurance that any forward-looking statement will be realized or that actual results will not be significantly different from that set forth in such forward-looking statement. Information about certain risks that could affect our business and cause actual results to differ from those expressed or implied in the forward-looking statements are contained in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and in the Company's Forms 10-Q for subsequent quarterly periods, which are filed with the Securities and Exchange Commission ("SEC") and are available on the SEC's website at www.sec.gov. Each forward-looking statement speaks only as of the date of this press release, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date on which it is made.
View original content to download multimedia:
SOURCE Patrick Industries, Inc. | https://www.whsv.com/prnewswire/2022/08/15/patrick-industries-inc-announces-expansion-credit-facility/ | 2022-08-15T12:52:23Z |
LONDON, Aug. 15, 2022 /PRNewswire/ -- Paul Hastings LLP today announced that Jason Raeburn has joined the firm's London office as a partner in its elite Intellectual Property practice.
Raeburn's broad and diverse practice includes intellectual property disputes relating to software development and licensing, cloud, and AI-related implementations, combined with deep experience in technology litigation and product counseling involving breach of contract, IT infrastructure, the misuse of data and reputational threats.
His arrival adds further depth to the firm's IP practice and builds on the recent growth of the London litigation team. The growth of litigation and finance in London coincides with the addition of a band one finance team, private equity specialist Tom Cartwright and structured finance partner Jason Brooks, who also joined the firm's London office in recent weeks.
"Jason's familiarity with advising the world's leading technology companies in high-growth and high-impact areas like artificial intelligence and cloud fits well into our strategy of investing in strategic areas that will be increasingly important to our clients as a result of macroeconomic trends," said Seth Zachary, chair of Paul Hastings. "He strengthens the breadth and depth of our IP practice while adding high-value expertise to our growing London office."
"Jason adds market-leading experience serving many of the world's leading technology companies in intellectual property disputes that are mission-critical for their business," said Bruce Wexler, Global Co-Chair of the Intellectual Property practice. "He has established himself on an international level, and we believe he will be a star within Paul Hastings' global platform."
"Widely recognized as a standout litigator, Jason is a gifted practitioner who is capturing notable international attention. We are thrilled to welcome him to our office," said Arun Birla, Chair of the firm's London Office. "Strong global competition and converging technologies leave many firms facing increasingly complex IP challenges, making this an ideal moment to grow this crucial practice area."
In addition to his private practice, Mr. Raeburn sits as a part-time judge in the English High Court, as a Deputy Master of the Chancery Division and as a Judge of the First-Tier Tribunal, hearing specialist appeals. His 2020 appointment to the bench is believed to have made him the youngest judge ever appointed to the High Court in the history of England and Wales.
"Paul Hastings' impressive growth, both in London and beyond, fostered by its collaborative and entrepreneurial culture was one of the most significant factors for making the move," said Mr. Raeburn. "I look forward to working with my new colleagues globally to build upon this exciting practice at the firm."
The London office had a strong financial 2021, increasing revenue by 41% on the back of strong demand in its Litigation, Private Equity, Finance, Structured Credit and Securities & Capital Markets practices, this latest addition signals further growth for the firm.
About Paul Hastings
With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment and real estate, Paul Hastings is a premier law firm providing superior intellectual capital and execution globally to the world's leading investment banks, asset managers and corporations.
Paul Hastings is ranked as one of the top firms in the world in The American Lawyer's "Premier League" for momentum, profit and prestige amongst firms in the 2022 American Lawyer 100.
View original content to download multimedia:
SOURCE Paul Hastings LLP | https://www.whsv.com/prnewswire/2022/08/15/paul-hastings-ip-practice-adds-preeminent-technology-partner-london/ | 2022-08-15T12:52:29Z |
Investment Supports McWilliams & Son's Rapid Expansion Through Organic Growth and Strategic Acquisitions in the Growing, Resilient and Highly Fragmented Residential Services Market
SAN FRANCISCO and LUFKIN, Texas, Aug. 15, 2022 /PRNewswire/ -- Percheron Capital ("Percheron"), a private equity firm focused on partnering with high-quality essential services businesses, today announced that it has signed a definitive agreement to acquire a majority stake in McWilliams & Son ("McWilliams" or the "Company"), a leading residential HVAC and plumbing services platform. Following the transaction, McWilliams' Chief Executive Officer, Trey McWilliams, will remain a significant investor and continue to lead the Company. Terms of the transaction were not disclosed.
Founded in 1974 in Texas by the McWilliams family, McWilliams & Son offers residential HVAC and plumbing maintenance, repair and replacement services with a reputation for outstanding quality and customer service. The Company's people-first values focused on service, trust and reliability have resulted in industry-leading customer satisfaction scores and consistent growth for over 45 years. McWilliams' commitment to providing advanced training programs, innovative technology and equipment to its technicians has made the Company an employer of choice in the markets it operates.
Under Trey McWilliams' leadership, the Company has successfully expanded its reach through strong organic growth, new branch openings and acquisitions of high-quality, partnership-focused residential HVAC and plumbing businesses. With Percheron's strategic support and operational resources, McWilliams is well-positioned to further accelerate its growth in new and existing markets.
Trey McWilliams said, "I am proud of our exceptional team and the strong business we have built together. We attribute our success to our people-centric approach and unwavering commitment to our customers, team members and community. Percheron embodies our values and brings significant experience and a strong track record supporting high-growth, acquisitive services businesses. I am excited about the significant opportunities our partnership with Percheron creates for our team members as we continue executing on our vision of building the premier provider of residential HVAC and plumbing services in the country."
Chris Lawler, Co-Founder and Managing Partner of Percheron, commented, "The residential HVAC and plumbing services market has been a thematic investment priority for Percheron given the industry's large size, non-discretionary services, strong and resilient growth and high fragmentation. We are thrilled to partner with Trey McWilliams and his team, who have built a rare platform with best-in-class operational and performance metrics, including leading customer service scores, technician productivity and retention. The Company is supported by advanced technology, systems and processes, and has a strong track record of growth through both organic initiatives and strategic acquisitions. We look forward to leveraging Percheron's deep operational capabilities to support the next phase of McWilliams' rapid growth."
McWilliams & Son is a leading HVAC and plumbing services business founded in 1974 in Texas by the McWilliams family. For over 45 years, McWilliams & Son has proudly served customers with a reputation for outstanding quality and customer service. A hometown company with hometown values, McWilliams & Son puts its customers, employees and community first. McWilliams & Son invests heavily in its team members, including providing industry-leading training programs and advanced technology and equipment, to enable team members to achieve their full potential and better serve our valued customers. For more information, please visit www.mcwilliamsandson.com.
Percheron Capital is a private equity firm focused on partnering with exceptional teams to build market-leading services businesses. The firm's purpose is to help high-quality businesses accelerate growth and enhance long-term value. Percheron has over $1 billion in assets under management and focuses on investing in strong services businesses in resilient end markets, including animal health, automotive, education, food & beverage, healthcare & wellness, and residential. For more information, please visit www.percheroncapital.com.
Woomi Yun / Erik Carlson
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
View original content:
SOURCE Percheron Capital | https://www.whsv.com/prnewswire/2022/08/15/percheron-capital-announces-partnership-with-mcwilliams-amp-son-leading-provider-residential-hvac-plumbing-services/ | 2022-08-15T12:52:35Z |
PETER SCHIFF, AND ATTORNEY LANNY DAVIS, TO HOLD TELEPHONIC PRESS CONFERENCE ON CIVIL/REGULATORY SETTLEMENT BETWEEN EURO PACIFIC BANK AND PUERTO RICAN BANK COMMISSIONER
Published: Aug. 15, 2022 at 8:25 AM EDT|Updated: 26 minutes ago
DAVIS TO CHALLENGE MEDIA, IRS, J5 ON FALSE INNUENDOS
OF MONEY LAUNDERING AND TAX EVASION
Audio Press Conference 2:00 pm EDT
WASHINGTON, Aug. 15, 2022 /PRNewswire/ --
OPPORTUNITIES FOR QUESTIONS / ANSWERS FROM REPORTERS
Contact: agconnolly@tridentdmg.com
(202) 993-4304
View original content:
SOURCE Lanny Davis
The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc. | https://www.whsv.com/prnewswire/2022/08/15/peter-schiff-attorney-lanny-davis-hold-telephonic-press-conference-civilregulatory-settlement-between-euro-pacific-bank-puerto-rican-bank-commissioner/ | 2022-08-15T12:52:42Z |
WALTHAM, Mass. and DUBLIN, Aug. 15, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.
ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP. Q32 has recently completed a biomarker-enabled Phase 1 study characterizing pharmacokinetics, pharmacodynamics and safety of ADX-914 that demonstrated pharmacological effect on T cells in healthy volunteers. Q32 expects to initiate a Phase 2 trial in atopic dermatitis later this year and is planning to initiate a Phase 2 trial in a second autoimmune disease next year.
"Horizon is a leader in the autoimmune and inflammatory disease space and brings to this collaboration both the resources and experience of a pharmaceutical company and the speed and agility of a biotech," said Michael Broxson, chief executive officer of Q32 Bio. "We're very excited to combine our strengths and expertise to continue to advance ADX-914 for autoimmune diseases, an area that is underserved by existing therapeutics and one where we hope to deliver life-changing medicines for patients in need."
Under the terms of the agreement, Horizon will fund development through completion of the two Phase 2 trials of ADX-914, with Q32 being operationally responsible for the conduct of all program-related activities. Horizon will receive an option to acquire the ADX-914 program, exercisable through a period following completion of the Phase 2 trials. During the option period, Q32 will receive $55 million in the form of initial consideration and staged development funding, of which Horizon expects to recognize as R&D expenses approximately $32.5 million in the third quarter of 2022, and the remainder in 2023. These payments will be included in Horizon's non-GAAP financial measures, including adjusted EBITDA. If Horizon exercises the option, Q32 may be eligible to receive up to an additional $645 million in closing and milestone payments, as well as tiered royalties on net sales, less certain amounts payable under a pre-existing license agreement.
"We are very pleased to begin our collaboration with Q32 to advance ADX-914 through the next phase of clinical development," said Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, Horizon. "By targeting the IL-7 and TSLP pathways, which are biologically and genetically implicated as central mediators of T cell-mediated pathologies, ADX-914 represents a novel approach to targeting a number of autoimmune diseases with the potential to restore healthy immune regulation."
Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.
The company's most advanced program, ADX-914, is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function and is being initially developed to treat an immune-mediated dermatological disease. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
Q32 Bio's lead program for innate immunity, ADX-097, is based on a pioneering approach enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio is currently conducting a first-in-human, Phase 1, ascending dose (SAD/MAD) clinical study of ADX-097 for the treatment of complement disorders. For more information, please visit www.Q32bio.com.
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
This press release contains forward-looking statements, including, but not limited to, statements related to expected activities and payments under the collaboration between Horizon and Q32, the potential benefits of the collaboration and ADX-914 and expected recognition of expenses and impact on Horizon's financial results. These forward-looking statements are based on Horizon's and Q32's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with development, regulatory approval and commercialization of novel therapeutic candidates, whether Horizon exercises its option to acquire the ADX-914 program, the timing of development activities and payments under the collaboration; the fact that the collaboration is subject to early termination and the fact that Horizon has limited control over the development of the ADX-914 program prior to exercising the option. For a further description of these and other risks facing Horizon, please see the risk factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon undertakes no obligation to update or revise these statements, except as may be required by law.
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
Investor Relations:
Tina Ventura
Senior Vice President, Chief Investor Relations Officer
Investor-relations@horizontherapeutics.com
U.S. Media:
Geoff Curtis
Executive Vice President, Corporate Affairs & Chief Communication Officer
media@horizontherapeutics.com
Ireland Media:
Gordon MRM
Ray Gordon
ray@gordonmrm.ie
View original content to download multimedia:
SOURCE Q32 Bio | https://www.whsv.com/prnewswire/2022/08/15/q32-bio-horizon-therapeutics-announce-collaboration-autoimmune-diseases/ | 2022-08-15T12:52:48Z |
Study to be conducted at two leading research institutions in the U.K.
Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate
WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the launch of a clinical trial designed to determine the baseline characteristics of patients diagnosed with recurrent symptomatic herpes simplex virus type 2 (HSV-2). In addition to assessing the typical baseline characteristics of population, the purpose of this study is also to determine the acceptance of clinical trial procedures and understand the interest of the target patient population to participate in a therapeutic Phase 1/2 HSV-2 vaccine study.
The study, "A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease," will be led by Dr. Rajul Patel, consultant physician for genitourinary and HIV medicine at Southampton University Hospital, Southampton, England. The trial will be conducted at Southampton University Hospital, and at Chelsea and Westminster Hospital, London, England.
"Most people living with herpes are unaware they have the infection leading to unrecognized transmission and spread of the virus. Patients who develop symptomatic herpetic disease suffer not only from recurrent physical symptoms, but may also suffer from social stigma and isolation because the infection is usually transmitted sexually," said Kerstin Westritschnig, M.D., chief medical officer of Rational Vaccines. "There is no cure for herpes. There are no approved vaccines or immunotherapies or sufficiently reliable diagnostics currently available1. Antiviral medications developed in the 1970s can help to reduce the severity and frequency of symptoms but cannot cure the infection."
"We look forward to initiating this clinical study as these findings will help inform the design of our Phase 1/2 clinical trial which will evaluate our lead vaccine candidate for HSV-2," added Dr. Westritschnig.
For More Information About This Clinical Trial
Please visit:
www.clinicaltrials.gov Identifier: NCT05500053
or click: HERE
About Herpes Simplex Virus (HSV)
The herpes simplex virus (HSV), commonly referred to as herpes, is categorized into two types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2). HSV-1 is the primary cause of oral herpes but can also cause genital herpes. HSV-2 is the primary cause of genital herpes. According to a 2020 report by the World Health Organization (WHO), herpes infects billions globally2 – about a half a billion people worldwide are living with genital herpes, and several billion have an oral herpes infection. Both HSV-1 and HSV-2 infections are lifelong.
While most herpes infections are asymptomatic, a significant number of people experience a range of symptoms that vary in frequency and severity. The most common symptoms for both types of herpes are painful blisters or ulcers. In addition, many patients experience debilitating neuralgia, skin splits, fissures, minor abrasions, erythema, fever, chills, and myalgias. Both viruses are most contagious during a symptomatic outbreak, but they can still be transmitted in the absence of symptoms. Strong evidence has emerged that HSV-1 is a major risk factor for Alzheimer's disease3.
About Rational Vaccines
Rational Vaccines is revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases with its rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates. Led by a team of world-renowned scientists, the Company is headquartered in Woburn, MA with locations in Miami, FL and Oxford, UK. For more information, please visit www.rationalvaccines.com.
1https:/www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus and Herpes - STI Treatment Guidelines (cdc.gov)
2WHO | First global and regional estimates of HIV infections attributable to HSV-2 infection
3https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075814/
View original content to download multimedia:
SOURCE Rational Vaccines | https://www.whsv.com/prnewswire/2022/08/15/rational-vaccines-announces-clinical-trial-determine-baseline-characteristics-patients-diagnosed-with-recurrent-symptomatic-herpes-simplex-type-2-hsv-2-virus/ | 2022-08-15T12:52:55Z |
Treatment Center Rolls Out Breakthrough Technology for South Florida Patients
DELRAY BEACH, Fla., Aug. 15, 2022 /PRNewswire/ -- The Recovery Team—an evidence-based treatment center—debuts a partnership with BrainsWay, a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The partnership and technology will bring relief and recovery through clinically supported Deep Transcranial Magnetic Stimulation (Deep TMS™).
BrainsWay's Deep TMS™ treatment is based on unique breakthrough technology producing functional modulation of targeted brain areas. Used in over 60 clinical trials worldwide, Deep TMS™ is FDA-cleared for the treatment of major depressive disorder, obsessive-compulsive disorder (OCD), and smoking addiction.
Deep TMS™ can alleviate chronic discomfort with treatment-resistant disorders that resist first-line medications and therapies. Enhancing care for patients with substance use and mental health disorders, Deep TMS™ will complement holistic treatment paths unique to each patient at The Recovery Team.
"We're delighted to benefit mental health in our community through BrainsWay technology. Aiming to push recovery rates for veterans and everyone in Florida, we want to improve the experience of getting help," said Binny Montenegro, Chief Operating Officer. "Deep TMS™ will help patients more easily overcome even the most persistent symptoms and disorders like severe depression."
New patients will see how The Recovery Team's compassionate professionals use Deep TMS™ to advance wellness in South Florida beyond the usual limits. To learn more, visit https://recoveryteam.org.
One of the longest-operating South Florida treatment centers founded in 1995, The Recovery Team supports individual and community-wide recovery through personal, medically integrated wellness paths. Its campuses treat substance use and co-occurring disorders through intensive, residential, outpatient, and traditional care with programs designed for at-risk populations like veterans, first responders, active military, families, and more.
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
View original content to download multimedia:
SOURCE The Recovery Team | https://www.whsv.com/prnewswire/2022/08/15/recovery-team-launches-brainsway-deep-tms/ | 2022-08-15T12:53:01Z |
This includes the analogous nature of articular cartilage, muscle fascia, and intervertebral disc confirmed by way of comparative Scanning Electron Microscope analysis
PENSACOLA, Fla., Aug. 15, 2022 /PRNewswire/ -- Regenative Labs, a leading HCT/P manufacturer, has co-authored a pioneering paper together with experts from The Institute of Regenative Medicine and the Department of Pharmacology and Chemical Biology, Baylor College of Medicine.
"This paper is a market disruptor and will be our most significant paper released to date. This is the first literature that we are aware of to utilize Scanning Electron Microscope (SEM) images of actual tissue samples to objectively demonstrate on a qualitative and quantitative basis that collagen structural tissue matrices in our post-processed Wharton's Jelly allografts and those in articular cartilage, muscle fascia, and intervertebral discs are analogous," said Regenative Labs CEO, Tyler Barrett.
This research highlights our commitment to the Regenerative Medicine community. We believe the combination of our IRB-approved observational studies, peer-reviewed publications, ISO-certified laboratory processes, and our commitment to compliance with FDA and American Association of Tissue Banks (AATB) standards, sets the standard for HCT/P manufacturers. Regenative Labs has pioneered the use of perinatal tissue allografts and is pleased that this paper supports our current homologous use practices, consistent with our 361 status.
Currently, the treatments for the Intervertebral Disc (DDD) range in cost and effectiveness from an $8 bottle of Ibuprofen to $150,000 for spinal fusion (1). Neither of these treatment options target the foundational issue of ECM cartilage breakdown in the intervertebral discs. By age 35, 30% of people show signs of DDD; by age 60, this increases to 90% (2). That we are aware of, this is the first perinatal tissue allograft in the medical marketplace that may be applied in a homologous fashion per FDA 361 guidelines to replace or supplement missing or damaged connective tissue. All other non-surgical paradigms focus on symptom management and do not address the disc's collagen structural degeneration. In collaboration with medical providers across the country, we are actively investigating additional homologous use applications for this technology in tissue defects associated with the load-bearing joints of the knee, hip, shoulder, spine, ankle, and foot.
Billions of dollars are spent annually on the surgical care and treatment of patients suffering from degeneration of load-bearing joints and intravertebral discs. We are honored to offer patients evidence-based and structural tissue defect-specific non-surgical applications on a global scale.
Additional Sources:
- How much does degenerative disc treatment cost? CostHelper. (n.d.). Retrieved August 10, 2022, from https://health.costhelper.com/degenerative-disc.html
- Degenerative disc disease. Columbia Neurosurgery in New York City. (2021, July 21). Retrieved August 10, 2022, from https://www.neurosurgery.columbia.edu/patient-care/conditions/degenerative-disc-disease#:~:text=Most%20people's%20spinal%20discs%20degenerate,does%20not%20necessarily%20cause%20pain.
About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient's conditions using Wharton's Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides non-addictive, non-invasive options for patients. Regenative Labs's expert product research and development team complies FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative's website: www.regenativelabs.com
View original content to download multimedia:
SOURCE Regenative Labs | https://www.whsv.com/prnewswire/2022/08/15/regenative-labs-announces-groundbreaking-whartons-jelly-research-demonstrating-hctp-compliance-after-processing/ | 2022-08-15T12:53:08Z |
BOSTON, Aug. 15, 2022 /PRNewswire/ -- Remedium Bio, Inc., a biotechnology company developing novel gene therapies, today announced that it has closed more than $2.3M in its expanded seed round financing. Funding from the raise is being used to study Remedium's lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders. The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.
Remedium's lead candidate is the only single injection gene therapy based on the clinically proven anabolic mechanism of FGF18, which has demonstrated the ability to reverse cartilage loss in a placebo controlled, multi-center, randomized clinical trial. Osteoarthritis is the largest unmet need in Rheumatology, presenting a market of $37B with no currently approved therapies capable of slowing or reversing disease progression. Remedium's novel solution offers the potential to arrest disease progression after a single injection and promote restoration of a more natural, youthful phenotype of articular cartilage.
"Our technology has the potential to reverse years of age-related cartilage loss, for a disease that currently has no approved therapeutic treatments capable of slowing or reversing progression," said Frank Luppino, President and CEO of Remedium Bio, Inc. "We are extremely excited about the progress made to date, and believe that our gene-augmentation technology can be translated to a number of other age-related pathologies with no currently available disease-modifying options."
Remedium was founded by orthopedics industry veterans with proven track records of developing leading therapeutics at companies ranging from start-ups to Fortune 500. Remedium has attracted a number of academic collaborators and medical KOLs to its advisory board including Dr. Timothy McAlindon, MD, MPH, Chief of the Division of Rheumatology at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Anastassios Pittas, MD, MS, Chief of the Division of Endocrinology, Diabetes, and Metabolism and Co-Director of the Diabetes and Lipid Center at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Jeff Ellsworth, PhD, the pioneer of rhFGF18 technology and CSO of Recardia Therapeutics; Dr. Li Zeng PhD, MA, MS, BA Associate Professor Immunology at Tufts University School of Medicine; and Dr. Kai Zou PhD, Assistant Professor, Department of Exercise and Health Sciences, at the University of Massachusetts, Boston.
Remedium's pipeline includes therapeutic indications in Osteoarthritis, Diabetes, Stroke, and other large unmet clinical needs.
Remedium Bio, Inc. is a preclinical-stage biotechnology company developing novel gene therapies for a broad range of highly debilitating diseases. The company's R&D approach focuses on modularly combining proven technologies to treat well-characterized disease pathology streamlining elements of the product development process. Remedium's pipeline includes a lead candidate first-in-class, single-injection, potentially disease-modifying gene therapy treatment for the treatment of Osteoarthritis and gene therapy treatments for the management of Diabetes and Stroke.
To learn more, visit www.remedium-bio.com
Contact Remedium: info@remedium-bio.com
View original content to download multimedia:
SOURCE Remedium Bio, Inc. | https://www.whsv.com/prnewswire/2022/08/15/remedium-bio-announces-successful-23m-expanded-seed-raise/ | 2022-08-15T12:53:15Z |
Arçelik, parent company to Beko and Grundig, will be at IFA 2022 in Berlin to unveil their latest in product innovation at IFA 2022, while Hakan Bulgurlu, CEO of Arçelik, will address the climate emergency during his keynote speech on Friday 2nd September at 2 p.m.
ISTANBUL , Aug. 15, 2022 /PRNewswire/ -- Arçelik, parent company to leading home appliance brands including Beko and Grundig, is challenging the traditional sustainability model that shapes so many consumer brands today. During his keynote speech at IFA Berlin on Friday 2nd September, Arçelik CEO Hakan Bulgurlu will call on industry leaders to consider how their companies are impacting the environment, in a speech that draws on his experience as a CEO and APPLiA President.
Tackling the subject of technological advancements and sustainability, Hakan Bulgurlu, will deliver a speech that aims to reshape how companies think about their environmental impact. Focusing on the notion of 'Richer People' on a 'Poorer Planet', he will explore the idea that some of the solutions unveiled by industries to reduce their impact on the planet in fact result in increased demand and consumption, leading to greater environmental damage.
Arçelik brands Beko and Grundig will be exhibiting at IFA in the Household Appliances section in Hall 3.1.
About Arçelik
Arçelik's has over 40,000 employees around the world, global operations including sales and marketing offices in 52 countries, and 28 production facilities in 9 countries with 12 brands (Arçelik, Beko, Grundig, Blomberg, ElektraBregenz, Arctic, Leisure, Flavel, Defy, Altus, Dawlance, Voltas Beko). As Europe's second-largest white goods company by market share (based on volumes), Arçelik reached a consolidated turnover of 6.5 billion Euros in 2021. Arçelik's 28 R&D and Design Centers & Offices across the globe, are home to over 2,000 researchers and hold more than 3,000 international patent applications to date. In 2021, Arçelik achieved the highest score in the DHP Household Durables category for the third year in a row in the Dow Jones Sustainability Index of the S&P Global Corporate Sustainability Assessment. Through its leadership position in sustainability and credible decarbonization roadmap for achieving net zero, Arçelik became the first and only company from its industry to receive the Terra Carta Seal by HRH Prince of Wales. Arçelik's mission is 'Respecting the World, Respected Worldwide'.
Photo - https://mma.prnewswire.com/media/1878113/Hakan_Bulgurlu_Arcelik_CEO.jpg
Logo - https://mma.prnewswire.com/media/1653921/Arcelik_Logo.jpg
View original content to download multimedia:
SOURCE Arçelik | https://www.whsv.com/prnewswire/2022/08/15/richer-people-poorer-planet-arelik-calls-greater-efficiency-ifa-2022-with-launch-its-new-cutting-edge-technology-enhance-sustainable-solutions-households/ | 2022-08-15T12:53:21Z |
VANCOUVER, BC, Aug. 15, 2022 /PRNewswire/ - Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm" or the "Company") (NYSE: SAND) (TSX: SSL) is pleased to announce the successful completion of the previously announced acquisition of Nomad Royalty Company Ltd. (NYSE: NSR) (TSX: NSR) ("Nomad") pursuant to a plan of arrangement under the Canada Business Corporations Act (the "Acquisition").
Sandstorm issued approximately 74.4 million common shares of the Company ("Sandstorm Shares") to former Nomad shareholders equal to an exchange ratio of 1.21 Sandstorm Shares for each common share of Nomad (each, a "Nomad Share"). The Company's shareholders approved the share issuance for the Acquisition at its special meeting of shareholders on August 9, 2022 (see press release dated August 9, 2022). The Sandstorm Shares issued pursuant to the Acquisition are expected to be listed and posted for trading on the Toronto Stock Exchange and New York Stock Exchange. With completion of the Acquisition, existing Sandstorm and former Nomad shareholders are expected to own approximately 73% and 27% of the outstanding shares of the pro forma Sandstorm, respectively1.
In conjunction with the previously announced closing of the BaseCore transaction (together with the Acquisition, the "Transactions") (see press releases dated May 2, 2022, and July 12, 2022) the Transactions are expected to provide several benefits to Sandstorm, including:
- Substantial increase in size and scale cementing Sandstorm's status as the highest-growth2 and most liquid mid-tier royalty and streaming company;
- Adds high-quality and low-cost assets with precious metals focus resulting in Sandstorm's expected revenue to be nearly 90% precious metals3 in 2025;
- Highest growth amongst peers4 where production is expected to grow more than 85% between 2022 and 2025;
- Industry-leading portfolio diversification with a resulting portfolio of 250 streams and royalties, of which 39 of the underlying assets are cash-flowing and no asset contributing more than 15% to the Company's consensus net asset value; and
- Bolsters financial strength and capital markets profile with a strong balance sheet, increased public float, liquidity, and access to capital, Sandstorm is expected to have a greater capacity to pursue further growth and return capital to Sandstorm shareholders.
Nolan Watson, President & CEO of the Company, remarked, "The completion of the Nomad Acquisition is another exciting milestone for Sandstorm shareholders this year. We began 2022 with a bold vision for Sandstorm and this is the next step in the growth strategy for the Company. We welcome the new shareholders of Sandstorm and appreciate your support as we continue to grow and build Sandstorm into the go-to precious metals royalty and streaming royalty company."
For more information about the details of the Acquisition, see the Company's press release dated May 2, 2022 and the Company's management information circular dated July 11, 2022.
The Company intends to cause Nomad to delist the Nomad Shares from the Toronto Stock Exchange, New York Stock Exchange and Frankfurt Stock Exchange, and to delist Nomad's listed warrants from the Toronto Stock Exchange. An application has been made for Nomad to cease to be a reporting issuer in all of the provinces of Canada. An application will also be made for Nomad to terminate its reporting obligations in the United States.
Certain securities issued pursuant to and under the Plan of Agreement are to be issued in reliance upon available exemptions from such registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
For more information about Sandstorm Gold Royalties, please visit our website at www.sandstormgold.com or email us at info@sandstormgold.com.
Sandstorm is a gold royalty company that provides upfront financing to gold mining companies that are looking for capital and in return, receives the right to a percentage of the gold produced from a mine, for the life of the mine. Sandstorm holds a portfolio of 250 royalties, of which 39 of the underlying mines are producing. Sandstorm plans to grow and diversify its low cost production profile through the acquisition of additional gold royalties. For more information visit: www.sandstormgold.com.
The financial information included or incorporated by reference in this press release or the documents referenced herein has been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, which differs from US generally accepted accounting principles ("US GAAP") in certain material respects, and thus are not directly comparable to financial statements prepared in accordance with US GAAP.
This press release and the documents incorporated by reference herein, as applicable, have been prepared in accordance with Canadian standards for the reporting of mineral resource and mineral reserve estimates, which differ from the previous and current standards of the United States securities laws. In particular, and without limiting the generality of the foregoing, the terms "mineral reserve", "proven mineral reserve", "probable mineral reserve", "inferred mineral resources,", "indicated mineral resources," "measured mineral resources" and "mineral resources" used or referenced herein and the documents incorporated by reference herein, as applicable, are Canadian mineral disclosure terms as defined in accordance with Canadian National Instrument 43-101 — Standards of Disclosure for Mineral Projects ("NI 43-101") and the Canadian Institute of Mining, Metallurgy and Petroleum (the "CIM") — CIM Definition Standards on Mineral Resources and Mineral Reserves, adopted by the CIM Council, as amended (the "CIM Definition Standards").
For United States reporting purposes, the United States Securities and Exchange Commission (the "SEC") has adopted amendments to its disclosure rules (the "SEC Modernization Rules") to modernize the mining property disclosure requirements for issuers whose securities are registered with the SEC under the Exchange Act, which became effective February 25, 2019. The SEC Modernization Rules more closely align the SEC's disclosure requirements and policies for mining properties with current industry and global regulatory practices and standards, including NI 43-101, and replace the historical property disclosure requirements for mining registrants that were included in SEC Industry Guide 7. Issuers were required to comply with the SEC Modernization Rules in their first fiscal year beginning on or after January 1, 2021. As a foreign private issuer that is eligible to file reports with the SEC pursuant to the multi-jurisdictional disclosure system, the Corporation is not required to provide disclosure on its mineral properties under the SEC Modernization Rules and will continue to provide disclosure under NI 43-101 and the CIM Definition Standards. Accordingly, mineral reserve and mineral resource information contained or incorporated by reference herein may not be comparable to similar information disclosed by United States companies subject to the United States federal securities laws and the rules and regulations thereunder.
As a result of the adoption of the SEC Modernization Rules, the SEC now recognizes estimates of "measured mineral resources", "indicated mineral resources" and "inferred mineral resources." In addition, the SEC has amended its definitions of "proven mineral reserves" and "probable mineral reserves" to be "substantially similar" to the corresponding CIM Definition Standards that are required under NI 43-101. While the SEC will now recognize "measured mineral resources", "indicated mineral resources" and "inferred mineral resources", U.S. investors should not assume that all or any part of the mineralization in these categories will be converted into a higher category of mineral resources or into mineral reserves without further work and analysis. Mineralization described using these terms has a greater amount of uncertainty as to its existence and feasibility than mineralization that has been characterized as reserves. Accordingly, U.S. investors are cautioned not to assume that all or any measured mineral resources, indicated mineral resources, or inferred mineral resources that the Company reports are or will be economically or legally mineable without further work and analysis. Further, "inferred mineral resources" have a greater amount of uncertainty and as to whether they can be mined legally or economically. Therefore, U.S. investors are also cautioned not to assume that all or any part of inferred mineral resources will be upgraded to a higher category without further work and analysis. Under Canadian securities laws, estimates of "inferred mineral resources" may not form the basis of feasibility or pre-feasibility studies, except in rare cases. While the above terms are "substantially similar" to CIM Definitions, there are differences in the definitions under the SEC Modernization Rules and the CIM Definition Standards. Accordingly, there is no assurance any mineral reserves or mineral resources that the Company may report as "proven mineral reserves", "probable mineral reserves", "measured mineral resources", "indicated mineral resources" and "inferred mineral resources" under NI 43-101 would be the same had the Company prepared the reserve or resource estimates under the standards adopted under the SEC Modernization Rules or under the prior standards of SEC Industry Guide 7.
This press release contains "forward-looking statements", within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation, concerning the business, operations and financial performance and condition of Sandstorm Gold Royalties. Forward-looking statements include, but are not limited to, expectations regarding the delisting of the Nomad Shares and Nomad's listed warrants; expectations regarding Nomad's reporting issuer status following completion of the Acquisition; expectations regarding the listing of Sandstorm Shares issued under the Acquisition on the Toronto Stock Exchange and New York Stock Exchange; expectations regarding the potential benefits and synergies of the Transactions and the ability of Sandstorm post-completion of the Transactions to successfully achieve business objectives, including integrating the companies or assets or the effects of unexpected costs, liabilities or delays; expectations regarding the growth potential of Sandstorm including in scale and production and the anticipated benefits of the Transactions; expectations regarding financial strength, trading liquidity, and capital markets profile; the future price of gold, silver, copper, iron ore and other metals; the estimation of mineral reserves and mineral resources, and realization of mineral reserve and mineral resource estimates; the timing and amount of estimated future production; and expectations for other economic, business, and/or competitive factors. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans", or similar terminology.
Forward-looking statements are made based upon certain assumptions and other important factors that, if untrue, could cause the actual results, performances or achievements of Sandstorm Gold Royalties to be materially different from future results, performances or achievements expressed or implied by such statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Sandstorm Gold Royalties will operate in the future, including the receipt of all required approvals, the price of gold and copper and anticipated costs. Certain important factors that could cause actual results, performances or achievements to differ materially from those in the forward-looking statements include, amongst others, failure to receive necessary approvals, changes in business plans and strategies, market conditions, share price, best use of available cash, gold and other commodity price volatility, discrepancies between actual and estimated production, mineral reserves and resources and metallurgical recoveries, mining operational and development risks relating to the parties which produce the gold or other commodity the Company will purchase, regulatory restrictions, activities by governmental authorities (including changes in taxation), currency fluctuations, the global economic climate, dilution, share price volatility and competition.
Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: the impact of general business and economic conditions, the absence of control over mining operations from which the Company will purchase gold, other commodities or receive royalties from, and risks related to those mining operations, including risks related to international operations, government and environmental regulation, actual results of current exploration activities, conclusions of economic evaluations and changes in project parameters as plans continue to be refined, risks in the marketability of minerals, fluctuations in the price of gold and other commodities, fluctuation in foreign exchange rates and interest rates, stock market volatility, as well as those factors discussed in the section entitled "Risks to Sandstorm" in the Company's annual report for the financial year ended December 31, 2021 and the section entitled "Risk Factors" contained in the Company's annual information form dated March 31, 2022 available at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements that are contained or incorporated by reference, except in accordance with applicable securities laws.
View original content to download multimedia:
SOURCE Sandstorm Gold Ltd. | https://www.whsv.com/prnewswire/2022/08/15/sandstorm-gold-royalties-completes-acquisition-nomad-royalty-company/ | 2022-08-15T12:53:28Z |
NEW YORK , Aug. 15, 2022 /PRNewswire/ -- A $25 million recreation, fitness and conference space named The Playground + Conference Center officially opened today in New York's iconic Seagram Building, fulfilling the vision of its owner, RFR, to "breathe oxygen into the workplace" by offering tenants "a whole life" – a community where people can work, socialize and exercise.
The 35,000-square-foot facility was conceived by RFR four years ago but gained urgency post-pandemic as the building's corporate tenants looked for incentives that would encourage their employees to return to the office after more than two years of working from home.
The expanse and cost of The Playground is thought to make it unique in New York commercial real estate. RFR cleared the way for the bilevel multisport complex by restructuring the building's underground parking garage to hold a 3,500-square-foot fitness center, a multisport open court, 22-foot-tall climbing wall, stadium seating for 150, 50-seat boardroom and 40-seat training room.
The fitness center features treadmills, ellipticals, Pelotons, Stairmaster, flat bench, incline bench, workout benches, power rack, dumbbells and Precor Queenax Functional System, used for high-intensity interval training. The facility's spin studio is equipped with a dozen bikes. Yoga, Pilates, martial arts and meditation classes are held in an adjacent Flex room.
The space also features recreational games, a hydration lounge and locker rooms equipped with showers and changing rooms. Allee Colon, a veteran in the field, has been brought on to serve as fitness director of The Playground.
The Playground's open court, designed for basketball, pickleball, volleyball and soccer, can be transformed into a 150-person theater for town hall meetings and large-screen presentations. With the push of a button, the court south's wall opens, and eight tiers of polished wood seating cascade onto the court.
At the north end of the open court, the climbing wall beckons adventurers with Expert, Difficult, Intermediate and Entry-Level routes and auto-belay safety harnesses that take up slack as climbers ascend and descend.
"Long before the pandemic, we recognized that parking garages in our buildings represent valuable space that could be better used to benefit our tenants," said Sheldon Werdiger, RFR head of marketing and design development. "At the Seagram Building, we saw an opportunity to create something extraordinary that will ensure it continues to remain the most celebrated office building in the world."
In preparation for this week's opening, RFR and Arch Amenities Group, The Playground's manager, worked with two tech firms – VTS Rise in Manhattan and BuildingEngines in Boston – to build a smartphone app that replaces the building's ID cards and makes it possible for employees to reserve time on the court and climbing wall and in the spinning, cardio and weight studios.
Tenants also can use the app's Mind-Body link sign up for high-intensity interval training and yoga, Pilates, martial arts and meditation classes. The app also provides self-guided tours of the fine art displayed throughout the building.
"This is where our approach to hospitality turns from a physical experience into a digital experience," said Zach Pointon, Arch Amenities Group's head of hospitality, adding that future functions will include real-time information about local transportation, including subways, buses and flights arriving at and departing from New York area's three major airports.
The Playground already has drawn the attention of other property owners, said AJ Camhi, RFR head of leasing. "The Playground is all the talk in the market right now. No other commercial building in New York has a court for basketball and pickleball. Landlords are trying to get tours of it. Brokers are talking to their landlord clients. It's the ultimate compliment."
Werdiger said RFR's investment in The Playground parallels the new priorities of its corporate tenants: to attract and retain the most qualified and talented employees. Corporate offices formerly were designed to please senior executives by providing them with spectacular office views and exclusive conveniences, like underground parking.
"Post-COVID, employers realize that they must make their office space more compelling than working from home in order to respond to the evolving work culture and encourage employees to return," he said. "Everyone who works in the Seagram Building now will gain, essentially, a free gym membership and a place to socialize with their coworkers – benefits they would not enjoy staying at home."
The strategy is working. The Seagram Building lost its major tenant just before the pandemic but now has leased 95% of that space to new tenants, a success that RFR attributes, in large part, to its investment in The Playground. "Tenants are promoting The Playground to encourage – not require – their employees to come back to the office," Camhi said.
RFR, which also owns and manages several other landmark buildings, continually looks for creative ways to attract tenants that might otherwise be tempted to move to the newest real estate coming on the market, Werdiger said. "You don't want these classic buildings to just turn into museums and dinosaurs. You want them to always continue to be relevant and the best."
Mike Flanagan, Arch Amenities Group chief growth officer, said The Playground exemplifies the type of amenity space that appeals to today's workforce. "We must create reasons for people to come back to work," he said. "To do that, we must blur the distinction between amenities and workspace and create very collaborative and highly hospitality-driven environments.
"Employees don't want to sit in a cubicle anymore. They want to go hang out in a lounge and different types of seating arrangements and work environments and be able to go to the fitness center and enjoy a coffee on the rooftop if they want."
The 38-story Seagram Building, at 375 Park Ave. between 52nd and 53rd street in Midtown Manhattan, was designed by Ludwig Mies van der Rohe with Philip Johnson. Constructed in 1956-58, it was designed as the headquarters for the Canadian distillers Joseph E. Seagram's & Sons. New York's Landmarks Preservation Commission designated the building and its plaza as a landmark in 1989. RFR gained full ownership in 2013 and continues to expand the significance of what the building means to New York and the world.
Studios Architecture of New York and Paris was The Playground project's architect. Graphic design was handled by GHD Partners, New York. The lighting designer was Focus Lighting Inc., New York. URBN Playground, New York, was the gym consultant. The structural engineer was Severud Associates, New York. The mechanical engineer was CFS Engineering, New York. Audio visual, acoustics and security systems were provided by Harvey Marshall Berling Associates, New York.
About RFR
RFR is a Manhattan-based, privately controlled real estate investment, development and management company founded in 1991 by Aby Rosen and Michael Fuchs. The company has built a world-class portfolio of commercial and residential real estate, including many of New York's signature office towers, ultra-luxury condominiums, hotels and high-end retail developments.
About Arch Amenities Group
Arch Amenities Group, based in Rockville, Maryland, is a leading provider of wellness, amenity and meeting services for commercial and residential properties, hotels and private clubs worldwide. Arch provides daily management services as well as feasibility studies, planning and design consultancy and pre-opening support. Arch is a portfolio company of private equity firm CI Capital Partners.
Click HERE to download photos of The Playground at the Seagram Building
View original content to download multimedia:
SOURCE RFR Holding LLC; Arch Amenities Group | https://www.whsv.com/prnewswire/2022/08/15/seagram-building-debuts-playground-bid-enhance-office-experience/ | 2022-08-15T12:53:35Z |
Firm to Remain a Minority Investor
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Sentinel Capital Partners, a private equity firm that invests in promising companies at the lower end of the middle market, today announced the closing of the merger of its portfolio company, Altima Dental, with 123Dentist, a leading dental support organization ("DSO") based in Vancouver, to create one of the largest DSOs in Canada. The transaction was financed through equity capital provided by 123Dentist's existing private equity sponsor, Peloton Capital Management, and new investors KKR, a leading global investment firm, and Heartland Dental, a KKR portfolio company and the leading dental support organization in the U.S. Sentinel will retain a minority equity stake in the combined company. Terms of the deal were not disclosed.
Altima Dental, headquartered in Toronto, was Sentinel's fifth investment in the dental sector at the time of the closing in 2016. In 2019, Altima merged with Quebec-based Lapointe Group, creating a leading DSO with offices in six provinces across Canada. In July 2022, Altima Dental and 123Dentist announced the plan to merge all three entities to create one of the largest DSOs in Canada with a network of 350 clinics servicing the entire country with a presence in every major metropolitan market. The merger creates a business with a national footprint across Canada and supports dental practices that provide a wide range of dental care to more than 800,000 patients, with more than 2.5 million patient visits annually.
"We expect this merger to benefit Canadian dentists, dental professionals, and patients alike, and will greatly expand support services for an already thriving dentist community that focuses on delivering exceptional care, improved access to high quality dentistry services, and greater opportunities for career advancement and mentorship for our team members," said Dr. Amin Shivji, CEO of 123Dentist.
"As a dentist-led organization for nearly 30 years, we have focused on bringing to patient care a dentist perspective as we built Altima Dental. Because 123Dentist has a similar focus, this combination will enable our supported dentists to continue to deliver an exceptional patient experience to Canadians," said Dr. George Christodoulou and Dr. Sven Grail, co-Founders and co-CEOs of Altima Dental. "Now, as part of the 123Dentist family, we are incredibly well-positioned to further develop our capabilities as one of the leading dental support organizations in Canada."
"We are grateful for the strong partnership we have had with the founders and management teams at Altima Dental and Lapointe Group," said Paul Murphy, Partner at Sentinel Capital Partners. "As an ongoing investor in the merger, we are looking forward to supporting Dr. Amin Shivji and the combined 123Dentist team as they continue to build a leading dentist-centric organization."
Sentinel has established a strong long-term record of investing in the dental sector dating back to its first platform investment in 2003. Besides Altima Dental, Sentinel's other dental investments include MB2 Dental, a dental partnership organization with a unique doctor-centric ownership model; Castle Dental and Metro Dentalcare, each a leading regional dental service provider; Northeast Dental Management, a leading dental service provider in the Northeast and Mid-Atlantic; and ReachOut Healthcare America, a leader in mobile dentistry.
Sentinel specializes in buying and building midmarket businesses in the United States and Canada in partnership with management. Sentinel targets aerospace and defense, business services, consumer, distribution, food and restaurants, franchising, healthcare, and industrial businesses. Sentinel invests in management buyouts, recapitalizations, corporate divestitures, going-private transactions, and structured equity investments of established businesses with EBITDA of up to $80 million. Sentinel also invests in special situations, including balance sheet restructurings, operational turnarounds, and minority junior capital solutions. For more information, please visit: sentinelpartners.com.
Altima Dental is one of Canada's longest-standing premier dental support organizations, founded and led by dentists, Dr. George Christodoulou and Dr. Sven Grail, who recognize the aspiration of providing exceptional healthcare and achieving personal and professional advancement. Altima Dental focuses on supporting superior patient care, best clinical practices, and true partnership with dentists. Altima Dental was named 2021 Best Workplaces in Health Care. For more information, please visit: altimadentalpartners.com.
Founded in 1987 by Larry and Yves Lapointe, Lapointe Group has been serving professionals and patients for 35 years. The Lapointe Group joined Altima Dental in 2019 and operates the Lapointe Dental Centres, a 100% Quebec banner of the Lapointe Group, with over 35 dental practices that provide the infrastructure for the practice of dental health professionals, offering a wide range of integrated services that enable dentists and denturists to optimize their practice and direct their full focus on patient care. The Lapointe Group also operates a high-tech integrated dental lab, Summum Dental Laboratory, including over 80 dental technicians, and expertise in all types of dental prosthetics. For more information, please visit: centreslapointe.com.
123Dentist is a leading dental support organization in Canada. It has grown from a single practice in Vancouver, owned by CEO Dr. Amin Shivji and two partners, to more than 250 supported practices and 3,500 team members. 123Dentist was founded on two key principles: putting patients above all else; and that supported dentists and staff are the most important factors in keeping patients happy. 123Dentist's vision is to be the dental support community all Canadian dentists and dental professionals want to belong to. 123Dentist offers alternative partnership models to meet the needs of each individual dentist, including the opportunity to retain ownership of the clinic. This unique model enables supported dentists to focus on providing optimal care to patients, while an experienced team provides a wide range of support services. For more information, please visit: 123dentist.com.
Contact: Roland Tomforde
Broadgate Consultants
212-232-2222
View original content:
SOURCE Sentinel Capital Partners | https://www.whsv.com/prnewswire/2022/08/15/sentinel-exits-altima-dental-via-merger-with-123dentist/ | 2022-08-15T12:53:41Z |
Iconic Snack Company and Beast Philanthropy – Official Non-Profit to YouTube Star MrBeast – Donate Around $200,000 in Snacks, School Supplies
FRESNO, Calif., Aug. 15, 2022 /PRNewswire/ -- As part of its kid-led Board of Imagination program – now in its second year – Sun-Maid is debuting their first philanthropic effort to turn creativity and imagination into back-to-school support. The iconic snack company and its innovative Board of Imagination partnered with one of the world's biggest YouTube celebrities, MrBeast, through his Beast Philanthropy channel to deliver around $200,000 in school supplies and Sun-Maid snacks to four schools in epic fashion.
The snack brand and YouTube superstar surprised-and-delighted four underfunded schools in MrBeast's (Jimmy Donaldson) backyard of Greenville, North Carolina and Ehrenberg Elementary in the town of Quartzsite, AZ, one of the most under-funded schools in America.
In addition to delivering mountains of Sun-Maid Fruity Raisin Snacks and Yogurt-Covered Raisins (MrBeast's favorite!), the YouTube video features the brand partnership providing busloads of school supplies to ECU Community School and South Greenville Elementary, donating a brand-new STEM Lab at Wellcome Elementary, gifting $10,000 to a beloved lunch lady and giving away a brand-new car to a teacher at Falkland Elementary who has faced unlucky times.
"Sun-Maid thrives on fostering the imaginative spirit in kids, which starts by getting them the snacks and supplies they need to kick off the school year right. For us, we couldn't think of a better match than Beast Philanthropy and MrBeast – who are among the most innovative and charitable groups on YouTube," said Harry Overly, President & CEO of Sun-Maid Growers of California. "It's a privilege to give back and start this school year by serving students and communities in need, and in turn, encouraging to our kid-led Board of Imagination to think charitably through their efforts of service."
The partnership between Sun-Maid and Beast Philanthropy highlights 'kids helping kids,' a mantra brought to life through Sun-Maid's Board of Imagination. The program selects kids from throughout the country to sit on a board that meets quarterly to help make decisions for the company. Two of the 'board members' had the chance of a lifetime as they helped prepare gift bags directly with Donaldson for grateful and enthusiastic students during the video shoot.
"Sun-Maid provided tremendous support in making this come to life. They're a great partner that supports Beast Philanthropy's mission to make the world a better place," said MrBeast, Jimmy Donaldson. "The video is one of the most exciting Beast Philanthropy has pushed out and it's a bit emotional with all of the happy surprises!"
For more information on Sun-Maid's raisin snacks portfolio and to find a local retailer near you, please visit www.sunmaid.com
About Sun-Maid Growers of California
Founded in 1912, Sun-Maid Growers of California is a farmer's cooperative of 750 grower families with vineyards in California's Central Valley. From childhood to adulthood and generation to generation, Sun-Maid's innovative snacks continue to feed imaginations one little red box at a time--because when imagination is used for good, there's nothing more delicious! And while some things change, our real, minimally processed and consistently good ingredients haven't. Always starting with a whole fruit you can see and taste, Sun-Maid continues to offer a trusted go-to snack that's simple, healthy and versatile--imagine that! For more information about Sun-Maid visit www.sunmaid.com and follow the brand on social media including TikTok, Instagram and Twitter.
About Beast Philanthropy
In June 2017, when Jimmy Donaldson (AKA MrBeast) received his first YouTube sponsorship deal of $10,000, he wondered, "how can I transform this money into something good?" Not wanting to keep the money for himself, Jimmy agreed to the sponsorship deal with one condition: he was able to give away all of the money. The sponsor agreed. Jimmy stayed true to his word and gave away the full $10,000, but he quickly realized that handing someone an envelope of cash was not enough. This first giveaway ignited a flame within Jimmy, and every charitable act fueled his desire to help those in need. And with a goal of making the world a better place, the idea for Beast Philanthropy was born.
Beast Philanthropy exists to leverage the power of social media to offer hope, education, and inspiration to MrBeast's massive audience while raising funds to alleviate the suffering of the most vulnerable and marginalized populations across the planet.
View original content to download multimedia:
SOURCE Sun-Maid | https://www.whsv.com/prnewswire/2022/08/15/sun-maid-feeds-imaginations-with-youtube-icon-mrbeast-beast-philanthropy-back-to-school-video/ | 2022-08-15T12:53:48Z |
VANCOUVER, BC, Aug. 15, 2022 /PRNewswire/ - Taseko Mines Limited (TSX: TKO) (NYSE American: TGB) (LSE: TKO) ("Taseko" or the "Company") is pleased to announce the U.S. Environmental Protection Agency ("EPA") has publicly issued a draft Underground Injection Control ("UIC") permit for its Florence Copper Project. The EPA has stated that the public comment period for the draft federal permit will last 45 days, ending on September 29, with a virtual public hearing to be held on September 15.
Stuart McDonald, Taseko's President and CEO, commented, "The UIC permit is the final key permit required for the construction and operation of the Florence Copper commercial facility. Our project has gone through extensive scrutiny by both the Arizona Department of Environmental Quality and the EPA over the past eight years and we are confident that the rigorous work completed by both these regulatory bodies will result in permitting success in the coming months."
Florence Copper is expected to have the lowest energy and greenhouse gas-intensity ("GHG") of any copper producer in North America, and will reduce the United States' reliance on foreign producers for a metal considered to be critical for the transition to a low-carbon economy.
"As the United States advances toward its goal of net-zero carbon emissions by 2050 – including 100% clean electricity by 2035 and 50% light-duty electrical vehicle sales by 2030 – the country will need to address its reliance on imports of critical metals. Low impact, environmentally sound projects like Florence Copper will help meet the growing U.S. demand for copper," concluded Mr. McDonald.
Stuart McDonald
President and CEO
No regulatory authority has approved or disapproved of the information contained in this news release.
This document contains "forward-looking statements" that were based on Taseko's expectations, estimates and projections as of the dates as of which those statements were made. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "outlook", "anticipate", "project", "target", "believe", "estimate", "expect", "intend", "should" and similar expressions.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the Company's actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These included but are not limited to:
- uncertainties about the future market price of copper and the other metals that we produce or may seek to produce;
- changes in general economic conditions, the financial markets, inflation and interest rates and in the demand and market price for our input costs, such as diesel fuel, reagents, steel, concrete, electricity and other forms of energy, mining equipment, and fluctuations in exchange rates, particularly with respect to the value of the U.S. dollar and Canadian dollar, and the continued availability of capital and financing;
- uncertainties resulting from the war in Ukraine, and the accompanying international response including economic sanctions levied against Russia, which has disrupted the global economy, created increased volatility in commodity markets (including oil and gas prices), and disrupted international trade and financial markets, all of which have an ongoing and uncertain effect on global economics, supply chains, availability of materials and equipment and execution timelines for project development;
- uncertainties about the continuing impact of the novel coronavirus ("COVID-19") and the response of local, provincial, state, federal and international governments to the ongoing threat of COVID-19, on our operations (including our suppliers, customers, supply chains, employees and contractors) and economic conditions generally including rising inflation levels and in particular with respect to the demand for copper and other metals we produce;
- inherent risks associated with mining operations, including our current mining operations at Gibraltar, and their potential impact on our ability to achieve our production estimates;
- uncertainties as to our ability to control our operating costs, including inflationary cost pressures at Gibraltar without impacting our planned copper production;
- the risk of inadequate insurance or inability to obtain insurance to cover material mining or operational risks;
- uncertainties related to the feasibility study for Florence copper project (the "Florence Copper Project" or "Florence Copper") that provides estimates of expected or anticipated capital and operating costs, expenditures and economic returns from this mining project, including the impact of inflation on the estimated costs related to the construction of the Florence Copper Project and our other development projects;
- the risk that the results from our operations of the Florence Copper production test facility ("PTF") and ongoing engineering work including updated capital and operating costs will negatively impact our estimates for current projected economics for commercial operations at Florence Copper;
- uncertainties related to the accuracy of our estimates of Mineral Reserves (as defined below), Mineral Resources (as defined below), production rates and timing of production, future production and future cash and total costs of production and milling;
- the risk that we may not be able to expand or replace reserves as our existing mineral reserves are mined;
- the availability of, and uncertainties relating to the development of, additional financing and infrastructure necessary for the advancement of our development projects, including with respect to our ability to obtain any remaining construction financing potentially needed to move forward with commercial operations at Florence Copper;
- our ability to comply with the extensive governmental regulation to which our business is subject;
- uncertainties related to our ability to obtain necessary title, licenses and permits for our development projects and project delays due to third party opposition, particularly in respect to Florence Copper that requires one key regulatory permit from the U.S. Environmental Protection Agency ("EPA") in order to advance to commercial operations;
- our ability to deploy strategic capital and award key contracts to assist with protecting the Florence Copper project execution plan, mitigating inflation risk and the potential impact of supply chain disruptions on our construction schedule and ensuring a smooth transition into construction once the final permit is received from the EPA;
- uncertainties related to First Nations claims and consultation issues;
- our reliance on rail transportation and port terminals for shipping our copper concentrate production from Gibraltar;
- uncertainties related to unexpected judicial or regulatory proceedings;
- changes in, and the effects of, the laws, regulations and government policies affecting our exploration and development activities and mining operations and mine closure and bonding requirements;
- our dependence solely on our 75% interest in Gibraltar (as defined below) for revenues and operating cashflows;
- our ability to collect payments from customers, extend existing concentrate off-take agreements or enter into new agreements;
- environmental issues and liabilities associated with mining including processing and stock piling ore;
- labour strikes, work stoppages, or other interruptions to, or difficulties in, the employment of labour in markets in which we operate our mine, industrial accidents, equipment failure or other events or occurrences, including third party interference that interrupt the production of minerals in our mine;
- environmental hazards and risks associated with climate change, including the potential for damage to infrastructure and stoppages of operations due to forest fires, flooding, drought, or other natural events in the vicinity of our operations;
- litigation risks and the inherent uncertainty of litigation, including litigation to which Florence Copper could be subject to;
- our actual costs of reclamation and mine closure may exceed our current estimates of these liabilities;
- our ability to meet the financial reclamation security requirements for the Gibraltar mine and Florence Project;
- the capital intensive nature of our business both to sustain current mining operations and to develop any new projects, including Florence Copper;
- our reliance upon key management and operating personnel;
- the competitive environment in which we operate;
- the effects of forward selling instruments to protect against fluctuations in copper prices, foreign exchange, interest rates or input costs such as fuel;
- the risk of changes in accounting policies and methods we use to report our financial condition, including uncertainties associated with critical accounting assumptions and estimates; and Management Discussion and Analysis ("MD&A"), quarterly reports and material change reports filed with and furnished to securities regulators, and those risks which are discussed under the heading "Risk Factors".
For further information on Taseko, investors should review the Company's annual Form 40-F filing with the United States Securities and Exchange Commission www.sec.gov and home jurisdiction filings that are available at www.sedar.com, including the "Risk Factors" included in our Annual Information Form.
View original content:
SOURCE Taseko Mines Limited | https://www.whsv.com/prnewswire/2022/08/15/taseko-mines-epa-issues-draft-permit-florence-copper-project/ | 2022-08-15T12:53:55Z |
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTV, UBX, AGS, CURV, and BBBY.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
- PSTV: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=PSTV&prnumber=081520221
- UBX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=UBX&prnumber=081520221
- AGS: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=AGS&prnumber=081520221
- CURV: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=CURV&prnumber=081520221
- BBBY: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=BBBY&prnumber=081520221
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
View original content to download multimedia:
SOURCE InvestorsObserver | https://www.whsv.com/prnewswire/2022/08/15/thinking-about-buying-stock-plus-therapeutics-unity-biotechnology-playags-torrid-or-bed-bath-amp-beyond/ | 2022-08-15T12:54:01Z |
WINTER HAVEN, Fla., Aug. 15, 2022 /PRNewswire/ -- The Tree Defender, LLC, the creator and industry leader in Individual Protective Cover (IPC) technology, has been awarded a key fourth U.S. patent for its technology, opening the door for the company to expand and grow.
"These patents establish The Tree Defender as the creator of IPC technology," said Scotty Thompson, the co-creator of The Tree Defender. "This will now allow us to explore joint ventures with other groups and further expand globally into the many other varied applications such as vertical farming. One very exciting path is that we are demonstrating much higher brix levels and beneficial phytochemical levels in the fruits and vegetables."
According to Thompson, these most recent issuances reflect technology innovations related to food security, vertical farming, herbicide reduction, fertilizer reduction, reduction in water usage, and cold protection. The approximate 80% water savings capability alone could be a huge benefit currently to growers in the western United States and other drought-stricken regions globally.
Thompson, along with Thomas A. Thayer — both from Central Florida — started The Tree Defender as a way to fight back against greening and other various diseases that have devastated the Florida citrus industry.
While many protective covers look the same, the patented Tree Defender is made with proprietary high-quality materials that have been proven in multiple studies to protect citrus trees from the Asian citrus psyllid and greening. In addition, The Tree Defender uses proprietary UV inhibitors that help create a healthy atmosphere where increased growth rates upwards of 30% have been observed.
According to research published by University of Florida Professor Fernando Alferez, the use of IPCs can modify the atmosphere within the covered canopy by altering relative humidity and temperature. This means the air under the cover contains more moisture, allowing the leaves to stay open longer and extend the length of time available for photosynthesis.
This increase in photosynthetic efficiency can improve a plant or tree's ability to sequester carbon from the atmosphere, which allows growers the possibility of exploring the carbon credit market for an added income stream, said Thompson.
"Under IPCs, the leaves were greener, larger, and with more chlorophyll, more soluble sugars, and less starch, indicating that they have been metabolically more active than noncovered trees," said Alferez. "Interestingly, trees under IPCs flushed earlier and more profusely, and the flushing was more synchronized compared to trees without IPCs, resulting in faster tree growth." In addition, Alferez confirmed that trees protected by IPCs produce higher-quality, more soluble solids.
The faster growth and healthier leaves on trees protected by The Tree Defender have a definite financial impact on many levels. With the ability to now grow young trees free of greening, it will help establish a path to recovery for Florida and the world's other citrus-growing regions.
For information, call (863) 439-2877 or visit thetreedefender.com.
Contact: Meg Wally
Telephone: 863-439-2877
Email: meg@thetreedefender.com
View original content:
SOURCE The Tree Defender | https://www.whsv.com/prnewswire/2022/08/15/tree-defender-awarded-fourth-us-patent/ | 2022-08-15T12:54:07Z |
Burtchville Twp. still under boil advisory after water main break; Whiter declares an emergency
Gov. Gretchen Whitmer has declared a state of emergency for communities in four southeastern Michigan counties, including St. Clair County after a regional water main break was reported this weekend.
However, Burtchville Township was — in addition to one business site — the only community in the county reportedly affected.
The Great Lakes Water Authority discovered a leak on a 120-inch water transmission main that distributes drinking water from its Lake Huron Water Treatment Facility in the early morning hours on Saturday.
Soon after, a boil water advisory was issued for communities across the region. The list of 23 communities, affecting an estimated 935,000 people, included Burtchville and the DTE Greenwood facility in the western half of St. Clair County, as well as Flint and many Detroit-area communities.
According to the water authority, the advisory was due to changing water pressure levels and out of an abundance of caution. Loss of water pressure, authorities said, can lead to bacterial contamination in the water system.
By Sunday, Burtchville remained under a boil advisory, along with Almont, Bruce Township, Imlay City, Shelby Township, Washington Township, the Greenwood site, and an industrial park in Romeo.
The remaining advisory area affected 133,000 residents, the authority reported. The water authority reported that some water pressure had been restored to all communities.
According to the authority’s release Sunday, crews isolated the break and began work to remove water from the site using four 8-inch pumps, preparing the area of repairs. A replacement pipe had been ordered and was being shipped via truck to Michigan from Texas.
The water authority reported the timeline for returning the pipeline to service to be two weeks, including one week for repairs and another for water quality testing.
According to St. Clair County’s emergency management, bottled water was being made available from 10 a.m. to 3 p.m. daily at the Burtchville Fire Department, 4000 Burtch Road, until the alert is lifted.
No other local water supplies were affected.
The state’s emergency operations center was activated as of 4 p.m. Saturday to respond to the ongoing water main break following requests for additional resources from local communities.
State emergency personnel were reportedly monitoring the situation and working with other state and local officials and private partners to coordinate resources.
By declaring a state of emergency, according to the governor’s office, state resources were made available to local response and recovery efforts in the designated areas. It also authorizes the Michigan State Police, Emergency Management and Homeland Security Division to coordinate efforts to help.
Under the precautionary boil water advisory, residents were advised not to drink water without first boiling it. They were also advised to bring water to a boil for at least one minute before letting it cool for use.
Boiled, bottled, or disinfected water could be used for drinking, making ice, washing dishes, brushing teeth, or preparing food until further notice.
Contact Jackie Smith at (810) 989-6270 or jssmith@gannett.com. Follow her on Twitter @Jackie20Smith. | https://www.thetimesherald.com/story/news/2022/08/14/burtchville-township-boil-water-advisory-governor-gretchen-whitmer-declares-emergency/10324551002/ | 2022-08-15T12:54:09Z |
Annual Transportation Event Dedicated to Enhancing Supply Chain Collaboration and Connectivity
ORLANDO, Fla., Aug. 15, 2022 /PRNewswire/ -- Trimble (NASDAQ: TRMB) kicked off its 2022 Insight Tech Conference + Expo by highlighting its focus on empowering and enabling carriers, shippers and brokers to work better together. In Monday's Opening Session, Trimble leaders detailed its Connect and Scale 2025 strategy, centered on building industry-leading cloud platforms to streamline the industry lifecycle of transportation—from procurement to planning to execution.
"We are creating a digital experience that seamlessly integrates data, solutions and workflows to transform the way our customers work,'' said Rob Painter, president and CEO of Trimble. "By facilitating these connections, Trimble is uniquely positioned to make transportation more collaborative, productive and sustainable—for our customers, our planet and everyone the supply chain serves."
To support this commitment to collaboration, the 2022 edition of Insight showcases a variety of transportation industry suppliers, including integration partners and providers of competing solutions. This inclusive approach provides attendees with an unparalleled opportunity to learn about technology trends, share ideas and gain inspiration to enhance all aspects of their operations.
After hosting the event virtually in 2020 and 2021, this year's in-person conference features four days of networking and educational opportunities among industry leaders. Monday's Opening Session also gave attendees the opportunity to learn about Trimble's continued commitment to creating an ecosystem for all transportation stakeholders to be more connected.
"Since we last gathered together in person three years ago, the world has changed—but this change has reinforced the crucial role of technology in reducing inefficiencies and maximizing utilization throughout the industry," said Ron Bisio, senior vice president of Trimble Transportation. "We remain dedicated to developing solutions that not only solve our customers unique business challenges but enable them to improve collaboration and connectivity with partners across the supply chain."
The 2022 Insight Tech Conference + Expo takes place Aug. 14-17 at the Walt Disney World Swan and Dolphin Resort in Orlando, Florida. Highlights from this year's agenda include hundreds of educational sessions, customer recognition through the 2022 Ovation Awards and an engaging keynote with Microsoft's Scott Guthrie, executive vice president, Cloud + AI Group.
For more information on Insight 2022, visit: transportation.trimble.com/insight-2022.
Trimble Transportation is transforming the supply chain by empowering stakeholders—drivers, carriers, intermediaries and shippers—to connect via a common platform in order to integrate data and optimize procurement, planning and execution workflows to effectively maximize resource utilization. The unmatched combination of Trimble's enterprise transportation management systems (TMS) and asset maintenance solutions for the back office, driver mobility solutions and routing and navigation capabilities enable customers to more holistically respond to the challenging transportation demands driven by today's dynamic supply chain. For more information, visit: transportation.trimble.com.
Trimble is an industrial technology company transforming the way the world works by delivering solutions that enable our customers to thrive. Core technologies in positioning, modeling, connectivity and data analytics connect the digital and physical worlds to improve productivity, quality, safety, transparency and sustainability. From purpose-built products to enterprise lifecycle solutions, Trimble is transforming industries such as agriculture, construction, geospatial and transportation. For more information about Trimble (NASDAQ:TRMB), visit: www.trimble.com.
GTRMB
View original content to download multimedia:
SOURCE Trimble | https://www.whsv.com/prnewswire/2022/08/15/trimble-showcases-customer-driven-platform-strategy-open-its-insight-tech-conference-expo/ | 2022-08-15T12:54:14Z |
Historic Citadel building in downtown Port Huron listed for sale
A prominent building at the north end of Port Huron’s Main Street — with theater and commercial space and upstairs lofts — has been put up for sale by the family who last redeveloped it several years ago.
The Citadel building at 309 Huron Ave. is listed with Kramer Commercial Realty at a price of $1.2 million, as of earlier this month.
Korissa Wilkins, a broker for the real estate company, said she’s garnered plenty of inquiries into the historic property, but no formal deal was yet in the works.
“It’s a terrific mixed-use building. The restoration the Witts did was phenomenal,” she said. Dave and Georgina Witt purchased the site in 2015 and it was among a host of properties the couple and other members of their family helped redevelop throughout the 2010s.
“You’ve got the Enter Stage Right theater tenant in there that has been terrific for the last six years,” Wilkins said. “There’s a couple other commercial spaces, which is the financial institution (Primerica) and also the Red Kettle Coffee Company, that they’ve really enjoyed having onsite as tenants.
“Then, there’s six additional lofts there on site. It’s just a unique property that stands out in downtown. It could be a great opportunity for an investor,” she said.
Wilkins said existing leases would be honored as part of the process.
Built in 1903, a variety of businesses utilized space on the site. It operated as the Salvation Army Citadel until the site's founding namesake moved to Court Street in the mid-1960s. It bloomed in the 1970s into the Citadel Mall and underwent a facelift for its centennial 19 years ago.
Under the Witts, newly renovated lofts debuted in 2016, and Enter Stage Right began to host productions on the Citadel Stage around the same time.
Dave Witt died in 2020. According to his obituary, he purchased his first building in Port Huron in 2007, renovating loft and retail spaces in 10 buildings in the years that followed.
“They’ve done a lot of restoration and a lot of terrific projects downtown, breathing life back into buildings," Wilkins said.
More on the Witts' presence downtown
Dave and Georgina's son Steve Witt and his wife Michelle also played a role in many landmark projects downtown, including through the couple’s Sanctum Contracting. As of last week, the website and listed phone number for the construction business were no longer in service.
In an email Friday, Michelle Witt declined to address personal details for the family but said, “Their main focus was to bring vitality back to the downtown, not to be long-term landlords. With that being said, Bens 314 Lofts was sold in May, and the Citadel Lofts were next on the list.”
She didn’t indicate if any other properties the family helped redevelop would be sold.
The Bens 314 lofts building farther south on Huron Avenue, which the Witts purchased in 2012, was sold in May. . The buyer is listed as RSS Investments LLC, whose state-registered agent is Robert Barnes and taxpayer address is Barnes' law firm in Lexington.
Barnes, also listed as the successor trustee for a revocable trust agreement in a land contract for the property, declined to confirm plans or details when reached by the Times Herald on Friday.
According to the St. Clair County register of deeds, mixed-use properties still owned by entities associated with a Witt family member include the Black River Harbor Place under Arashi LLC in the 500 block of Quay Street, the McKeough, Malmok, and Tecumseh buildings at 215, 221 and 231 Huron Ave., and Midtown Lofts at 411 Grand River Ave.
“The Witt family spearheaded the revitalization of multiple downtown properties because they believed there was a bright future for downtown,” Michelle Witt wrote Friday. “They had a dream of what downtown could become, even before others felt the same way. They went into each venture with aspirations larger than the previous project.”
Contact Jackie Smith at (810) 989-6270 or jssmith@gannett.com. Follow her on Twitter @Jackie20Smith. | https://www.thetimesherald.com/story/news/2022/08/15/citadel-building-downtown-port-huron-listed-sale/10299116002/ | 2022-08-15T12:54:15Z |
~ Debt Financing Further Extends Maturity Profile ~
DELRAY BEACH, Fla., Aug. 15, 2022 /PRNewswire/ -- UpHealth, Inc. ("UpHealth" or the "Company") (NYSE: UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced the sale of $67.5 million in aggregate principal amount of a new series of variable rate convertible senior secured notes due December 15, 2025 (the "2025 Notes") in a private placement transaction, raising approximately $22.5 million in gross cash proceeds after paying for a repurchase of $45.0 million of its 6.25% convertible senior notes due 2026. The 2025 Notes are convertible into shares of UpHealth common stock at a conversion price of $1.75 per share, which represents a 101% premium over the most recent closing price of UpHealth's common stock.
The 2025 Notes will be senior secured obligations of UpHealth and will accrue interest at a rate equal to the daily secured overnight financing rate ("SOFR") plus 9.0% per annum, with a minimum rate of 10.5% per annum, payable quarterly in arrears. The 2025 Notes will mature on December 15, 2025, unless earlier repurchased, redeemed or converted. Holders will have the right to convert their 2025 Notes at any time. UpHealth will settle conversions solely in shares of its common stock, except for payments of cash in lieu of fractional shares.
"We are pleased to announce this milestone transaction. Importantly, the proceeds of this offering will be used to repay the outstanding Seller Notes that mature on September 1, 2022, as well as provide us with the liquidity to execute against our growth plans," commented Martin Beck, CFO of UpHealth. "This transaction provides us with more than three years until any significant borrowings reach maturity, while maintaining the Company's total leverage."
The 2025 Notes were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and, along with the shares of common stock underlying the 2025 Notes, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the 2025 Notes and the underlying shares of common stock may not be offered, sold, pledged or otherwise transferred except to a qualified institutional buyer (within the meaning Rule 144A under the Securities Act) pursuant to an effective Securities Act registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.
Oppenheimer & Co Inc. served as exclusive placement agent for the 2025 Notes.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
UpHealth is a global digital health company that delivers digital-first technology, infrastructure and services to dramatically improve how healthcare is delivered and managed. The UpHealth platform creates digitally enabled "care communities" that improve access and achieve better patient outcomes at lower cost, through digital health solutions and interoperability tools that serve patients wherever they are, in their native language. UpHealth's clients include global governments, health plans, healthcare providers and community-based organizations. For more information, please visit https://uphealthinc.com and follow us at @UpHealthInc on Twitter and UpHealth Inc on LinkedIn.
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Such forward-looking statements include, but are not limited to, statements regarding payments pursuant to the terms of UpHealth's debt obligations and the conversion or maturity of such debt. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of UpHealth in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on UpHealth as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting UpHealth will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the ability of UpHealth to service or otherwise pay its debt obligations, the mix of services utilized by UpHealth's customers and such customers' needs for these services, market acceptance of new service offerings, the ability of UpHealth to expand what it does for existing customers as well as to add new customers, that UpHealth will have sufficient capital to operate as anticipated, and the impact that the novel coronavirus and the illness, COVID-19, that it causes, as well as government responses to deal with the spread of this illness and the reopening of economies that have been closed as part of these responses, may have on UpHealth's operations, the demand for UpHealth's products, global supply chains and economic activity in general. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Investor Relations:
Shannon Devine (MZ North America)
Managing Director
203-741-8811
UPH@mzgroup.us
Media Inquiries:
Kelsie Aziz (Ketchum)
Vice President, Financial Communications
972-408-7103
kelsie.aziz@Ketchum.com
View original content to download multimedia:
SOURCE UpHealth, Inc. | https://www.whsv.com/prnewswire/2022/08/15/uphealth-announces-675-million-convertible-debt-financing/ | 2022-08-15T12:54:20Z |
Here's how you can support St. Clair County crime victims
When P.S. You're My Hero founder Mara McCalmon endured criminal proceedings in the year following her husband's murder in 2010, there were few resources or crime victims like her.
Now, the St. Clair County Victim's Rights Office offers a comfort room, refreshments, financial support and a therapy dog, all funded through P.S. You're My Hero.
Residents have the chance to support crime victims through the nonprofit's annual 5K Run/2 Mile Walk, set for 9 a.m. Sept. 18 in front of the YMCA of the Blue Water Area.
McCalmon said the event will also include a gift basket raffle, a silent auction that will include vacation packages and food truck No Forks Given.
To register, visit psyouremyhero.org/. Registration before Sept. 10 is $30; after that, it's $35.
While last year's turnout was smaller due to the COVID-19 pandemic, McCalmon said she hopes this year's event returns to larger numbers. The race is the nonprofit's largest fundraiser.
The nonprofit accepts donations year-round. Mail checks made payable to P.S. You're My Hero to the St. Clair County Courthouse at 201 McMorran Blvd., Port Huron, MI, 48060, with attn: Victim's Rights #3308.
More on P.S. You're My Hero
P.S. You're My Hero provides financial assistance to crime victims in various ways, such as counseling packages, rent and utility assistance, medical bills or food vouchers while attending court hearings, McCalmon said.
"This is a way to value victims, to say hey, we care about you. We're here for you, and if nothing else, we're acknowledging you and I think that's super important," McCalmon said.
The nonprofit has also funded several projects at the St. Clair County Victims Rights Office, which helps victims navigate the criminal justice system and access financial assistance.
In 2018, P.S. You're My Hero helped fund the purchase of Bruin, a golden retriever trained to comfort victims during testimony, in between court hearings and in interviews with prosecutors.
A year later, a comfort room was opened in the St. Clair County Crime Victim's Rights Office with the help of the nonprofit. The area offers two rooms filled with comfortable furniture and refreshments to give victims and their families a place to gather before and after hearings.
Victims Rights Coordinator Cortney Carl said the room was especially helpful during the COVID-19 pandemic, when victims weren't allowed in the courtroom due to gathering restrictions. Some victims could watch proceedings or testify from a laptop in the comfort room.
This April, P.S. You're My Hero helped support crime victims through donations to the St. Clair County Child Abuse and Neglect Council and Blue Water Safe Horizons.
"It was really cool for us because we know that victims are affected in so many different ways ... so this is just another way to help victims through other organizations," McCalmon said.
Carl and McCalmon said P.S. You're My Hero has improved crime victims' experience by acknowledging them and helping address their needs.
"There was no real amenities or ways to help people. There is now and we hope just to build and strengthen that," McCalmon said. "Always putting victims first, that's our goal."
Contact Laura Fitzgerald at (810) 941-7072 or lfitzgeral@gannett.com. | https://www.thetimesherald.com/story/news/2022/08/15/ps-youre-my-hero-supports-st-clair-county-crime-victims/10284678002/ | 2022-08-15T12:54:21Z |
Second Quarter Revenue of $43.7 million, a 21% increase on a Sequential Basis
Gross Margin Expanded to 51%, compared to 43% on a Sequential Basis
Nearly 50% of Transformation Initiatives Completed To-Date
Subsequent to Quarter End, Company Under New Leadership of CEO Samuel J. Meckey
Announced $67.5M Convertible Debt Financing, Further Extending Company's Maturity Profile
DELRAY BEACH, Fla., Aug. 15, 2022 /PRNewswire/ -- UpHealth, Inc. ("UpHealth" or the "Company") (NYSE: UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced financial results for the second quarter ended June 30, 2022.
UpHealth CEO Sam Meckey said, "I joined UpHealth because the Company's assets are uniquely situated within the healthcare ecosystem, to solve some of the most pressing problems in healthcare today. The opportunities for UpHealth to create value for our clients are significant and I am eager to contribute my experience and knowledge in healthcare, to help drive our future growth."
"I am pleased to say that with the company's strategies in place and the foundation to support our transformation, we are well positioned for long-term growth. Together, we look forward to further implementing our strategic vision, uncovering additional ways to unlock value, and delivering for all constituents of UpHealth."
Meckey also said that he is focused on: "driving growth across all verticals; delivering high-quality, predictable revenue streams; conserving cash; and improving operational excellence, all while creating a culture that attracts and retains top talent who focus intensely on client needs and client service."
Second Quarter 2022 Financial Highlights:
- Revenue for the second quarter of 2022 was $43.7 million, a 37% increase compared to GAAP revenue for the second quarter of 2021 of $31.9 million and an 11% increase compared to pro forma revenue for the second quarter of 2021 of $39.2 million. Gross margin expanded to 51%, up from GAAP and pro forma gross margin in the second quarter of 2021 of 36%.
- Revenue and gross margin by segment for the second quarter of 2022 were:
- Operating loss for the second quarter of 2022 was $(10.0) million, a 72% improvement compared to operating loss in the second quarter of 2021 of $(35.5) million.
- Adjusted EBITDA for the second quarter of 2022 was $4.0 million, compared to GAAP and pro forma Adjusted EBITDA for the second quarter of 2021 of $2.2 million and $2.4 million, respectively.
Please refer to the discussion and tables under "Non-GAAP Financial Information."
Year-to-Date Second Quarter 2022 Financial Highlights:
- Year-to-date revenue for the second quarter of 2022 was $79.6 million, a 78% increase compared to year-to-date GAAP revenue for the second quarter of 2021 of $44.7 million and a 14% increase compared to year-to-date pro forma revenue for the second quarter of 2021 of $69.8 million. Year-to-date gross margin for the second quarter of 2022 expanded to 47%, up from year-to-date GAAP and pro forma gross margin for the second quarter of 2021 of 41% and 40%, respectively.
- Year-to-date revenue and gross margin by segment for the second quarter of 2022 were:
- Year-to-date operating loss for the second quarter of 2022 was $(28.0) million, a 27% improvement compared to year-to-date operating loss for the second quarter of 2021 of $(38.3) million.
- Year-to-date Adjusted EBITDA for the second quarter of 2022 was $2.6 million, compared to year-to-date GAAP and pro forma Adjusted EBITDA for the second quarter of 2021 of $2.9 million and $5.4 million, respectively.
Please refer to the discussion and tables under "Non-GAAP Financial Information."
Significant Second Quarter Business Highlights:
- 240 of the over 600 specific transformation milestones completed as of quarter end, and an expectation to be at approximately 80% completion by the end of the third quarter.
- Martti™ currently supports 224,000 encounters per month and over 34,000 video endpoints at over 2,300 healthcare locations in the U.S. During the second quarter, the Company closed 46 new Martti™ contracts, with over 90 implementations in healthcare facilities nationwide.
- Executed a contract extension and expansion with the L.A. County Department of Mental Health, expanding UpHealth's work for an additional 12 months, contributing $7.9 million to revenues.
- The Company recorded its largest volume of telehealth use ever in the U.S. with over 10.6 million minutes of consultations in Q2, compared to 9.4 million minutes in Q1 2022.
- HelloLyf consultations in India experienced growth of over 4x with patient consultations increasing by 416K, from 115K in Q2 2021 to 531K in Q2 2022.
- Finalized a contract with a hospital system to provide an education program for their staff on providing health care for minority populations with the goal of driving better outcomes, reducing readmittance rates and reducing legal penalties for the hospital.
- Announced the hiring of operations veteran, Daniel Mandoli, as Executive Vice President of our Services Business. Operations optimizations are underway across the pharmacy business.
- Subsequent to quarter end, the independent directors of UpHealth welcomed the termination of litigation that delayed the Annual Meeting of Stockholders. As a result of the termination of the litigation, the Company will hold its Annual Meeting of Stockholders as soon as practicable.
Convertible Debt Financing
The Company announced today the sale of $67.5 million in aggregate principal amount of a new series of variable rate convertible senior secured notes due December 15, 2025 (the "2025 Notes") in a private placement transaction, raising approximately $22.5 million in gross cash proceeds after paying for a repurchase of $45.0 million of its 6.25% convertible senior notes due 2026. The 2025 Notes are convertible into shares of UpHealth common stock at a conversion price of $1.75 per share, which represents a 101% premium over the most recent closing price of UpHealth's common stock.
The 2025 Notes will be senior secured obligations of UpHealth and will accrue interest at a rate equal to the daily secured overnight financing rate ("SOFR") plus 9.0% per annum, with a minimum rate of 10.5% per annum, payable quarterly in arrears. The 2025 Notes will mature on December 15, 2025, unless earlier repurchased, redeemed or converted. Holders will have the right to convert their 2025 Notes at any time. UpHealth will settle conversions solely in shares of its common stock, except for payments of cash in lieu of fractional shares.
"We are pleased to announce this milestone transaction. Importantly, the proceeds of this offering will be used to repay the outstanding Seller Notes that mature on September 1, 2022, as well as provide us with the liquidity to execute against our growth plans," commented Martin Beck, CFO of UpHealth. "This transaction provides us with more than three years until any significant borrowings reach maturity, while maintaining the Company's total leverage."
The 2025 Notes were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and, along with the shares of common stock underlying the 2025 Notes, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the 2025 Notes and the underlying shares of common stock may not be offered, sold, pledged or otherwise transferred except to a qualified institutional buyer (within the meaning Rule 144A under the Securities Act) pursuant to an effective Securities Act registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.
Oppenheimer & Co Inc. served as exclusive placement agent for the 2025 Notes.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Balance Sheet and Cash Flow
At June 30, 2022, UpHealth reported $41.1 million of cash, cash equivalents and restricted cash. On April 9, 2022, the Company repaid its forward share purchase agreement according to the terms of the contract.
Conference Call
UpHealth management will host a live question-and-answer session with investors and analysts beginning at 8:30 a.m. Eastern Time today, August 15, 2022. The call can be accessed live over the telephone by dialing (877) 344-8082, passcode 150118, from the U.S. or International callers can dial (213) 992-4618, passcode 150118. There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://investors.uphealthinc.com/events-and-presentations/default.aspx or directly here. The webcast will be archived for approximately 30 days.
About UpHealth, Inc.
UpHealth is a global digital health company that delivers digital-first technology, infrastructure and services to dramatically improve how healthcare is delivered and managed. The UpHealth platform creates digitally enabled "care communities" that improve access and achieve better patient outcomes at lower cost, through digital health solutions and interoperability tools that serve patients wherever they are, in their native language. UpHealth's clients include global governments, health plans, healthcare providers and community-based organizations. For more information, please visit https://uphealthinc.com and follow us at @UpHealthInc on Twitter and UpHealth Inc on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Such forward-looking statements include, but are not limited to, the financial statements of UpHealth, its product offerings and developments and reception of its product by customers, statements regarding payments pursuant to the terms of UpHealth's debt obligations and the conversion or maturity of such debt and UpHealth's expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future revenue and the business plans of UpHealth's management team. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of UpHealth in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on UpHealth as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting UpHealth will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the ability of UpHealth to service or otherwise pay its debt obligations, the mix of services utilized by UpHealth's customers and such customers' needs for these services, market acceptance of new service offerings, the ability of UpHealth to expand what it does for existing customers as well as to add new customers, that UpHealth will have sufficient capital to operate as anticipated, and the impact that the novel coronavirus and the illness, COVID-19, that it causes, as well as government responses to deal with the spread of this illness and the reopening of economies that have been closed as part of these responses, may have on UpHealth's operations, the demand for UpHealth's products, global supply chains and economic activity in general. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Investor Relations:
Shannon Devine (MZ North America)
Managing Director
203-741-8811
UPH@mzgroup.us
Media Inquiries:
Kelsie Aziz (Ketchum)
Vice President, Financial Communications
972-408-7103
kelsie.aziz@Ketchum.com
UPHEALTH, INC.
NON-GAAP FINANCIAL INFORMATION
Non-GAAP Financial Information
This press release includes financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). To supplement UpHealth's condensed consolidated financial statements presented in accordance with GAAP, UpHealth presents investors with non-GAAP financial measures, including pro forma revenue, pro forma gross margin and adjusted EBITDA.
- Pro forma revenue consists of GAAP revenue and revenue from UpHealth's subsidiaries prior to their acquisition.
- Pro forma gross margin consists of GAAP gross margin and gross margin from UpHealth's subsidiaries prior to their acquisition.
- Adjusted EBITDA consists of net income (loss) attributable to UpHealth, Inc., excluding depreciation and amortization; stock-based compensation; lease abandonment expenses; goodwill/intangible asset impairment; acquisition, integration, and transformation costs; other income (expense); income tax benefit (expense); income (loss) from equity method investment; net income (loss) attributable to noncontrolling interests; and other non-recurring charges to GAAP net income (loss) attributable to UpHealth, Inc. Other non-recurring charges to GAAP net income (loss) attributable to UpHealth, Inc. may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments, the cumulative effect of a change in accounting principles, or other expenses determined to be non-recurring.
UpHealth believes that the presentation of these non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to UpHealth's financial condition and results of operations. Management believes that the items described above provide an additional measure of UpHealth's operating results and facilitates comparisons of UpHealth's core operating performance against prior periods and business model objectives. This information is provided to investors in order to facilitate additional analyses of past, present, and future operating performance and as a supplemental means to evaluate UpHealth's ongoing operations. UpHealth believes that these non-GAAP financial measures are useful to investors in their assessment of UpHealth's operating performance.
Pro forma revenue, pro forma gross margin and adjusted EBITDA are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. You should not consider these measures in isolation or as a substitute for analysis of UpHealth's results as reported under GAAP. UpHealth compensates for these limitations by prominently disclosing GAAP financial measures and providing investors with reconciliations from UpHealth's GAAP operating results to the non-GAAP financial measures for the relevant periods.
The accompanying tables provide more details on the GAAP financial measures that are most directly comparable to the non-GAAP financial measures described above and the related reconciliations between these financial measures.
UPHEALTH, INC.
SEGMENT INFORMATION AND RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
(In thousands, unaudited)
View original content to download multimedia:
SOURCE UpHealth, Inc. | https://www.whsv.com/prnewswire/2022/08/15/uphealth-announces-second-quarter-2022-financial-results/ | 2022-08-15T12:54:27Z |
- Quarterly revenue of $4.5 million, compared to $0.1 million in Q2 2021
- Significant growth from acquisition while continuing organic growth trend
- Net Loss of $12.6 million in Q2 2022 (inclusive of non-cash write off of $11.2 million related to the SPAC), compared to $1.4 million in Q2 2021
- Adjusted EBITDA(1) of ($0.3) million, compared to ($0.9) million in Q2 2021
- Cash of $3.8 million as of June 30, 2022
ROCHESTER, N.Y., Aug. 15, 2022 /PRNewswire/ -- VerifyMe, Inc. (NASDAQ: VRME) ("VerifyMe," "we," "our," or the "Company"), together with its subsidiary PeriShip Global LLC ("PeriShip Global"), provides brand owners time and temperature sensitive logistics, authentication, supply chain monitoring, and data-rich consumer engagement features using unique smartphone readable codes on their products, announced today the Company's financial results for the second quarter ended June 30, 2022 ("Q2 2022").
Key Financial Highlights for Q2 2022:
- Quarterly consolidated revenue of $4.5 million, an increase of 3,527% compared to $0.1 million for the three months ended June 30, 2021
- Gross profit of $1.7 million or 37% for the three months ended June 30, 2022, compared to $0.1 million or 79% for the three months ended June 30, 2021
- Net loss of $12.6 million or ($1.53) fully diluted loss per share for the three months ended June 30, 2022, which included approximately $11.2 million non-cash impairment related to the SPAC liquidation announced in July 2022, compared to a net loss of $1.4 million or ($0.18) fully diluted loss per share for the three months ended June 30, 2021
- Cash of $3.8 million as of June 30, 2022
Patrick White, VerifyMe's CEO stated, "We are excited to share the impact that the acquisition of PeriShip has had on our financial results for the quarter in addition to our organic revenue growth of approximately 115%. Bear in mind that due to the timing of the acquisition PeriShip's results were roughly 9 weeks of the 12-week quarter. In addition, historically PeriShip's largest quarters are in the third and fourth quarter which are heavily influenced by vaccine distribution and holiday gift season. With the liquidation of G3 VRM Acquisition Corp. (the "SPAC"), which impacted our results for the quarter but not cashflow, now behind us, we look forward to focusing on our core businesses and sharing improved financial results for the remaining year."
Recent Business Highlights
- Barrington Research analyst coverage and VerifyMe will present at their 15th Annual Barrington Research Virtual Fall Conference on September 8, 2022
- Added two former FedEx executives to Board of Directors of PeriShip Global
- Made the decision not to extend the period for the SPAC to consummate a business combination and accordingly the SPAC has dissolved and liquidated in accordance with its charter
- Initiated a new $1.5 million share repurchase program for a period of 12 months
Financial Results for the Three Months Ended June 30, 2022:
Revenue for the three months ended June 30, 2022, was $4.5 million, a 3,527% increase as compared to $0.1 million for the three months ended June 30, 2021. The increase in revenue is primarily related to the acquisition of the PeriShip business on April 22, 2022. Our legacy VerifyMe Solutions segment revenue increased by $0.1 million or approximately 115%, primarily from new customers using our authentication serialization technology.
Gross profit for the three months ended June 30, 2022, was $1.7 million, compared to $0.1 million for the three months ended June 30, 2021. The resulting gross margin was 37% for the three months ended June 30, 2022, compared to 79% for the three months ended June 30, 2021, principally due to the lower margins of our recently acquired PeriShip solutions segment.
Operating loss for the three months ended June 30, 2022, was $1.3 million, a decrease of $0.1 million compared to $1.4 million for the three months ended June 30, 2021. The decrease is primarily related to the increased gross profit, partially offset by the additional operating expenses from the acquisition of the PeriShip business.
Our net loss for the three months ended June 30, 2022, increased by $11.2 million to $12.6 million compared to a net loss of $1.4 million for the three months ended June 30, 2021. The increased loss was primarily due to the impairment of our equity investment of $11.2 million, partially offset by the decreases discussed above. The resulting loss per share for the three months ended June 30, 2022, was ($1.53) per diluted share, compared to a loss per diluted share of ($0.18) for the three months ended June 30, 2021.
Adjusted EBITDA for the three months ended June 30, 2022, was a loss of $0.3 million, a decreased loss of $0.6 million, compared to a loss of $0.9 million for the three months ended June 30, 2021. Adjusted EBITDA is a non-GAAP financial measure. Please see "Use of Non-GAAP Financial Measures" for a discussion of this non-GAAP measure. A reconciliation to the most directly comparable GAAP measure, net loss, is included as a schedule to this release.
At June 30, 2022, VerifyMe had a $3.8 million cash balance and $4.0 million in working capital.
As of June 30, 2022, VerifyMe had 8,666,002 shares issued and 8,467,046 shares outstanding.
Earnings Call
The Company has scheduled an earnings conference call and webcast for 11:00 a.m. Eastern Time on Tuesday, August 16, 2022. Prepared remarks regarding the company's financial and operational results will be followed by a question and answer period with VerifyMe' executive management team. The conference call may be accessed via webcast at:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=INYqmNgS or by calling +1 (844) 282-4569 within the US, or +1 (412) 317-5614 internationally, and requesting the "VerifyMe Call." Participants must be logged in via telephone to submit a question to management during the call. Participants may optionally pre-register for the conference call and webcast at: https://dpregister.com/sreg/10169959/f3e2ff549a.
The webcast will be archived on the Investors section of VerifyMe's website and will remain available for 90 days.
About VerifyMe, Inc.
VerifyMe, Inc. (NASDAQ: VRME), is a technology solutions provider specializing in products to connect brands with consumers and, through our wholly owned subsidiary, PeriShip Global, LLC, providing brands with high-touch, end-to-end logistics management for their products. We provide logistics management from a sophisticated IT platform with proprietary databases, package and flight-tracking software, weather, and flight status monitoring systems, as well as dynamic dashboards with real-time visibility into shipment transit and last-mile events. In addition, VerifyMe technologies give brand owners the ability to gather business intelligence while engaging directly with their consumers. VerifyMe technologies also provide brand protection and supply chain functions such as counterfeit prevention, authentication, serialization, and track and trace features for labels, packaging and products. For additional information, please visit: https://www.verifyme.com .
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements regarding revenue opportunities, recurring revenue, commercialization efforts, our sales pipeline and opportunities, and the acquisition of the assets of PeriShip, LLC. The words "believe," "may," "anticipate," "intend," "should," "plan," "could," "potential," "opportunity," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the impact of the COVID-19 pandemic, intellectual property litigation, the successful development of our sales and marketing capabilities, the successful integration of our acquisitions (including the acquisition of the assets of PeriShip, LLC), our ability to retain key management personnel, our ability to work with partners in selling our technologies to businesses, production difficulties, our inability to enter into contracts and arrangements with future partners, issues which may affect the reluctance of large companies to change their purchasing of products, acceptance of our technologies and the efficiency of our authenticators in the field. These risk factors and uncertainties include those more fully described in VerifyMe's Annual Report and Quarterly Reports filed with the Securities and Exchange Commission, including under the heading entitled "Risk Factors." Should one or more of these risks or uncertainties materialize, or should any of our underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Use of Non-GAAP Financial Measures
This press release includes both financial measures in accordance with U.S. generally accepted accounting principles ("GAAP"), as well as non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flows that either excludes or includes amounts that are not normally included or excluded in the most directly comparable measure calculated and presented in accordance with GAAP. Non-GAAP financial measures should be viewed as supplemental to and should not be considered as alternatives to any other GAAP financial measures. They may not be indicative of the historical operating results of VerifyMe nor are they intended to be predictive of potential future results. Investors should not consider non-GAAP financial measures in isolation or as substitutes for performance measures calculated in accordance with GAAP.
VerifyMe's management uses and relies on EBITDA and Adjusted EBITDA, which are non-GAAP financial measures. The Company believes that both management and shareholders benefit from referring to EBITDA and Adjusted EBITDA in planning, forecasting and analyzing future periods. The Company's management uses these non-GAAP financial measures in evaluating its financial and operational decision making and as a means to evaluate period-to-period comparison. The Company's management recognizes that EBITDA and Adjusted EBITDA, as non-GAAP financial measures, have inherent limitations because of the described excluded items.
The Company defines EBITDA as net income (loss) before income tax expense (benefit), interest expense, depreciation and amortization. Adjusted EBITDA represents EBITDA plus stock-based compensation and the fair value of options, restricted stock awards, restricted stock units, and warrants issued in exchange for services, loss on equity investments and one-time professional expenses for acquisitions. VerifyMe believes EBITDA and Adjusted EBITDA are important measures of VerifyMe's operating performance because they allow management, investors and analysts to evaluate and assess VerifyMe's core operating results from period-to-period after removing the impact of items of a non-operational nature that affect comparability.
A reconciliation of EBITDA and Adjusted EBITDA to the most comparable financial measure, net income (loss), calculated in accordance with GAAP is included in this press release. The Company believes that providing the non-GAAP financial measures, together with the reconciliation to GAAP, helps investors make comparisons between VerifyMe and other companies. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measure and the corresponding GAAP measure provided by each company under applicable SEC rules.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
View original content to download multimedia:
SOURCE VerifyMe, Inc. | https://www.whsv.com/prnewswire/2022/08/15/verifyme-reports-significant-revenue-growth-second-quarter-2022-results/ | 2022-08-15T12:54:34Z |
LONDON, ON, Aug. 15, 2022 /PRNewswire/ - VersaBank ("VersaBank" or the "Bank") (TSX: VBNK) (NASDAQ: VBNK), today announced that it has received approval from the Toronto Stock Exchange ("TSX") to proceed with a Normal Course Issuer Bid ("NCIB") for its common shares.
"Recent market conditions have presented an exceptional opportunity to purchase VersaBank shares at an attractive value and this NCIB represents an excellent use of our capital," said David Taylor, President and Chief Executive Officer, VersaBank. "We feel that our stock is undervalued and the current trading price represents less than 0.8 times book value. VersaBank has abundant excess capital to make meaningful purchases through this NCIB, as well as to fund our significant growth opportunities."
Pursuant to the NCIB, VersaBank may purchase for cancellation up to 1,700,000 of its common shares representing approximately 9.54% of its public float. As of August 10, 2022, the public float comprised 17,817,350 common shares and there were 27,441,082 issued and outstanding Common Shares in total. The average daily trading volume ("ADTV") of VersaBank's Common Shares on the TSX for the six months of February 1, 2022 – July 31, 2022 (the "Preceding Six Month Period") was 4,731 shares. Daily purchases under the NCIB will be limited to 25% of the ADTV, which is 1,182 common shares, other than block purchase exceptions. During the Preceding Six-Month Period, 1,054,624 VersaBank common shares were traded on all Canadian exchanges. Of that total, 591,481 shares were traded on the TSX and the remaining 463,143 shares were traded on a number of alternate exchanges and trading systems.
The purchases may commence on August 17, 2022 and will terminate on August 16, 2023, or such earlier date as VersaBank may complete its purchases pursuant to the NCIB. The purchases will be made by VersaBank through the facilities of the TSX and alternate trading systems and in accordance with the rules of the TSX or such alternate trading systems, as applicable, and the prices that VersaBank will pay for any Common Shares will be the market price of such shares at the time of acquisition. VersaBank will make no purchases of Common Shares other than open market purchases. All shares purchased under the NCIB will be cancelled.
VersaBank is a Canadian Schedule I chartered bank with a difference. VersaBank became the world's first fully digital financial institution when it adopted its highly efficient business-to-business model using its proprietary state-of-the-art financial technology to profitably address underserved segments of the Canadian banking market in the pursuit of superior net interest margins while mitigating risk. VersaBank obtains all of its deposits and provides the majority of its loans and leases electronically, with innovative deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, VersaBank established wholly owned, Washington, DC-based subsidiary, DRT Cyber Inc. to pursue significant large-market opportunities in cyber security and develop innovative solutions to address the rapidly growing volume of cyber threats challenging financial institutions, multi-national corporations and government entities on a daily basis.
VersaBank's Common Shares trade on the TSX and on NASDAQ under the symbol VBNK. Its Series 1 Preferred Shares trade on the TSX under the symbol VB.PR.A.
Visit our website at: www.versabank.com
Follow VersaBank on Facebook, Instagram, LinkedIn and Twitter.
View original content to download multimedia:
SOURCE VersaBank | https://www.whsv.com/prnewswire/2022/08/15/versabank-receives-tsx-approval-normal-course-issuer-bid/ | 2022-08-15T12:54:41Z |
Neil Merchant, Mark Dirzulaitis, and Angela Yun Promoted to Principal;
Alex Veronneau Promoted to Vice President
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Vestar Capital Partners, a leading U.S. private equity firm, announced today the promotions of several investment professionals at the firm. The promotions include Neil Merchant, Mark Dirzulaitis, and Angela Yun to Principal, and Alex Veronneau to Vice President.
"We congratulate Neil, Mark, Angela and Alex on their promotions in recognition of their impressive growth, development and meaningful contributions to the Firm," said Dan O'Connell, Founder and CEO of Vestar. "We are fortunate to have such talented and resourceful young professionals who subscribe to our core values of hard work, creativity, transparency and teamwork."
Mr. Merchant, a member of the Firm's Business & Technology Services group, joined Vestar in 2018. He previously worked at Welsh, Carson, Anderson & Stowe focusing on healthcare and technology investments. Mr. Merchant holds both a BS in Economics, cum laude, and an MBA in Finance and Management, with Honors, from the Wharton School of the University of Pennsylvania.
Mr. Dirzulaitis, a member of the Firm's Business & Technology Services group, joined Vestar in 2019. Prior to Vestar, he worked at American Securities where he focused on private equity investments across a variety of sectors. Mr. Dirzulaitis began his career at Goldman Sachs, where he focused on growth equity investments in technology companies. He received a joint BA / MA from Johns Hopkins University, where he was elected to Phi Beta Kappa, and an MBA with Honors from the Wharton School of the University of Pennsylvania.
Ms. Yun, a member of the Firm's Consumer group, joined Vestar in 2019. Previously, she worked at Alliance Consumer Growth, a consumer- and retail-focused growth equity firm. Ms. Yun began her career in the Leveraged Finance Group and Financial Sponsors Group at Wells Fargo Securities. She holds a BS in Economics, cum laude, from Duke University, and an MBA from the Wharton School of the University of Pennsylvania.
Mr. Veronneau joined Vestar in 2019 after previously working as an Analyst in the Consumer & Retail Investment Banking Group at J.P. Morgan. He received a Bachelor of Commerce degree with first class honors from McGill University.
About Vestar Capital Partners
Vestar Capital Partners is a leading U.S. middle-market private equity firm specializing in management buyouts and growth capital investments. Vestar invests and collaborates with incumbent management teams and private owners to build long-term enterprise value, with a focus on Consumer, Business & Technology Services and Healthcare. Since inception in 1988, Vestar funds have invested $11 billion in 89 companies – as well as more than 200 add-on acquisitions – with a total value of approximately $52 billion. For more information on Vestar, please visit www.vestarcapital.com.
Contact:
Lambert
Jennifer Hurson
(845) 507-0571
jhurson@lambert.com
or
Joanne Lessner
(212) 222-7436
jlessner@lambert.com
View original content to download multimedia:
SOURCE Vestar Capital Partners | https://www.whsv.com/prnewswire/2022/08/15/vestar-capital-partners-announces-promotions/ | 2022-08-15T12:54:47Z |
SAN JUAN, Puerto Rico, Aug. 15, 2022 /PRNewswire/ -- Vivaris Capital, LLC, a multi-strategy fund offering hybrid hedge and private equity structures, announced today that it has partnered with Salt Lake City-based B10 Capital to offer private investors, family offices, and businesses a free personalized assessment regarding how best to defer and/or eliminate capital gains and income taxes.
In conjunction with B10 Capital, Vivaris Capital will help clients focus on reducing, deferring, and mitigating the impact of income tax or capital gains tax. B10 Capital helps clients strategically plan for more efficiencies with ordinary income and capital gains tax liabilities through the utilization of specialized tax credit filings as well as highly sophisticated tax strategies.
The money that clients save with more efficient tax positions may then be invested with Vivaris Capital, currently raising capital from industry partners, financial institutions, family offices, and individual investors for the VICAN Fund. The VICAN Fund provides investors with access to institutional quality alternative investments with high-growth, high-return potential while securing their principal.
"Many business owners will spend hours writing off business expenses like insurance, utilities, and payroll, yet they are not aware of more impactful strategies to reduce their taxes. Most see taxes as an inevitable cost with few offset options. Fortunately, there are powerful ways to reduce and offset taxes and we're proud to bring these experts' strategies to our clients and friends," said President and CEO J. Christopher Mizer.
"We are constantly surprised by the amount of businesses that are eligible but are not claiming their tax credits for Research and Development, 179D deductions, cost segregation benefits or benefiting from strategic charitable contributions, and much more. Our team is dedicated to simplifying sophisticated tax and financial innovations to make them accessible to those who need them most," said B10 Capital Regional Director-Texas Julienna Viegas.
The VICAN Fund is led by President and Chief Executive Officer J. Christopher Mizer, a 25-year veteran of the alternative investment industry who founded Vivaris Capital in 1998 to invest in and acquire middle-market businesses in a broad range of industries that are leaders in their market niches. He is supported by an eight-member team that includes leading physicians, environmental and climate technology experts, alternative investment professionals, and global finance and business specialists.
For further information, visit https://www.vivariscapital.com/, call +1.619.727.8497 or email vican@vivariscapital.com.
About B10 Capital
B10 Capital helps business owners, entrepreneurs, creators, and qualified individuals access non-obvious tax credits solutions and financial strategies that help maximize their liquidity, flexibility, and long-term financial security.
About Vivaris Capital
Vivaris Capital, LLC invests in and acquires middle-market businesses in healthcare, life sciences, and technology that are leaders in their market niches. The Vivaris team is led by J. Christopher Mizer who is the chairman of each of the portfolio companies and guides key strategic decisions and their execution. He also serves as the operating president on an interim basis when companies are going through periods of ownership succession and new management team members are being assembled.
Media Contact:
Charlotte Luer
+1.239.404.6785
cluer@vivariscapital.com
Disclaimers:
This press release is neither an offer to sell nor the solicitation of an offer to buy any security. Only the Private Placement Memorandum can make such an offer. The Private Placement Memorandum must be read in order to fully understand all of the implications and risks of the offering of securities to which it relates.
Vivaris Capital does not offer investment, tax, financial, or legal advice, nor do we endorse any products, investments, or companies that provide such advice and investments. All parties are strongly encouraged to perform their due diligence and consult with the appropriate professional(s) licensed in that area before entering any investment. Performing due diligence helps protect against fraud.
No information presented should be used or considered as an offer to sell or a solicitation of an offer to buy any interest in any investment fund. Any such offer or solicitation can and will be made only by means of the confidential offering memorandum of each such investment fund, and only in jurisdictions in which such an offer would be lawful and only to individuals who meet the investor suitability and sophistication requirements of each such investment fund, including qualifying as "accredited investors" within the meaning of the Securities Act of 1933, as amended and "qualified purchasers" within the meaning of the Investment Company Act of 1940, as amended. Access to information about the investment funds is similarly limited to individuals who meet the applicable investor suitability and sophistication requirements.
View original content:
SOURCE Vivaris Capital, LLC | https://www.whsv.com/prnewswire/2022/08/15/vivaris-capital-llc-partners-with-b10-capital-provide-business-assessment-support/ | 2022-08-15T12:54:54Z |
CALGARY, AB AND MOUNTAIN VIEW, CA, Aug. 15, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, has released its financial and operating results for the three months ended June 30, 2022, reporting significant progress to its operational platform, leadership and strong liquidity.
"The second quarter saw us take the next step in the evolution of our product portfolio with a new partnered pharmaceutical project", said Dr. Peter Seufer-Wasserthal, Willow's Interim President and Chief Executive Officer. "Over the last three and a half years we have built out a fully integrated team that covers the entire production spectrum from the lab to commercialization. We are in a strong position to continue product development of our FutureGrown™ CBG and add new partnerships at this time and believe that the company is set up today to be a leader in the coming bio-revolution of tomorrow."
Willow's unaudited consolidated interim financial statements and related management's discussion and analysis for the quarter ended June 30, 2022 are available on SEDAR at www.sedar.com.
- On May 11, 2022, Willow announced that it had successfully completed the initial toxicological assessment for Generally Recognized as Safe ("GRAS") for its FutureGrown™ cannabigerol ("CBG") product in the United States. An important milestone for biosynthetically produced cannabinoids, Willow has successfully completed the Stage 1 toxicological assessment of its FutureGrown™ CBG product for oral product applications. The assessment concluded that FutureGrownTM CBG caused no adverse effects and was non-mutagenic, non-clastogenic and non-genotoxic, completing the first step toward designating Willow's FutureGrown™ CBG as GRAS in the United States. Willow anticipates initiating its Stage 2 pivotal toxicological assessment in Q3 2022.
- On May 11, 2022, Willow announced the expansion of its precision fermentation manufacturing network with the signing of a Manufacturing Services Agreement ("MSA") with a second Contract Development and Manufacturing Organization ("CDMO"), increasing fermentation capacity to produce Willow's FutureGrown™ products, including CBG. Willow's new partner has a strong track record in the large-scale production of food, nutritional, and pharmaceutical products and holds all necessary certifications to serve these markets. This new CDMO partnership allows Willow to accommodate new programs, both internal and partnered, in addition to its cannabinoid portfolio.
- On May 31, 2022, Willow announced that is has been engaged by a specialty pharmaceutical company (the "Counterparty") to optimize a biosynthetic pathway vital to the development of a large volume Active Pharmaceutical Ingredient (API) used in nutraceutical and pharmaceutical products. The Counterparty is partnered with a large-cap, multi-national healthcare company. The project consists of research & development and commercialization phases, with revenue coming from both research fees and milestone payments. Following commercialization, Willow anticipates an on-going revenue stream from license payments.
- Subsequent to the quarter, on July 18, 2022, Willow appointed Dr. Peter Seufer-Wasserthal as Interim President and Chief Executive Officer, effective July 17, 2022, in connection with Trevor Peters' retirement as President and CEO. Mr. Peters continues to serve as a Director of the Company. Guided by his extensive experience in biotech, pharma, nutrition, and consumer care, the Company has already advanced several partnership discussions in the food and nutrition sectors. He will continue to build and lead the organization needed to successfully execute on the Company's mission.
- Willow ended the quarter in a strong financial position, with approximately $22.1 million in working capital and $22.1 million of cash on hand.
Willow has begun consolidating Research & Development (R&D) at its Mountain View, California site by closing its Burnaby, British Columbia facility. Willow expects to complete the closure and relocate key personnel to Mountain View by the end of September 2022. The motivation for the consolidation is the operational benefits of having the Company's entire R&D team under one roof. Our San Francisco Bay Area site was selected because of its position as the global biotech hub, where the Company can recruit and retain top scientific talent.
Willow is positioned to become a leader in precision fermentation by capturing key intellectual property around what the Company anticipates being the most cost-effective methods to produce highly pure ingredients. The Company's operational capabilities, along with its strategic partners, span the entire product development pathway, and Willow's integrated R&D team in California has the full capabilities to deliver at all stages of the development cycle. The Company's established technology, capabilities, and manufacturing network can now enable biobased production for a diverse set of industries.
While the market for biosynthetically produced cannabinoids has not materialized to the extent originally anticipated, Willow remains optimistic about the long term market potential for these ingredients and continues to optimize its production process.
While the market for biosynthetically produced cannabinoids continues to develop, Willow will utilize it's proven FutureGrownTM platform to partner with companies in the personal care, food and beverage, and pharmaceutical markets, providing access to pure, consistent and sustainable functional ingredients. With our first non-cannabinoid program announced this year, we are excited to continue adding partnerships and products, expanding our platform and de-risking our portfolio. We look forward to updating stakeholders on our progress in the coming quarters.
Willow develops and produces high-purity ingredients for the personal care, food and beverage, and pharmaceutical markets. Willow's FutureGrownÔ biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans and operations, and, more particularly, statements concerning: the MSA, including the ability to accommodate new programs and to expand capabilities; the continued development of Willow's FutureGrown™ CBG; the demand and market size potential of the synthetic ingredients industry; and the business plan of the Company, generally, including becoming a leader in precision fermentation, research and production of functional ingredients. When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of Willow's strategic partnerships, including the development of future strategic partnerships; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results biotechnology industry in general; the success of the Company's research and development strategies; infringement on intellectual property; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; import/export and research restrictions for cannabinoid-based operations; the size of the medical-use and adult-use cannabinoid market; competition from other industry participants; adverse U.S., Canadian and global economic conditions; adverse global events and public-health crises, including the current COVID-19 outbreak; failure to comply with certain regulations; departure of key management personnel or inability to attract and retain talent; and other factors more fully described from time to time in the reports and filings made by the Company with securities regulatory authorities. Please refer to the Company's most recent annual information form and management's discussion and analysis for additional risk factors relating to Willow, which can be accessed either on Willow's website at www.willowbio.com or under the Company's profile on www.sedar.com.
Any financial outlook and future-oriented financial information contained in this document regarding prospective financial performance, financial position, cash balances or revenue is based on assumptions about future events, including economic conditions and proposed courses of action based on management's assessment of the relevant information that is currently available. Projected operational information contains forward-looking information and is based on a number of material assumptions and factors, as are set out above. These projections may also be considered to contain future-oriented financial information or a financial outlook. The actual results of the Company's operations for any period will likely vary from the amounts set forth in these projections and such variations may be material. Actual results will vary from projected results. Readers are cautioned that any such financial outlook and future-oriented financial information contained herein should not be used for purposes other than those for which it is disclosed herein.
The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
View original content to download multimedia:
SOURCE Willow Biosciences Inc. | https://www.whsv.com/prnewswire/2022/08/15/willow-biosciences-reports-second-quarter-2022-results/ | 2022-08-15T12:55:01Z |
DPW Amsterdam 2022 will bring together bright minds in procurement and technology to confer on solutions for the future
AMSTERDAM, Aug. 15, 2022 /PRNewswire/ -- Digital Procurement World (DPW), the world's largest and most influential tech event for the procurement industry, today announced their final event agenda, highlighting the notable speakers set to participate at this year's event. The annual flagship conference, held both online and at the monumental Beurs van Berlage in Amsterdam on September 21-22, brings together innovative minds from across industries and geographies to discuss tech-inspired solutions to the largest issues facing procurement today.
Now in its third year, DPW has grown to over 5,000 attendees, 120 speakers, and 25 exhibiting startups hailing from over 80 countries around the world. This year's themes include digital transformation, sustainability, resilience, diversity and inclusion, and the future of work.
Just a few of the many notable speakers participating in the 2022 hybrid event include:
- Taavi Rõivas, Former Prime Minister of Estonia
- Ulrike Sapiro, Chief Sustainability Officer at Henkel
- Amanda Davies, Chief Procurement and Sustainability Officer at Mars Wrigley
- Jennifer Han, Chief Product Supply Officer, Nutrition at Unilever
- Andries Feikema, Global Director, Procurement Center of Excellence & Digitalization at DSM
- Dr. Elouise Epstein, Partner at Kearney
"From inflationary pressures to supply chain woes and sustainability concerns, procurement is up against more hurdles than ever. That's why it's the perfect time to bring together diverse voices from across the world to discuss how we can use technology to envision a better future for the industry and the world," said Matthias Gutzmann, founder of DPW. "We are very proud that every year so many incredible solutions are discussed and valuable partnerships are born right here at DPW. I can't wait to see what this year's speakers and attendees bring to the table."
To find out more about DPW Amsterdam 2022 and to secure your ticket, please visit conference.dpw.ai
DPW is the tech ecosystem for the global procurement industry, bringing together a diverse network of startup founders, investors, executives from technology and advisory firms, business leaders and academics to collaboratively tackle industry-wide challenges.
View original content:
SOURCE Digital Procurement World (DPW) | https://www.whsv.com/prnewswire/2022/08/15/worlds-leading-procurement-technology-event-announces-notable-speakers/ | 2022-08-15T12:55:08Z |
SHANGHAI, Aug. 15, 2022 /PRNewswire/ -- Yum China Holdings, Inc. (the "Company" or "Yum China") (NYSE: YUMC and HKEX: 9987) today announced that the Company applied for a voluntary conversion of its secondary listing status to a primary listing status (the "Proposed Primary Conversion") on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKEX"). On August 15, 2022, the Company received the acknowledgement from the HKEX in respect of the application for the Proposed Primary Conversion.
To comply with the Hong Kong listing rules applicable to a dual primary listed issuer, the Company will call a Special Meeting of Stockholders (the "Special Meeting") to be held on October 11, 2022 Beijing/Hong Kong time, to seek stockholder approval on certain proposed items. Conditional upon and subject to receiving stockholder approval on all proposed items at the Special Meeting and obtaining the necessary approvals from the HKEX, the Company will become dual primary listed on the New York Stock Exchange (the "NYSE") and the HKEX. The effective date of the Proposed Primary Conversion is expected to be October 24, 2022. The Company's common stock on the two exchanges will continue to be fully fungible and investors can continue to choose to trade their shares on either stock exchange.
"Since our secondary listing in Hong Kong in 2020, we have enhanced access to our shareholders in Asia. We have diversified our investor base and tapped into additional capital pools," said Joey Wat, CEO of Yum China. "Dual primary listing would bring us even closer to our employees, customers and other stakeholders. This strategic move would further broaden our shareholder universe, increase liquidity and mitigate the risk of delisting from the NYSE. Looking ahead, we are excited about our long-term prospects in China and remain deeply committed to building a stronger, more resilient and innovative company."
There are three items to be approved at the Special Meeting. The first two items will relate to the proposed share issuance and repurchase mandates, granting authority to the Board of Directors (the "Board") of the Company to issue up to 20% and repurchase up to 10% of its total outstanding shares, respectively. Under Delaware law and the NYSE rules, the Board of the Company has the authority to issue and repurchase its shares. However, under the Hong Kong listing rules, the Company is required to obtain stockholder approval with respect to these two items. The Company is seeking approval solely to comply with the Hong Kong listing rules. Both are routine items in Hong Kong. The third item is the proposed adoption of a new equity incentive plan. The features of the new plan are largely based on the existing equity incentive plan, with certain provisions changed to comply with the Hong Kong listing rules and certain other administrative changes.
Additional Information and Where to Find It
This press release has been prepared in connection with the Proposed Primary Conversion and may be deemed to be soliciting material relating to the Special Meeting. In connection with the Special Meeting, the Company will file relevant materials with the U.S. Securities and Exchange Commission (the "SEC"), including a proxy statement on Schedule 14A. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy statement and a proxy card to each stockholder entitled to vote at the Special Meeting. STOCKHOLDERS OF YUM CHINA ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE SPECIAL MEETING THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED PRIMARY CONVERSION, AND THE SPECIAL MEETING. The preliminary proxy statement, the definitive proxy statement and other relevant materials in connection with the Special Meeting (when they become available), and any other documents filed by the Company with the SEC, may be obtained free of charge at the SEC's website at http://www.sec.gov or at Yum China's Investor Relations website at http://ir.yumchina.com.
The announcement on the Proposed Primary Conversion made in accordance with Hong Kong listing rules is published on the HKEX website at https://www1.hkexnews.hk or accessible at Yum China's Investor Relations website at http://ir.yumchina.com.
Participants in the Solicitation
Yum China and certain of its directors, officers, and other employees may be deemed to be participants in the solicitation of proxies from Yum China's stockholders with respect to the Special Meeting. Additionally, the Company has retained Georgeson LLC to act as a proxy solicitor. Certain information about the Company's directors and executive officers and their ownership of the Company's common stock is set forth in the Company's proxy statement on Schedule 14A relating to its Annual Meeting of Stockholders, filed with the SEC on April 14, 2022. Information regarding the identity of the participants, and their direct or indirect interests in the transaction, by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with SEC in connection with the Special Meeting.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as "expect," "expectation," "believe," "anticipate," "may," "could," "intend," "belief," "plan," "estimate," "target," "predict," "project," "likely," "will," "continue," "should," "forecast," "outlook", "commit" or similar terminology. These statements are based on current estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable under the circumstances, but there can be no assurance that such estimates and assumptions will prove to be correct. Forward-looking statements include, without limitation, statements regarding the future strategies, growth, business plans, investment, dividend and share repurchase plans, earnings, performance and returns of Yum China, anticipated effects of population and macroeconomic trends, the expected impact of the COVID-19 pandemic, the anticipated effects of our innovation, digital and delivery capabilities and investments on growth and beliefs regarding the long-term drivers of Yum China's business, developments relating to the listing of Yum China's common stock on the NYSE and the HKEX, the details, timing, and completion of the Proposed Primary Conversion, future issuances of stock or stock repurchases, and compensation arrangements, including pursuant to the proposed new equity incentive plan. Forward-looking statements are not guarantees of performance and are inherently subject to known and unknown risks and uncertainties that are difficult to predict and could cause our actual results or events to differ materially from those indicated by those statements. We cannot assure you that any of our expectations, estimates or assumptions will be achieved. The forward-looking statements included in this press release are only made as of the date of this press release, and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances, except as required by law. Numerous factors could cause our actual results or events to differ materially from those expressed or implied by forward-looking statements, including, without limitation: whether we are able to achieve development goals at the times and in the amounts currently anticipated, if at all, the success of our marketing campaigns and product innovation, our ability to maintain food safety and quality control systems, changes in public health conditions, including the COVID-19 pandemic and regional outbreaks caused by existing or new COVID-19 variants, our ability to control costs and expenses, including tax costs, as well as changes in political, economic and regulatory conditions in China and the United States. In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any such forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. You should consult our filings with the Securities and Exchange Commission (including the information set forth under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q) for additional detail about factors that could affect our financial and other results.
About Yum China Holdings, Inc.
Yum China Holdings, Inc. is a licensee of Yum! Brands in mainland China. It has exclusive rights in mainland China to KFC, China's leading quick-service restaurant brand, Pizza Hut, the leading casual dining restaurant brand in China, and Taco Bell, a California-based restaurant chain serving innovative Mexican-inspired food. Yum China also owns the Little Sheep, Huang Ji Huang and COFFii & JOY concepts outright. In addition, Yum China has partnered with Lavazza to explore and develop the Lavazza coffee shop concept in China. The Company had 12,170 restaurants in over 1,700 cities at the end of June 2022.
In 2021, Yum China was selected as a member of both Dow Jones Sustainability Indices (DJSI): World Index and Emerging Market Index. In 2022, Yum China ranked # 359 on the Fortune 500 list. The Company was also named to the Bloomberg Gender-Equality Index and was certified as a Top Employer 2022 in China by the Top Employers Institute, both for the fourth consecutive year. For more information, please visit http://ir.yumchina.com.
View original content:
SOURCE Yum China Holdings, Inc. | https://www.whsv.com/prnewswire/2022/08/15/yum-china-applies-voluntary-conversion-primary-listing-hong-kong-stock-exchange/ | 2022-08-15T12:55:14Z |
PENSACOLA, Fla., Aug. 15, 2022 /PRNewswire/ -- ZA Group, Inc. (OTC: ZAAG) ("ZAAG" or "the Company"), a company specializing in emerging industries acquisitions today announced that its subsidiary—E-Roots Manufacturing Inc—received a purchase order in the amount of US$400,000 for the supply of the first two vertical farming modules to the company's Australia and New Zealand partnership group—Eden Growers Pty Ltd. That company recently reported that they have generated considerable excitement within the country for their plans to bring the E-Roots vertical farming technology to their part of the world. Michael Lee, their main spokesperson, commented, "These first two modules are going to be strategically located in a community with close proximity to agricultural produce distribution centers, and potentially the new Sydney international airport. We also have additional immediate plans to develop E-Roots Growtainer vertical farms in Rockhampton, a region in Queensland which is an established national and international food hub. Our strategy is to develop quickly in select locations within the country to foster rapid acceptance and geographic expansion of the E-Roots technology throughout our region of the world." Besides being a managing partner of Eden Growers, Mr. Lee is a professional hotelier and a former CIO of The Banyan Tree Group—one of the world's leading independent, multi-branded hospitality groups, respected for their purpose-driven approach centred on well-being and sustainability.
Chris Gongaware, Operations Manager of E-Roots Manufacturing Inc expressed that—"I am excited with the potential we have in Australia and New Zealand. Mr. Lee has assembled a very knowledgeable and enthusiastic business group that really understands the potential for vertical farming and is eager now to learn all the details. That's where we come in." It's an assignment that Mr. Gongaware is more than qualified to step into. He is an experienced horticultural specialist with a college degree in this sector and has gained significant growing and managerial experience in the hydroponic vertical farming sector. He has also been a managing partner in Grow Zone, a successful company with a 15 year history of supplying horticultural products as well as grower training and troubleshooting.
John Morgan, ZAAG CEO responded as follows to this latest announcement—"The team of professionals at E-Roots Manufacturing is expanding their operations in order to establish the company as the leading manufacturer and supplier of all vertical farming equipment and supplies covering everything from seeds to final product packaging and sales. This latest announcement is evidence of plans being fulfilled. Furthermore, the company has a demonstrated team of professionals capable of achieving those results."
About ZAGroup, Inc. (ZAAG)
ZA Group, Inc. is a company specializing in emerging industries acquisitions with an emphasis in the direct to consumer apparel and manufacturing self-sustainable farms. Its goal is to take its brands to the next level whether to own, license, or manage. Currently ZA Group, Inc. owns 60% of E-Roots Manufacturing, Inc., to manufacture self-sustaining vertically integrated farms, and NFID as a wholly owned subsidiary, an online retail outlet offering apparel (visit website).
To learn more, please visit: www.zagroupusa.com
Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed in this press release may contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape, or manner of our future financial condition or stock price.
View original content:
SOURCE ZA Group, Inc. | https://www.whsv.com/prnewswire/2022/08/15/za-group-inc-zaag-announces-vertical-farm-module-sales-australia-new-zealand/ | 2022-08-15T12:55:20Z |
Wilderness first aid course offered online for the Two Virginias
BLUEFIELD, W.Va. (WVVA) - For some, outdoor excursions can be stressful if dealing with unique medical conditions.
WVVA spoke with Dr. Natalie Bonthius about the issue -- and her ongoing effort to educate people in hopes of alleviating some such anxiety. Through a virtual course, Bonthius said attendees are able to learn the proper ways to act, should a medical emergency arise while out in the wilderness.
“We go through a whole bunch of medical survival cases, based on true things that we’ve seen in the emergency department in true search and rescue calls, so we teach the most common incidents that we run into out there,” said Bonthius.
Upon completion of the course, participants will be able to receive a certificate, valid for three years after passing an exam.
Those interested in the course can find out more about offerings for the Two Virginias here.
Copyright 2022 WVVA. All rights reserved. | https://www.whsv.com/2022/08/14/wilderness-first-aid-course-offered-online-two-virginias/ | 2022-08-15T12:58:10Z |
British regulator 1st to OK Moderna’s updated COVID-19 booster
LONDON (AP) — British drug regulators have become the first in the world to authorize an updated version of Moderna’s coronavirus vaccine that aims to protect against the original virus and the omicron variant.
In a statement on Monday, the Medicines and Healthcare Regulatory Agency said it had given the green light to Moderna’s combination “bivalent” vaccine, which will be used as an adult booster shot.
Each dose of the booster shot will target both the original COVID-19 virus that was first detected in 2020 and the omicron BA.1 variant that was first picked up in November. British regulators said the side effects were similar to those seen for Moderna’s original booster shot and were typically “mild and self-resolving.”
“What this (combination) vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve,” said Dr June Raine, the head of Britain’s health care and medicines regulator.
Such an approach is used with flu shots, which are adjusted each year depending on the variants that are circulating and can protect against four influenza strains.
Stephane Bancel, Moderna’s Chief Executive, said in a statement that it was the first regulatory authorization for a vaccine aiming to fight the omicron variant, predicting the booster would have an “important role” to play in protecting people against COVID-19 in the winter.
Britain’s health officials have not yet decided whether the tweaked vaccine will be used in its fall strategy. In July, the government said everyone 50 and over would get a COVID booster in the fall.
On Friday, Germany’s health minister said the European Medicines Agency might clear tweaked COVID-19 boosters next month.
In June, the U.S. Food and Drug Administration told vaccine makers that any booster shots tweaked for the fall would have to include protection against the newest omicron variants, meaning BA.4 and BA.5, not the BA.1 subvariant included in Moderna’s latest shot.
Last month, the FDA said it was no longer considering authorizing a second COVID-19 booster for all adults but would instead focus on revamped vaccines for the autumn that target the newest viral subvariants.
Both Moderna and Pfizer are currently brewing updated versions of their vaccine to include BA.5 in addition to the original COVID-19 virus.
According to the World Health Organization, the latest global surge of COVID-19 has been driven by omicron subvariant BA.5, which is responsible about 70% of the virus samples shared with the world’s largest public virus database. The subvariant BA.5 is even more infectious than the original version of omicron and has some genetic differences that earlier vaccines might not address.
Scientists have warned that the continued genetic evolution of COVID-19 means drugmakers will likely be one step behind the virus in their efforts to tailor their vaccines.
“The virus is unlikely to stand still, and Omicron-targeted immunity might push the virus down other evolutionary paths,” warned Jonathan Ball, a professor of virology at Britain’s University of Nottingham. Still, he said the new Moderna vaccine would likely still be protective.
“Unless there is a major shift in the virus, immunity will continue to protect the vast majority from serious disease caused by emerging variants,” he said in a statement.
___
Follow AP’s coverage of the pandemic at https://apnews.com/hub/coronavirus-pandemic
___
AP Medical Writer Lauran Neergaard in Washington, D.C. contributed.
Copyright 2022 The Associated Press. All rights reserved. | https://www.wvva.com/2022/08/15/british-regulator-1st-ok-modernas-updated-covid-19-booster/ | 2022-08-15T13:48:48Z |
Flash flooding underway in parts of Fayette County
FAYETTE COUNTY (WVVA) - We are learning more this afternoon about various communities in the Fayette County area hit by flash flooding.
Fayette County Commissioner, Allison Taylor, tells our Annie Moore that the community of Smithers, WV seems to be one of the hardest hit as of this posting.
Taylor confirms that the creek is flooded.
The county initially was setting up Smithers Elementary as an emergency shelter but due to power outages that plan has been redirected.
As soon as we learn more regarding new emergency shelter WVVA will bring that to you on-air and online.
The commissioner also confirmed rock slides in the Gauley Bridge and Chimney Corner areas of the county.
The county has activated emergency response teams and if you at home are concerned about high water she urges you to leave your home and get to somewhere safe.
If you are on the roadways and see visible high water, please turn around and do not attempt to drive through.
Copyright 2022 WVVA. All rights reserved. | https://www.wvva.com/2022/08/15/flash-flooding-underway-parts-fayette-county/ | 2022-08-15T13:48:55Z |
Judge: Sen. Graham must testify in Georgia election probe
ATLANTA (AP) — A federal judge on Monday said U.S. Sen. Lindsey Graham must testify before a special grand jury in Atlanta that is investigating whether former President Donald Trump and his allies broke any laws while trying to overturn his narrow 2020 general election loss in the state.
Attorneys for Graham, R-S.C., had argued that his position as a U.S. senator provided him immunity from having to appear before the investigative panel and asked the judge to quash his subpoena. But U.S. District Judge Leigh Martin May wrote in an order Monday that immunities related to his role as a senator do not protect him in this case, and he must appear before the special grand jury on Aug. 23.
Fulton County District Attorney Fani Willis opened the investigation last year, and a special grand jury with subpoena power was seated in May at her request. Last month she filed petitions seeking to compel testimony from seven Trump advisers and associates.
Prosecutors have indicated they want to ask Graham about phone calls they say he made to Georgia Secretary of State Brad Raffensperger and his staff in the weeks following the election.
Graham had argued that a provision of the Constitution provides absolute protection against a senator being questioned about legislative acts. But the judge found there are “considerable areas of potential grand jury inquiry” that fall outside that provision’s scope. The judge also rejected Graham’s argument that the principle of “sovereign immunity” protects a senator from being summoned by a state prosecutor.
Graham also argued that Willis, a Democrat, had not demonstrated extraordinary circumstances necessary to compel testimony from a high-ranking official. But the judge disagreed, finding that Willis has shown “extraordinary circumstances and a special need” for Graham’s testimony on issues related to alleged attempt to influence or disrupt the election in Georgia.
Kevin Bishop, a Graham spokesman, said Monday the senator had no comment but referred to what Graham said when asked about the probe last week. During a news conference in Columbia, S.C., Graham said, “We will take this as far as we need to take it” when asked about his efforts to fight appearing to testify.
“I was chairman of the Senate Judiciary Committee and had to vote on certifying an election,” Graham told reporters. “This is ridiculous. This weaponization of the law needs to stop. So I will use the courts. We will go as far as we need to go and do whatever needs to be done to make sure that people like me can do their jobs without fear of some county prosecutor coming after you.”
During the calls cited by Willis, Graham “questioned Secretary Raffensperger and his staff about reexamining certain absentee ballots cast in Georgia in order to explore the possibility of a more favorable outcome for former President Donald Trump,” Willis wrote in a petition.
Graham also “made reference to allegations of widespread voter fraud in the November 2020 election in Georgia, consistent with public statements made by known affiliates of the Trump Campaign,” she wrote.
Republican and Democratic state election officials, courts and even Trump’s attorney general found there was no evidence of any voter fraud sufficient to affect the outcome of his 2020 presidential election loss to Democrat Joe Biden.
___
Associated Press writer Meg Kinnard contributed reporting.
Copyright 2022 The Associated Press. All rights reserved. | https://www.wvva.com/2022/08/15/judge-sen-graham-must-testify-georgia-election-probe/ | 2022-08-15T13:49:01Z |
King’s Hawaiian recalls some of its buns
(CNN) - Take a look in your pantry. If you have some of King’s Hawaiian products, you might need to throw them out.
The company is recalling Pretzel Slider Buns, Pretzel Hamburger Buns and Pretzel Bites.
It is a voluntary decision, but the company said it just wants to be extra careful after one of the ingredients used in the pretzel products was recalled by another company.
Lyon Magnus recently had a voluntary recall after concerns that dozens of its products could potentially have bacteria in them that could make people really sick.
There have not been any reports of the products getting anyone sick, and King’s Hawaiian has not found any of the concerning bacteria, but the company said to throw away the products just in case.
More information can be found on the Food and Drug Administration’s website.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.wvva.com/2022/08/15/kings-hawaiian-recalls-some-its-buns/ | 2022-08-15T13:49:08Z |
Police help groom who nearly missed his wedding
BOSTON (WVCB) - A Boston groom was stranded on his wedding day with his groomsmen while the bride was left waiting, but the Boston Police Harbor Patrol saved the day.
Patrick and Hannah Mahony’s big day almost never happened after mechanical issues put the harbor between the bride and groom.
“I was in a little bit of a panic,” Patrick Mahony said.
The couple’s wedding was to take place on Thompson Island, and the boat the groom was supposed to take broke down. He was left stranded at the dock.
“It was our florist, our DJ, all of the groomsmen, the groom. So I think it would have just been a bunch of girls sitting on the island waiting around if that happens,” Hannah Mahony said.
This is when authorities stepped in to help.
The replacement ferry ended up leaving about 40 minutes late from the harbor, but the officers were able to make up time on the water.
Officers Joseph Matthews and Stefani McGrath were able to get everyone to the island safely, and Matthews said he hopes the police escort will be a fun memory to look back on.
“We had six minutes to spare,” Matthews said. “It will give them something to remember. Getting a ride on a police boat is kind of special for their big night.”
Despite the rocky start to the day, Patrick Mahony said nothing would have stopped him from tying the knot with his bride.
Copyright 2022 WVCB via CNN Newsource. All rights reserved. | https://www.wvva.com/2022/08/15/police-help-groom-who-nearly-missed-his-wedding/ | 2022-08-15T13:49:14Z |
Russian shells slam into eastern Ukraine, killing 3 people
KYIV, Ukraine (AP) — At least three Ukrainian civilians have been killed and nearly 20 others wounded in the latest artillery barrages from the Russian military, Ukrainian officials said Monday.
The eastern region of Donetsk, one of the two provinces making up the country’s industrial heartland of Donbas that has been the focus of a Russian offensive, has faced the most intense shelling.
Regional officials said at least three people died and another 13 were wounded by Russian shelling that hit numerous towns and villages in the Donetsk region during the last 24 hours. The barrage has damaged dozens of residential buildings and civilian infrastructure.
In the country’s second-largest city of Kharkiv, five civilians were wounded in the latest Russian shelling early Monday, according to the city’s mayor, Ihor Terekhov.
The Russian forces also struck several other regions of Ukraine with rockets and artillery.
For their part, the Ukrainian military claimed to have destroyed more than 10 Russian warehouses with ammunition and military equipment in the past week.
In other developments Monday:
- Lawyers for American basketball star Brittney Griner filed an appeal against her nine-year Russian prison sentence for drug possession, Russian news agencies reported. Griner, a center for the Phoenix Mercury and a two-time Olympic gold medalist, was convicted on Aug. 4. She was arrested in February at Moscow’s Sheremetyevo Airport after vape canisters containing cannabis oil were found in her luggage.
- The Ukrainian parliament, Verkhovna Rada, extended martial law and the country’s general mobilization for another 90 days.
“Ukraine has always longed and longs for peace and many times in various negotiation formats has offered the Russian leadership to end the war and free Ukrainian land from occupation,” Ukrainian President Volodymyr Zelenskyy said in a video late Sunday. “But so far, Russia believes in terror, remains in the grip of its propaganda illusions and still hopes that it can supposedly achieve something through various forms of blackmail. It won’t.”
He emphasized that “we must defend ourselves,” adding that “the stronger Ukraine will be, the weaker Russia will be, and therefore, the less time this war will last.”
- Zelenskyy dismissed the heads of three regional branches of Ukraine’s top security agency, SBU, in the Kyiv, Lviv and Tarnopil regions. Zelenskyy’s office didn’t elaborate on the reasons behind the move. Last month, he dismissed SBU chief Ivan Bakanov and a chief prosecutor, saying their departments had too many people who faced accusations of collaborating with the Russians.
___
Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved. | https://www.wvva.com/2022/08/15/russian-shells-slam-into-eastern-ukraine-killing-3-people/ | 2022-08-15T13:49:21Z |
‘Stranger Things’ star Millie Bobby Brown enrolled at Purdue University
Published: Aug. 15, 2022 at 9:12 AM EDT|Updated: 37 minutes ago
(CNN) – “Stranger Things” star Millie Bobby Brown is a Purdue Boilermaker.
According to a new interview with Allure magazine, Brown is an online college student at Purdue University.
The 18-year-old is studying the field of human services, which includes human development and family studies.
Ironically, the Netflix TV series she stars in takes place in Indiana and makes reference to Purdue and other Hoosier universities.
In season three, a Purdue T-shirt that appeared in an episode of the show went viral and became a top seller online.
Balancing her online studies, the British actress’ next movie is called “The Electronic State,” which begins production in Atlanta this fall.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.wvva.com/2022/08/15/stranger-things-star-millie-bobby-brown-enrolled-purdue-university/ | 2022-08-15T13:49:28Z |
UVA updates COVID-19 guidelines as students ready to return
CHARLOTTESVILLE, Va. (WVIR) - The University of Virginia is making sure its students, faculty, and staff are taking safety precautions against COVID-19 as the semester gets ready to start.
“We’re excited to welcome UVA students back,” Deputy Spokesperson Bethanie Glover said. “As the new academic year approaches, we’re reminding everyone in the university community to do their part.”
Glover says following CDC guidelines is advised.
“While the majority of university students, faculty, and staff are fully vaccinated, we strongly encourage all community members to stay up-to-date on receiving the latest available vaccines and boosters,” she said.
The CDC also recommends those exposed to COVID-19 to wear high-quality masks for 10 days and to get tested on day five.
Glover says masks are not required to be worn at UVA, but people should still keep a mask with them.
“We lifted the mask requirements late in the spring semester last year and our approach this semester is going to be largely the same. Of course, if we do need to adjust our approach for any reason that’ll be shared with our community,” the spokesperson said.
Although social distancing is not being implemented within classrooms, UVA does encourage it.
Copyright 2022 WVIR. All rights reserved.
Do you have a story idea? Send us your news tip here. | https://www.whsv.com/2022/08/14/uva-updates-covid-19-guidelines-students-ready-return/ | 2022-08-15T14:15:51Z |
Fiona’s baby brother officially has a name
CINCINNATI (WXIX/Gray News) – It’s official! The Cincinnati Zoo has announced Fiona’s little brother will be called Fritz.
The hippo care team selected Ferguson and Fritz as the final name candidates from thousands of suggestions and asked the public to weigh in on which they liked better.
Fritz got 56% of the more than 220,000 votes.
“We would have been happy with either name, but we really think the name Fritz fits this spunky little guy’s personality,” said Cincinnati Zoo’s head hippo keeper Wendy Rice. “We also thought it was funny that it was suggested because ‘Fritz’ is here due to Bibi’s birth control being ‘on the fritz’.”
Bibi gave birth to her calf on Aug. 3 around 10 p.m.
The zoo said Fiona and Tucker are being kept away from Bibi while she bonds with her new baby boy.
Mom and baby will stay behind the scenes for a while, but the zoo is sharing photos and videos on social media.
Copyright 2022 WXIX via Gray Media Group, Inc. All rights reserved. | https://www.whsv.com/2022/08/15/fionas-baby-brother-officially-has-name/ | 2022-08-15T14:15:52Z |
Judge: Sen. Graham must testify in Georgia election probe
ATLANTA (AP) — A federal judge on Monday said U.S. Sen. Lindsey Graham must testify before a special grand jury in Atlanta that is investigating whether then-President Donald Trump and his allies broke any laws while trying to overturn his narrow 2020 general election loss in the state.
Attorneys for Graham, R-S.C., had argued that his position as a U.S. senator provided him immunity from having to appear before the investigative panel and asked the judge to quash his subpoena. But U.S. District Judge Leigh Martin May wrote in an order Monday that immunities related to his role as a senator do not protect him from having to testify. Graham’s subpoena instructs him to appear before the special grand jury on Aug. 23, but he is expected to appeal the judge’s ruling.
Fulton County District Attorney Fani Willis opened the investigation last year, and a special grand jury with subpoena power was seated in May at her request. Last month she filed petitions seeking to compel testimony from seven Trump advisers and associates.
Prosecutors have indicated they want to ask Graham about phone calls they say he made to Georgia Secretary of State Brad Raffensperger and his staff in the weeks following Trump’s election loss to Democrat Joe Biden.
Graham had argued that a provision of the Constitution provides absolute protection against a senator being questioned about legislative acts. But the judge found there are “considerable areas of potential grand jury inquiry” that fall outside that provision’s scope. The judge also rejected Graham’s argument that the principle of “sovereign immunity” protects a senator from being summoned by a state prosecutor.
Graham also argued that Willis, a Democrat, had not demonstrated extraordinary circumstances necessary to compel testimony from a high-ranking official. But the judge disagreed, finding that Willis has shown “extraordinary circumstances and a special need” for Graham’s testimony on issues related to alleged attempt to influence or disrupt the election in Georgia.
May, the judge, last month rejected a similar attempt by U.S. Rep. Jody Hice, R-Ga., to avoid testifying before the special grand jury. Former New York mayor and Trump attorney Rudy Giuliani had argued he couldn’t travel to Atlanta to testify because of health issues, but Fulton County Superior Court Judge Robert McBurney, who’s overseeing the special grand jury, instructed him to appear on Wednesday.
A Graham spokesperson, Kevin Bishop, said Monday the senator had no comment but referred to what Graham said when asked about the probe last week. During a news conference in Columbia, S.C., Graham said, “We will take this as far as we need to take it” when asked about his efforts to fight his subpoena.
“I was chairman of the Senate Judiciary Committee and had to vote on certifying an election,” Graham told reporters. “This is ridiculous. This weaponization of the law needs to stop. So I will use the courts. We will go as far as we need to go and do whatever needs to be done to make sure that people like me can do their jobs without fear of some county prosecutor coming after you.”
In calls made shortly after the 2020 general election, Graham “questioned Secretary Raffensperger and his staff about reexamining certain absentee ballots cast in Georgia in order to explore the possibility of a more favorable outcome for former President Donald Trump,” Willis wrote in a petition.
Graham also “made reference to allegations of widespread voter fraud in the November 2020 election in Georgia, consistent with public statements made by known affiliates of the Trump Campaign,” she wrote.
Republican and Democratic state election officials across the country, courts and even Trump’s attorney general found there was no evidence of any voter fraud sufficient to affect the outcome of his 2020 presidential election loss.
___
Associated Press writer Meg Kinnard in Columbia, S.C., contributed reporting.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/08/15/judge-sen-graham-must-testify-georgia-election-probe/ | 2022-08-15T14:15:53Z |
King’s Hawaiian recalls some of its buns
(CNN) - Take a look in your pantry. If you have some of King’s Hawaiian products, you might need to throw them out.
The company is recalling Pretzel Slider Buns, Pretzel Hamburger Buns and Pretzel Bites.
It is a voluntary decision, but the company said it just wants to be extra careful after one of the ingredients used in the pretzel products was recalled by another company.
Lyon Magnus recently had a voluntary recall after concerns that dozens of its products could potentially have bacteria in them that could make people really sick.
There have not been any reports of the products getting anyone sick, and King’s Hawaiian has not found any of the concerning bacteria, but the company said to throw away the products just in case.
More information can be found on the Food and Drug Administration’s website.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.whsv.com/2022/08/15/kings-hawaiian-recalls-some-its-buns/ | 2022-08-15T14:15:55Z |
Nicholas Evans, “The Horse Whisperer” author, dies at 72
LONDON (AP) — Nicholas Evans, the British author of the bestselling novel “The Horse Whisperer,” has died at 72, his representatives said Monday.
United Agents said Evans died “suddenly” on Aug. 9 following a heart attack.
Published in 1995, “The Horse Whisperer” was Evans’ debut novel and sold more than 15 million copies worldwide. The story of a trainer hired to help an injured teenager and her horse back to health was adapted into a Hollywood movie starring Robert Redford as the title character and Scarlett Johansson playing young rider Grace MacLean in her breakout role.
Born in 1950 in Worcestershire, England, Evans studied law at Oxford University and worked as a journalist in the 1970s.
He worked as a screenwriter and television documentary producer before beginning work on his debut novel. His other books include “The Loop,” “The Smoke Jumper,” “The Divide” and “The Brave.”
In 2008, Evans became seriously ill after cooking and eating poisonous mushrooms picked in Scottish forests. He and his family were hospitalized and had to undergo kidney treatments.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/08/15/nicholas-evans-horse-whisperer-author-dies-72/ | 2022-08-15T14:16:02Z |
Russian shells slam into eastern Ukraine, killing 3 people
KYIV, Ukraine (AP) — At least three Ukrainian civilians have been killed and nearly 20 others wounded in the latest artillery barrages from the Russian military, Ukrainian officials said Monday.
The eastern region of Donetsk, one of the two provinces making up the country’s industrial heartland of Donbas that has been the focus of a Russian offensive, has faced the most intense shelling.
Regional officials said at least three people died and another 13 were wounded by Russian shelling that hit numerous towns and villages in the Donetsk region during the last 24 hours. The barrage has damaged dozens of residential buildings and civilian infrastructure.
In the country’s second-largest city of Kharkiv, five civilians were wounded in the latest Russian shelling early Monday, according to the city’s mayor, Ihor Terekhov.
The Russian forces also struck several other regions of Ukraine with rockets and artillery.
Russian Defense Ministry spokesman Lt. Gen. Igor Konashenkov said Monday that Russian warplanes have struck Ukrainian army positions in the southern Kherson region and in the Donetsk region. He added that the Russian air force also hit a facility in the Kharkiv region, killing at least 100 and wounding 50 “mercenaries” from Poland and Germany. His claims couldn’t be independently verified.
Speaking at the opening of an arms show outside Moscow, Russian President Vladimir Putin hailed the military’s action in Ukraine, declaring that it “fights for Russia ... and fulfilling all the tasks that were set, liberating the Donbas step by step.”
For their part, the Ukrainian military claimed to have destroyed more than 10 Russian warehouses with ammunition and military equipment in the past week.
In other developments Monday:
__ Lawyers for American basketball star Brittney Griner filed an appeal against her nine-year Russian prison sentence for drug possession, Russian news agencies reported. Griner, a center for the Phoenix Mercury and a two-time Olympic gold medalist, was convicted on Aug. 4. She was arrested in February at Moscow’s Sheremetyevo Airport after vape canisters containing cannabis oil were found in her luggage.
__ The Ukrainian parliament, Verkhovna Rada, extended martial law and the country’s general mobilization for another 90 days.
“Ukraine has always longed and longs for peace and many times in various negotiation formats has offered the Russian leadership to end the war and free Ukrainian land from occupation,” Ukrainian President Volodymyr Zelenskyy said in a video late Sunday. “But so far, Russia believes in terror, remains in the grip of its propaganda illusions and still hopes that it can supposedly achieve something through various forms of blackmail. It won’t.”
He emphasized that “we must defend ourselves,” adding that “the stronger Ukraine will be, the weaker Russia will be, and therefore, the less time this war will last.”
__ Zelenskyy dismissed the heads of three regional branches of Ukraine’s top security agency, SBU, in the Kyiv, Lviv and Tarnopil regions. Zelenskyy’s office didn’t elaborate on the reasons behind the move. Last month, he dismissed SBU chief Ivan Bakanov and a chief prosecutor, saying their departments had too many people who faced accusations of collaborating with the Russians.
Speaking in an interview with Singapore’s CNA television, Ukrainian first lady Olena Zelenska, said that “no one in the world can take a neutral stand in that war,” adding that “you can either be on the aggressor’s side or the one who has come under attack, there is no other choice.”
“People in other countries should know — it’s not Ukraine to blame for soaring prices, it’s the aggressor who started the war,” she said.
___
Follow the AP’s coverage of the war at https://apnews.com/hub/russia-ukraine
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/08/15/russian-shells-slam-into-eastern-ukraine-killing-3-people/ | 2022-08-15T14:16:11Z |
‘Stranger Things’ star Millie Bobby Brown enrolled at Purdue University
Published: Aug. 15, 2022 at 9:12 AM EDT|Updated: 1 hour ago
(CNN) – “Stranger Things” star Millie Bobby Brown is a Purdue Boilermaker.
According to a new interview with Allure magazine, Brown is an online college student at Purdue University.
The 18-year-old is studying the field of human services, which includes human development and family studies.
Ironically, the Netflix TV series she stars in takes place in Indiana and makes reference to Purdue and other Hoosier universities.
In season three, a Purdue T-shirt that appeared in an episode of the show went viral and became a top seller online.
Balancing her online studies, the British actress’ next movie is called “The Electronic State,” which begins production in Atlanta this fall.
Copyright 2022 CNN Newsource. All rights reserved. | https://www.whsv.com/2022/08/15/stranger-things-star-millie-bobby-brown-enrolled-purdue-university/ | 2022-08-15T14:16:18Z |
Six projects slated for Regional Economic Acceleration and Development Initiative (READI) Grants
FORT WAYNE, Ind., Aug. 15, 2022 /PRNewswire/ -- The Northeast Indiana Regional Development Authority ("RDA") has approved $18 million in new Regional Economic Acceleration and Development Initiative ("READI") grants for six innovative projects.
At the end of 2021, the Northeast Indiana Regional Development Authority (RDA) was awarded $50 million to invest in regionally catalytic projects through the State of Indiana's READI program, administered by the Indiana Economic Development Corporation. This latest award accounts for more than 35% of the region's available READI funds.
"The Northeast region is a rapidly evolving area of the state," said Vincent Ash, vice president of development at the Indiana Economic Development Corporation. "This latest round of funding is key in helping beautify the area, increase quality of life and, importantly, ensure residents have more opportunities. These six projects are great examples of exactly why I'm so thrilled by where READI funding is going."
The $18 million in investments has been approved for six unique regional projects.
The Northeast Indiana Regional Partnership, a leading regional economic development organization in Indiana, provides executive leadership for the RDA. "Northeast Indiana is a hub of innovation and development. These new grants will fund everything from an airport expansion and technical upgrades to affordable housing. This is just the beginning of the growth we have planned for our community," said NEIRP CEO, Stéphane Frijia.
The six projects, approved in Allen, Huntington, Noble, and Wabash counties, are:
- $3 million for the expansion of the Fort Wayne International Airport, which will increase terminal square footage, provide access to larger aircrafts, and upgrade the mechanical system, including air filtration.
- $6 million for Riverfront Phase II, a recreational project that will expand Promenade Park in downtown Fort Wayne by adding boat docks, a bouldering mound, walking trails, a hammock grove, and more.
- $6 million for Village Premier, a housing project in southeast Fort Wayne that will ultimately promote more than 275 affordable entry level workforce housing units and create "a vibrant, walkable neighborhood."
- $2.44 million for Legacy Heights, a 52-unit workforce housing development in Wabash.
- $198,450 for Industry 4.0/iSmart Factory Lab, a robotics lab in Kendallville that will train high school students and adults at the Community Learning Center.
- $249,000 for Rivergreen Housing, a 48-unit apartment complex renovation project by Biggs Development.
This new grant follows expansion throughout the region, including Fort Wayne's Electric Works, a 1.2 million square foot technology and innovation campus. NEIRP is excited to play a key role in these major development projects, which will increase vibrancy, support entrepreneurship, and foster community in Northeast Indiana.
Media Contact: Jonathon Sackett
jonathon@neindiana.com
630-291-0151
View original content:
SOURCE The Northeast Indiana Regional Partnership | https://www.whsv.com/prnewswire/2022/08/15/18-million-grant-approved-northeast-indiana/ | 2022-08-15T14:16:25Z |
Allied's new silver-level sponsorship further underscores its award-winning commitment to inclusivity and will help Women in Electronics fund key DEI, ESG and growth initiatives.
FORT WORTH, Texas, Aug. 15, 2022 /PRNewswire/ -- Allied Electronics & Automation, a trading brand of RS Group plc (LSE: RS1), a global omni-channel provider of product and service solutions, is now a silver-level sponsor of Women in Electronics, a nonprofit, 501(c)(3) social impact organization dedicated to expanding the opportunities for women and diverse talent in the electronics industry and related end-user markets.
Women in Electronics (WE) empowers women in the electronics industry by facilitating networking events, ranging from chapter meetings and forums to its annual conference, and offering a monthly leadership growth program and quarterly life balance series to help members develop both personally and professionally. WE also advocates for members through its global mentorship program and development resources, including its "Leader in Highlight" podcast, and celebrates both members and sponsor organizations for their accomplishments and strides in diversity, equity and inclusion (DEI) efforts.
Allied's sponsorship of Women in Electronics further underscores its award-winning commitment to inclusivity and will help fund the organization's efforts to promote DEI, improve environmental, social and governance (ESG) policies and support the continued growth of the electronics industry. Women currently only hold 10% of the leadership roles in the electronics industry but, according to data that WE collected from the Peterson Institute for International Economics and Cloverpop, companies with leadership teams at least half comprised of women earn 19% more equity on average. In addition, boards with a higher-than-average percentage of women outperform those with a lower-than-average percentage by 36% and companies with boards in the top quartile of gender diversity are 28% more likely to financially outperform than their peers. Similarly, the data shows that companies with leadership exhibiting age, gender and geographic diversity make better business decisions up to 87% of the time, achieving up to 60% better outcomes twice as fast with half the meetings.
"Allied is committed to fostering a diverse and inclusive workplace environment, and we are very proud of our continued efforts to further improve on our current successes," said Katie Cartwright, VP of People at Allied Electronics & Automation. "Sponsoring Women in Electronics gives us access to memberships that will allow our employees to capitalize on the organization's wealth of personal and professional career development resources and allows us to bolster our own DEI and ESG initiatives while funding work aimed at improving those initiatives throughout the industries we serve."
"Women in Electronics is a collaborative community of progressive leaders working to advance meaningful cultural and systemic change throughout the channel in the electronics industry, and we're thrilled to partner with the Allied team under shared organizational values of honor, authenticity, courage and commitment," said Jackie Mattox, Founder and Chief Executive Officer at Women in Electronics. "Together, I believe we can make a positive impact on the face of leadership in the electronics industry and, in particular, the rapidly expanding and increasingly important industrial automation industry."
About Women in Electronics
Women in Electronics (WE) was founded in 2017 by a group of women professionals to offer a sense of community, develop together, and unite with their male colleagues to advance results in gender parity in the Electronics Industry and related End User Markets. As a 501(c)(3) public charity, WE is focused on four organizational goals: empower, advocate, develop, and celebrate, providing leadership growth and development, mentorship, networking, thought-leadership events, and resources. Women in Electronics is supported by leading industry organizations and reaches the broader Electronics Industry through regional chapter meetings and virtual events throughout the U.S. and Europe, with plans to reach a global community. WE is a social impact organization that ensures inclusivity for anyone who would like to be a part of their mission.
To learn more about Women in Electronics, visit https://www.womeninelectronics.com.
Allied Electronics & Automation, part of RS Group
Allied Electronics & Automation is a trading brand of RS Group plc (formerly Electrocomponents plc), a leading global omni-channel industrial product and service solutions provider to customers who are involved in designing, building and maintaining industrial equipment and operations, safely and sustainably. RS Group plc stocks more than 700,000 industrial and electronic products, sourced from over 2,500 leading suppliers, and provides a wide range of product and service solutions to over 1.2 million industrial customers. With operations in 32 countries, we trade through multiple channels and ship nearly 60,000 parcels daily.
We support customers across the product life cycle, whether via innovation and technical support at the design phase, improving time to market and productivity at the build phase, or reducing purchasing costs and optimizing inventory in the maintenance phase. We offer our customers tailored product and service propositions that are essential for the successful operation of their businesses and help them save time and money.
RS Group plc is listed on the London Stock Exchange with stock ticker RS1 and in the fiscal year that ended March 31, 2022, reported revenue of $3.3 billion.
For more information about Allied Electronics & Automation, please visit www.alliedelec.com/ or connect with us via social media on Facebook, Twitter and LinkedIn.
Image Download:
https://bit.ly/3PUMZFT
Editorial Contact & Media Inquiries:
Karen Gavenda
Allied Electronics & Automation, part of RS Group
Karen.Gavenda@alliedelec.com
View original content to download multimedia:
SOURCE Allied Electronics & Automation | https://www.whsv.com/prnewswire/2022/08/15/allied-electronics-amp-automation-invests-women-electronics/ | 2022-08-15T14:16:32Z |
-- FDA Clears Initiation of Efficacy Trial for C3 Glomerulopathy (C3G)
CLEVELAND, Aug. 15, 2022 /PRNewswire/ -- NovelMed Therapeutics is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for complement-mediated rare diseases. The Company announced today that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational drug NM8074 to initiate an Efficacy trial in patients with C3G in the First Quarter of 2023. NM8074 has recently completed a Phase I trial in forty (40) healthy volunteers with no safety concerns.
Seeking Partners/Investors to Advance the Development of NM8074 as a Robust Treatment for C3G
"The FDA's decision conveys the unmet clinical need for and importance of NM8074 as a treatment for C3G," stated Rekha Bansal, Ph.D., Chief Executive Officer of NovelMed. "We believe that our drug's novel and well-differentiated mechanism of action is expected to result in a superior safety and efficacy profile compared to those in development for C3G indication"
NM8074 functions by binding Bb and selectively blocking the alternative pathway by neutralizing the activity of C3 convertase and C5 convertase, the two powerful proteases of the alternative pathway (AP). Further, NM8074 also blocks the formation of these proteases by impairing the amplification loop of the AP. Interestingly, NM8074 does not block the classical pathway (CP) which is critical for host defense against infections.
The AP plays a key role in the initiation and propagation of C3b deposition, inflammation, and tissue damage, as evident in complement-mediated diseases including C3G. AP-specific C3 convertase is responsible for the conversion of C3 to C3a/C3b, while AP C5 convertase is responsible for the conversion of C5 to C5a/C5b and Membrane Attack Complex (MAC). As a result, NM8074 would provide the selectivity and the specificity required for developing a novel treatment for C3G, a rare disease. "Given the role of the AP in multiple complement-mediated rare diseases, NM8074 has the potential to treat not only C3G but several other complement-mediated and complement-associated diseases as well," said Dr. Bansal.
C3G is a rare disease collectively characterized by the deposition of C3/C3b on kidney cells, proteinuria, and reduced eGFR. In addition to C3G, other complement-mediated renal diseases include C3-glomerulonephritis (C3GN), dense deposit disease (DDD), membranoproliferative glomerulonephritis (MPGN), and immune complex membranoproliferative glomerulonephritis (IC-MPGN). "Whereas each of these diseases is rare, market size is significant," stated Dr. Bansal. With each potential indication's patient population combined and the price of a complement blocker (Soliris) applied, the annual market size could reach in billions of USD.
In a Phase I placebo-controlled, a double-blind, single-ascending-dose study in healthy patients, NM8074 was shown to be safe while effectively inhibiting the AP in human serum over an extended period of time, indicating that it would be successful in treating C3G as well as other chronic diseases. Given NM8074's effectiveness in selectively blocking the AP, and its ability to maintain the CP and host defense, NM8074 has the potential to capture a significant portion of this market.
NM8074 is a humanized monoclonal antibody that binds Bb with picomolar affinity and exhibits dual specificity. First, NM8074 selectively blocks the AP. Second, it is specific to Bb without binding Factor B, which is present in large amounts. In essence, this protease inhibitor monoclonal antibody blocks the formation of two powerful proteases (C3 and C5 convertases) produced by the activation of the AP. The dual specificity of NM8074 is important in the initiation and propagation of C3b deposition, inflammation, and tissue damage, as evident in complement-mediated and complement-associated chronic rare diseases. Mechanistically, AP-specific C3 convertase is responsible for the conversion of C3 to C3a/C3b, while AP C5 convertase is responsible for the conversion of C5 to C5a/C5b and MAC. Treatment with NM8074 would provide selectivity and specificity to the AP while sustaining the activity of the CP. Therefore, patients will be able to maintain their host defense mechanisms that are critical for the prevention of infections. The investigational drug product, NM8074, has been extensively studied in several AP model systems to demonstrate that it:
a) Blocks AP activation upstream, confirming that NM8074 would prevent C3b deposition in C3G
b) Blocks the formation of two potent anaphylatoxins responsible for acute and chronic inflammatory cascades
c) Blocks the formation of MAC that causes tissue damage
d) Is well differentiated from Soliris®/Ultomiris® and Empaveli® having no effect on CP-mediated host defense against infections
Collectively, the drug is expected to benefit patients suffering from a variety of kidney disorders including C3G, where activation of the AP is the key driver of pathogenesis. Further, NM8074 is expected to be therapeutically effective across a broad range of rare and common AP-mediated diseases, including hemolytic, ocular, neurological, and inflammatory disorders. NM8074 has the potential to treat many complement-mediated and complement-associated illnesses, especially those for which there are inadequate treatment regimens or complete unavailability of treatment.
As a clinical-stage biopharmaceutical company, we are committed to innovating and developing novel biologics for the treatment of rare (orphan) diseases. Our goal is to develop an alternative pathway specific drug that can treat a multitude of rare diseases and provide patients with low-cost treatment.
NovelMed has created a strong portfolio of intellectual property with broad applications to rare and common diseases. This includes the use of NM8074 as a treatment for a range of complement-mediated disorders related to uncontrolled activation of the AP. As part of its antibody platform, NovelMed's portfolio also includes humanized antibodies to C3b and Factor P (Properdin) that also block the formation of C3/C5 convertases. NovelMed is currently seeking licensing, partnership, and acquisition opportunities to drive its antibody development through Phase III and approval in multiple rare disease indications. For more information, please visit www.NovelMed.com.
Laurie Toth
Business Development Team
bd@novelmed.com
Ltoth@novelmed.com
View original content to download multimedia:
SOURCE Novelmed Therapeutics | https://www.whsv.com/prnewswire/2022/08/15/alternative-pathway-blocker-anti-bb-antibody-nm8074-receives-us-fda-clearance-start-efficacy-trial-c3-glomerulopathy-c3g-patients/ | 2022-08-15T14:16:40Z |
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Apogem Capital ("Apogem") held a final close for PA Secondary Fund VI (the "Fund" or "PASF VI") on June 30, 2022, with approximately $614 million in total commitments. The Fund exceeded its target fund size of $500 million and more than doubled the size of its predecessor fund. Apogem's Secondaries Team, implementing the same investment strategy, is continuing to build a diversified portfolio of complex and traditional growth, buyout and turnaround investments in the North American middle market through negotiated secondary market purchases.
PASF VI is already capitalizing on the firm's larger market presence as Apogem, a $39 billion private markets' investment manager, through its expansive private equity sponsor relationships and increased deal flow generated by the broader platform. The team is aiming to facilitate deals with a research advantage, or a more limited competitive dynamic achieved through existing relationships.
"We believe our leadership position in the middle market is even stronger following the closing of the merger with PA Capital, Madison Capital and GoldPoint Partners," said Michael Zeleniuch, Managing Director at Apogem Capital. "We offer innovative and timely solutions to LPs and GPs and believe our PASF VI program1, which represents almost $900 million in committed capital, has never been more relevant. The addressable universe of middle market LP and GP secondaries that we pursue continues to grow, and we feel we are exceptionally well positioned given our multi-decade history in the space."
The Fund's limited partner base consists of several new investors, including single family offices and pension funds, as well as many existing investors from the firm's prior Secondary funds.
Chris Stringer, Interim CEO of Apogem said, "We are grateful for the support of our partners in this fundraise, and we are excited to continue delivering creative secondary market solutions well into the future."
Apogem employees and the firm's parent, New York Life, also made meaningful commitments.
About Apogem Capital
Apogem Capital was formed in April 2022 through the combination of PA Capital, Madison Capital Funding and GoldPoint Partners to create a singular and unified, world class private markets' investment firm. With approximately $39 billion in assets under management as of March 31, 2022, we believe Apogem has the deep relationships, data, and history in the middle market to deliver innovative solutions to both clients and sponsors. Apogem Capital offers investors access to the middle market's growth engine through investments in leading private companies and funds. The Firm manages a streamlined suite of capital solutions, including direct lending, junior debt, primary fund investments, secondary investments, equity-co-investments, GP stakes, private real assets and long/short equity. Apogem Capital is a wholly owned subsidiary of New York Life Insurance Company ("NYLIC"), through New York Life Investment Management Holdings, LLC ("NYLIM").
Media Contacts
Allison Scott
allison_scott@nylim.com
Zef Vataj
zvataj@sloanepr.com
1 Includes the PA Secondary Fund VI, LP fund vehicle as well as separate accounts invested alongside the fund.
View original content:
SOURCE Apogem Capital | https://www.whsv.com/prnewswire/2022/08/15/apogem-capital-closes-its-sixth-largest-secondary-fund-614m/ | 2022-08-15T14:16:47Z |
Joint Venture between Advanced Computer Learning Company (ACLC) and OneWeb Technologies awarded opportunity to provide services on GSA contract
FAYETTEVILLE, N.C., Aug. 15, 2022 /PRNewswire/ -- Aquila Integrated Technologies (AIT), a Joint Venture between Advanced Computer Learning Company (ACLC), LLC and OneWeb Technologies Inc., is pleased to announce that they have been awarded the General Services Administration (GSA) 8(a) Streamlined Technology Acquisition Resources for Services (STARS) III Government-wide Acquisition Contract (GWAC) vehicle. The 8(a) STARS III GWAC has a $50 billion ceiling spanning over 8 years and offers government users flexible access to customized IT solutions and emerging technologies from a diverse pool of industry partners.
"We are thrilled to be awardees on this important contract vehicle," stated Bradd Chi, Founder and Owner of ACLC. "We look forward to working with our Joint Venture partner, OneWeb Technologies, to offer unique IT solutions to a host of current and future government clients."
The 8(a) STARS GWACs are known government-wide as best-in-class, easy-to-use, streamlined procurement solutions to purchase IT services from 8(a) prime contractors. The U.S. Department of Defense (DoD) and Civilian agencies throughout the government will benefit from obtaining their services from preapproved and vetted STARS prime contractors.
"This win catapults AIT's growth and enables us to deliver unique and advanced IT solutions and services to more customers while growing our Joint Venture partner, ACLC," said Ian Canning, Vice President, AIT and COO, OneWeb Technologies. "This contract now allows us the opportunity to provide our reliable, innovative, secure and cost-effective satellite communications solutions to government and enterprise customers within the GSA."
For more information on GSA 8(a) STARS III, visit the U.S. GSA website at: HTTP://WWW.GSA.GOV/STARS3
About AIT
Aquila Integrated Technologies (AIT) is a Joint Venture between Advanced Computer Learning Company (ACLC), LLC and OneWeb Technologies Inc., and a highly capable awardee on the General Services Administration (GSA) 8(a) Streamlined Technology Acquisition Resources for Services (STARS) III Government-wide Acquisition Contract (GWAC) vehicle. AIT's partner companies have strong individual and combined capabilities all task areas within the scope of the 8(a) STARS III contract.
For more information on Aquila Integrated Technologies, please visit www.AquilaITsvcs.net or email: stars3@AquilaITsvcs.net.
About Advanced Computer Learning Company (ACLC)
ACLC's mission is to create long-term partnerships with our Department of Defense (DoD) and Federal customers. Since 2003, we have grown our core competencies in Training and Education (T&E), Mission Support, and Technology Integration. ACLC builds partnerships within our core competencies as a trusted and responsive Service-Disabled Veteran-Owned Small Business (SDVOSB). ACLC is an experienced, mature, and stable company with the infrastructure in place to support large efforts.
About OneWeb Technologies
OneWeb Technologies is a global provider of high-speed, low latency, secure, multi-orbit, satellite network solutions to commercial and government customers. Formerly TrustComm, OneWeb Technologies is the U.S. Proxy entity of OneWeb, focused on designing secure end-to-end commercial satcom solutions for the Five Eyes (FVEY) nations and other governmental organizations. As OneWeb's proxy organization, it has access to the company's Low Earth Orbit (LEO) satellite constellation and takes a consultative and adaptable approach toward providing reliable, innovative, secure and cost-effective satellite communications solutions to its customers. Learn more at www.onewebtechnologies.net.
View original content to download multimedia:
SOURCE OneWeb Technologies | https://www.whsv.com/prnewswire/2022/08/15/aquila-integrated-technologies-ait-receives-award-gsas-50b-8a-gwac-streamlined-technology-acquisition-resource-services-stars-iii/ | 2022-08-15T14:16:55Z |
Award recognizes leading third-party logistics and cold storage providers in the cold food and beverage industry
AUSTIN, Texas, Aug. 15, 2022 /PRNewswire/ -- Arrive Logistics, a multimodal transportation and technology company, announced today that the company was named as a winner of the 2022 Top 3PL & Cold Storage Providers award, which recognizes leading third-party logistics and cold storage providers in the refrigerated food and beverage industry.
"These past 18 months have been so challenging for U.S. supply chains. It's the continuous bottlenecks that require fleets to re-tool and pivot accordingly. But, it's the drivers, the fleet, the warehouses and software/technologies that really keep today's supply chains in line," says Marina Mayer, Editor-in-Chief of Food Logistics and Supply & Demand Chain Executive. "These 3PLs and cold storage providers have collaborated on all facets of their operations to achieve full visibility, complete forecasting, end-to-end leverage and the ultimate in sustainability. Now is the time to honor and celebrate those companies making magic happen behind the frontlines."
Recognizing the unique challenges involved in transporting sensitive freight, Arrive Logistics works closely with its transportation partners to solve problems that can impact commodities like produce, meat, fish, dairy and other perishable freight. In turn, they offer shippers custom capacity solutions that deliver the flexibility and consistency required to meet the rigorous demands of a rapidly evolving industry.
"It is an honor to receive this prestigious recognition from Food Logistics," said Mitchell Mazzaro, Director of Temperature-Controlled Solutions, Arrive Logistics. "Moving sensitive freight, like produce and other food and beverage products, efficiently through the cold chain is absolutely critical. Each commodity has distinct and often stringent shipping requirements that must be maintained to ensure goods arrive on time and in peak condition. Our team leverages advanced technology and personal service to drive efficiency for our shipping partners by optimizing delivery and maintaining quality and freshness amid even the most challenging transit conditions."
Arrive Logistics and other recipients of this year's award will be profiled in Food Logistics' July/Aug 2022 print issue as well as online at www.FoodLogistics.com. Go to www.foodlogistics.com/awards to learn more about other Food Logistics awards. Please visit www.arrivelogistics.com to learn more about Arrive Logistics and its ARRIVEFRESH service for moving time-sensitive freight.
Arrive Logistics is a leading multimodal transportation and technology company delivering unparalleled service and custom strategic solutions. With over 1,500 employees, 4,000 customers, and 50,000 carriers in its network, Arrive is one of the largest firms in the 3PL industry, having surpassed $1.6 billion in 2021 revenue. The company has been recognized as a top workplace in Austin by Built in Austin and The Austin Statesman and in Chicago by The Chicago Tribune. Learn more at www.arrivelogistics.com.
Food Logistics reaches more than 26,000 supply chain executives in the global food and beverage industries, including executives in the food sector (growers, producers, manufacturers, wholesalers and grocers) and the logistics section (transportation, warehousing, distribution, software and technology) who share a mutual interest in the operations and business aspects of the global cold food supply chain. Food Logistics and sister publication Supply & Demand Chain Executive are also home to L.I.N.K. and L.I.N.K. Educate podcast channels, L.I.N.K. Live, SCN Summit, SupplyChainLearningCenter.com and more. Go to www.FoodLogistics.com to learn more.
Media contact:
Nicole Paleologus
arrive@nextpr.com
View original content to download multimedia:
SOURCE Arrive Logistics | https://www.whsv.com/prnewswire/2022/08/15/arrive-logistics-earns-food-logistics-2022-top-3pl-amp-cold-storage-providers-award/ | 2022-08-15T14:17:02Z |
The top training and business coaching provider for the contracting industry connects dealers with innovative online Equipment Exchange
SEATTLE, Aug. 15, 2022 /PRNewswire/ --Business Development Resources (BDR), the training and business coaching authority for home services industry professionals, announces the launch of a unique online resource to help HVACR dealers work together to ensure they are properly equipped for new 2023 efficiency standards.
BDR's Equipment Exchange allows individual dealers to connect online and arrange transfers of equipment impacted by a range of changing local, state and federal energy regulations set to take effect on Jan. 1, 2023.
"With the unprecedented number of new standards starting at the beginning of 2023, dealers may find some of their inventory is outdated overnight," said Bruce Wiseman, president and owner of BDR. "BDR's new online Equipment Exchange network allows individual dealers to post their available equipment, see listed products, and negotiate agreements so everyone has the equipment they need to serve their customers."
The Equipment Exchange is a free service for dealers directly affected by rapidly changing energy standards and is intended for limited exchanges. BDR is not involved in any transactions and recommends dealers always contact their distributor partner first for their product needs.
"The goal of our Equipment Exchange is the overall benefit of our industry during a period of enormous potential disruption," Wiseman said. "Without a program like this, dealers could be stuck with equipment they can't use, forcing them to absorb significant losses or pass them on to contractors and their customers. BDR remains committed to the distributors who are an essential part of this industry."
For more information about BDR's Equipment Exchange, visit https://www.bdrco.com/exchange/.
About Business Development Resources (BDR)
BDR (Business Development Resources) is the premier provider of business training and coaching to HVAC contractors and distributors, established in 1998. BDR's Profit Coach program has a membership of 600 leading contractors. Ten thousand HVAC professionals across North America attend BDR training courses annually. Nearly 1,000 industry professionals attend Profit Launch, BDR's planning workshop. For more information, please visit www.bdrco.com.
MEDIA CONTACT:
Heather Ripley
Ripley PR
(865) 977-1973
hripley@ripleypr.com
View original content to download multimedia:
SOURCE Business Development Resources (BDR) | https://www.whsv.com/prnewswire/2022/08/15/bdrs-bold-new-tool-helps-hvac-dealers-manage-2023-efficiency-standards/ | 2022-08-15T14:17:09Z |
SINGAPORE, Aug. 15, 2022 /PRNewswire/ -- .bit (did.id) has raised $13 million to build cross-chain decentralized identity protocol. The Series A round, completed one year after the startup's launch, was led by CMB International, HashKey Capital, QingSong Fund, GSR Ventures, GGV Capital, and SNZ.
.bit's open-source blockchain protocol will provide permissionless decentralized identification for individual users and DAOs. Over the past 12 months, the project's user and developer communities have experienced strong growth. Almost 100 mainstream wallets and dApps have already integrated with .bit and more than 38k independent addresses have registered for more than 110k .bit accounts.
In the web2 era, social profiles are stored on centralized databases by tech giants who can revoke access or alter data at will. Accounts may be blocked or deactivated at any time, leading to censorship and deplatforming. Utilizing web3 technology, .bit will empower individuals to truly own and control their data. Users will enjoy identity sovereignty, both as private persons and as corporate entities.
Further use cases for .bit's decentralized identity product include supporting the one billion citizens who lack legal identification. This makes it impossible for them to prove their identity, obtain basic government benefits or healthcare, enroll in education, or exercise their right to vote.
Forthcoming features under development include NameDAO, which will assign a portion of .bit protocol revenue to DAOs, and sub-accounts which will be issued to DAO members, brand adopters, and loyal supporters to strengthen web3 communities, and further lower the threshold for registering accounts, 4-9 digits accounts available to 100% and open up 3 digits accounts, which will announce the specific rules on the official Twitter very soon.
About .bit
View original content to download multimedia:
SOURCE .bit | https://www.whsv.com/prnewswire/2022/08/15/bit-raises-13m-build-cross-chain-decentralized-identity-protocol/ | 2022-08-15T14:17:12Z |
Marketing veteran brings more than 20 years of expertise to the company
BOSTON, Aug. 15, 2022 /PRNewswire/ -- BitSight, the Standard in Security Ratings, today announced it has appointed Catherine Harrell as Chief Marketing Officer (CMO). Catherine joins BitSight from Brightly, a SaaS provider of asset and maintenance management software, where she was CMO and a key member of the executive team that achieved significant revenue growth and profitability during her three-plus year tenure. Brightly has 800 employees serving around 12,000 customers, across the U.S., Canada, U.K. and Australia, and was recently acquired by Siemens Smart Infrastructure.
"Catherine brings a wealth of knowledge, experience and a proven track record of results, and will help shape the company as we continue our accelerated growth," said Stephen Harvey, CEO, BitSight. "BitSight is transforming how organizations measure and manage cyber risk and Catherine will play an integral part, strengthening and leading the marketing team to bring innovative new analytics and risk quantification capabilities to market. She will help us tell our story of the importance of transparency and data quality, so our customers can engage more confidently in the digital economy."
Harrell brings two-plus decades of extensive experience in strategic marketing in the high-tech software industry, with the last 10 years being at the executive level. In her role as CMO, Harrell will drive strategy and execution across all of BitSight's marketing functions and teams. Catherine's proven ability to build and lead successful marketing teams that continuously deliver strong value for customers and business results will be extremely valuable for BitSight.
In her position at Brightly, Harrell led the company through its successful global rebranding, and expanded its marketing capabilities and impact to growth across multiple customer segments, industry verticals, and geographies. Prior to her role at Brightly, she was the EVP of Global Marketing at PrecisionLender, VP of Marketing at Citrix, and held multiple senior level marketing roles at Intuit.
"In these times, it is more critical than ever for companies across every industry to properly assess their cyber risk ─ BitSight is the industry leader, driving innovation through its objective cyber risk governance solutions," Harrell said. "I am incredibly excited to join this talented, customer-focused team of professionals who are dedicated to transforming the ways organizations around the globe monitor their security performance and manage cyber risk."
About BitSight
BitSight creates trust in the digital economy and transforms how organizations manage cyber risk. The BitSight Security Ratings Platform applies sophisticated algorithms, producing daily security ratings that range from 250 to 900, to help organizations manage their own security performance; mitigate third party risk; underwrite cyber insurance policies; conduct financial diligence; and assess aggregate risk. With the largest ecosystem of users and information, BitSight is the Standard in Security Ratings. For more information, please visit www.bitsight.com, read our blog or follow @BitSight on Twitter.
View original content to download multimedia:
SOURCE BitSight | https://www.whsv.com/prnewswire/2022/08/15/bitsight-appoints-catherine-harrell-chief-marketing-officer/ | 2022-08-15T14:17:18Z |
THE WOODLANDS, Texas, Aug. 15, 2022 /PRNewswire/ -- BJ Energy Solutions has entered into a three-year fracturing services agreement to provide Aethon Energy with a second TITAN™ next-generation fracturing fleet. The TITAN fleet will be deployed for Aethon in the first quarter of 2023, representing what will be BJ's 5th TITAN fleet operating in the Haynesville basin.
"There is a tremendous feeling of pride and ownership across the BJ Energy and Aethon Teams for what has been achieved in the last year with the very first TITAN Fleet", said Caleb Barclay, Chief Operating Officer of BJ Energy Solutions. "We are excited to enter into a second TITAN contract with Aethon, further validating the technology, and providing BJ the opportunity to continue supporting Aethon's business needs for many years to come."
"We continue to believe that natural gas-fueled fracturing fleets represent an evolutionary step forward in the efficiency and improved environmental impact of completions technology," said John Sparling, Vice President of Completions at Aethon Energy. "Our partnership with BJ Energy Solutions to pilot and deploy the first TITAN fracturing fleet continues to deliver reliable, high-quality service with significant cost savings, and we look forward to doubling the scale of its benefits next year with our second TITAN fleet."
Aethon Energy deployed the first 8-pump natural gas fueled BJ TITAN fleet in February of 2021. Since deployment, the first TITAN Fleet has:
- Performed over 7,000 pumping hours;
- Displaced over 10.1 million gallons of diesel;
- Reduced greenhouse gases by 26,400 MT of CO2e as compared to conventional equipment, and;
- Improved well site efficiencies with consistent utilization over 450 hours per month.
At the core of BJ's TITAN Technology is the TITAN Pump, powered by a 5,000-horsepower direct drive natural gas-fired turbine that delivers one of the most efficient 'power to pump' combinations available. Expanding on the success of the TITAN pump technology, BJ has continued to innovate, designing a complimentary set of electric-powered support equipment, including the new 260 bpm TruDuo Electric Blender. This unit will further enhance well site efficiencies and equipment footprint, while enabling TITAN's differentiation in Simulfrac operations.
About BJ Energy Solutions
With a rich legacy beginning in 1872, BJ has 150 years of technology innovation. Today, BJ Energy's strategy is to champion sustainable products and emissions reduction through the investment, development, and commercialization of technologies that reduce carbon footprint. BJ's latest introduction of the TITAN technology platform supports the industry's endeavor to continually improve its environmental impact and social responsibilities. For more information, please visit our website at www.bjenergy.com.
BJ Energy Solutions Company Contact:
Ernesto Bautista III
Chief Financial Officer
ebautista@bjenergy.com
View original content to download multimedia:
SOURCE BJ Energy Solutions | https://www.whsv.com/prnewswire/2022/08/15/bj-energy-solutions-aethon-energy-enter-into-second-titan-next-generation-fracturing-services-agreement/ | 2022-08-15T14:17:32Z |
Companies rush to participate before the September 30 deadline
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- The number and diversity of companies that have applied to be included in the 2023 Bloomberg Gender-Equality Index (GEI) has risen sharply ahead of the September 30 deadline, Bloomberg announced today.
Publicly traded companies voluntarily participate in the GEI, which analyses the performance of their diversity and equality policies compared to their peers. The 2022 GEI listing included 418 companies from 11 different sectors in 45 countries. This year, Bloomberg is already seeing an increase in participants and the amount of details being disclosed over last year.
GEI data so far shows:
- the number of accounts registered has risen 40% in the U.S., 39% in Europe, Middle East & Africa, 18% in Asia Pacific and three percent in Latin America
- new country participants include Colombia, Peru, Uruguay, and Pakistan
- while financial companies have traditionally led the list, now companies in the aerospace, pharmaceutical and technology sectors are participating
"We are gratified to see so many more companies use the GEI to identify and strengthen their policies regarding equal pay and gender pay parity," said Patricia Torres, Global Head of Bloomberg's Sustainable Finance Solutions, which includes the GEI. "This transparency helps companies attract employees and gives investors the data they need to make decisions."
The GEI evaluates companies on five key pillars:
- Leadership and Talent Pipeline
- Equal pay and gender pay parity
- Inclusive Culture
- Anti-Sexual Harassment Policies
- External Brand
For the 2023 evaluation, companies asked that Bloomberg add two other areas for exploration -- LGBTQ+, race and ethnicity. Disclosure of this data will begin in the US and UK markets; these questions are optional and will not be scored.
Companies participate voluntarily at no cost via the Bloomberg GEI website. The deadline for submission to the 2023 GEI is September 30, 2022. After submitting data, Bloomberg's GEI team analyses the data and provides the company a scorecard based on the methodology. The team will review the results with the companies, so they know how they were scored and why, prior to the announcement of the GEI results in January 2023.
"Companies can also use the GEI as an internal worksheet," Torres added. "They can go online, without obligation, and see what the methodology entails. This is helpful in enhancing their gender-equality programs."
The Bloomberg GEI team held a webinar recently to explain the index and show companies how to participate. The webinar can be replayed via this link.
The standardised GEI reporting framework allows investors to compare how companies around the world are investing in women in the workplace, supply chain and communities in which they operate. Submitting data through Bloomberg's gender reporting framework is voluntary and has no associated cost. The GEI is a benchmark index and is not used as a financial benchmark. The index is not ranked. Companies included in this year's index scored at or above an overall value set by Bloomberg to reflect a high level of disclosure and overall performance across the five pillars of the framework. To learn more, visit the
. Bloomberg subscribers can access the GEI at {BGEI Index DES
View original content to download multimedia:
SOURCE Bloomberg | https://www.whsv.com/prnewswire/2022/08/15/bloomberg-gender-equality-index-interest-increases-globally/ | 2022-08-15T14:17:38Z |
The iconic retailer will kick-off its biggest anniversary campaign during New York Fashion Week teaming with Harper's BAZAAR to host their annual ICONS fête and announces special celebrations across the country with top designers, exclusive merchandise, immersive events and much more this September
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- Bloomingdale's announced today its line-up of star-studded events, world-class designer collaborations, immersive in-store events and new social and digital activations that will be part of the leading retailer's 150th anniversary celebration beginning this September.
"Bloomingdale's has pioneered the modern retail experience for one hundred and fifty years," stated Tony Spring, Chairman and CEO, Bloomingdale's. "We are a company with a rich heritage and this September, we have so much to celebrate as we look ahead to the future. As we commemorate this milestone, we want to make everyone part of the celebration. Bloomingdale's will share this occasion with the customers, colleagues, partners and communities who have made us who we are and who are coming with us on the journey into Bloomingdale's next era."
A COLLECTION LIKE NO OTHER
On September 8th, Bloomingdale's will launch its 150th Anniversary Collection of exclusive merchandise. The company's biggest and most impressive collection of limited-edition designer collaborations to-date includes over 300 exclusive products and styles developed in partnership with top brands and designers, including special luxury selections, across women's and men's fashion, accessories, beauty, home, fine jewelry and more.
"As a multi-category luxury retailer, we are proud to be able to feature the most coveted selection of brands and products across every single department," said Denise Magid, Executive Vice President and General Merchandising Manager, Bloomingdale's. "Having such an impressive group of the most in-demand designers and labels partner with us to create exclusive, limited-edition designs to commemorate our 150th anniversary is truly an honor, and we could not be more excited about the collection they've created."
Some of the brands who have created exclusive designs for Bloomingdale's 150th include Gucci, Balenciaga, Prada, Valentino, David Yurman, Maison Francis Kurkdjian, Byredo, and many more. This exclusive collection will launch in Bloomingdale's locations across the country and online at Bloomingdales.com beginning on September 8th, with new items debuting regularly through the holiday season.
A VIRTUAL SHOP LIKE NO OTHER
Throughout its 150 years, Bloomingdale's has been a destination that has always innovated the shopping experience. To carry on that tradition as the brand marks its milestone anniversary, Bloomingdale's will launch an immersive virtual store with Emperia, a pioneer in ecommerce's technology frontier. Debuting September 8th, the futuristic virtual space will allow visitors to discover exclusive products, play games and unlock a surprise and delight room.
LIMITED-EDITION BIG BROWN BAGS
Bloomingdale's world-famous Big Brown Bag created a sensation when it first hit stores in 1973—and remains one of the most iconic—and recognizable—bags of all time. Originally designed by legendary graphic designer Massimo Vignelli, the presciently sustainable shopper gets a special anniversary update with five designer-inspired styles, available at all stores for a limited time beginning September 8th.
A CELEBRATION LIKE NO OTHER
The celebration continues on September 9th, when Bloomingdale's and Harper's BAZAAR come together for an unforgettable night celebrating both the iconic retailer's 150th anniversary and BAZAAR's global ICONS portfolio. For the first time, BAZAAR's annual ICONS event will be hosted at Bloomingdale's revered 59th Street flagship location. The fun and festive NYFW cocktail party draws inspiration from iconic New York City nostalgia and will bring together the biggest names influencing style and culture today. The evening will also feature a surprise performance by one of today's most popular new talents.
"This year, as we honor the next generation of BAZAAR ICONS, we couldn't ask for a better partner than Bloomingdale's to help us celebrate," said Samira Nasr, Editor in Chief, Harper's BAZAAR. "We cannot wait to toast Bloomingdale's 150th anniversary and this visionary group of young people who are redefining what it means to be an ICON today in one of NYC's most iconic locations."
A CELEBRATION FOR EVERYONE
That same night, Bloomingdale's and Harper's BAZAAR take the celebration on the road with mini versions of the event at Bloomingdale's across the US, including top markets Florida, Massachusetts, and California. These inaugural events will kick-off an exciting and exclusive line-up of special experiences for customers that will roll-out at Bloomingdale's locations across the country, as well as on Bloomingdales.com, and continue through the 2022 holiday season.
A GENERATION OF SHOPPERS LIKE NO OTHER
On Saturday, September 10th, all Bloomingdale's stores will host an Anniversary Bash. These events will take inspiration from "Saturday's Generation" – a term endearingly attributed to Bloomingdale's clientele in the 1970s – with storewide interactive experiences. Customers will be invited to partake in the festivities with in-store events, special shopping activations, entertainment and more.
"Bloomingdale's has always been at the forefront of innovative marketing," explained Frank Berman, Executive Vice President and Chief Marketing Officer, Bloomingdale's. "For this significant milestone, it was important for us to commemorate the innovation, creativity and company philosophies that have defined our last hundred and fifty years, while also continuing to look ahead at what's next. Saturday's Generation is such a unique part of our history, and in honor of our anniversary we've reimagined this trend of yesteryear in a way that is new, fresh, surprising and – most importantly – ideally suited to today's modern consumer."
Saturday's Generation events will take place on Saturday, September 10th from 1-5pm local time.
THE MAKEUP DATE x 150TH
Bloomingdale's will bring a special 150th anniversary beauty experience to life, in all stores, with a New York-inspired beauty festival. On Saturday, September 17th, customers can enjoy a curated beauty experience at counter events and offerings. Select stores will also host a Beauty Trend Show like no other on September 17th. Top beauty customers will receive special perks and gifts from featured brands, have the chance to participate in brand partner trend discussions, enjoy complimentary treats and more.
Additionally, Bloomingdale's will kick-off The Makeup Date events via Bloomingdale's On Screen on Wednesday, September 14th. This virtual event will feature fashion director finds and a trend conversation with top beauty experts.
DESIGNER POP-UPS & INSTALLATIONS
Throughout the fall season, select Bloomingdale's stores will host special experiences as part of the 150th Anniversary celebration in collaboration with a line-up of the hottest leading design partners and brands. Immersive pop-up shops, trunk shows and original, shoppable installations will be activated with brands ranging from La Prairie, Ralph Lauren, and Louis Vuitton to Bernardaud, Devialet and many more.
Additional 150th anniversary campaign celebrations and special programming will be activated through the holiday season. More information will be announced this fall and details can be found online at www.bloomingdales.com.
About Bloomingdale's
Bloomingdale's is America's only nationwide, full-line, upscale department store. A division of Macy's, Inc. (NYSE: M), it currently operates 34 Bloomingdale's stores and 20 Bloomingdale's The Outlet stores, in California, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Texas, and Virginia, along with 1 Bloomie's location in Virginia. In addition, Bloomingdale's has an international presence with a location in Dubai. Founded in 1872, the iconic retailer is celebrating its 150th anniversary this year. Be sure to follow @bloomingdales on social media, become a Loyallist, and for more information, or to shop any time, visit www.bloomingdales.com
PRESS CONTACT:
Malisa Meresman, Bloomingdales@finnpartners.com
Kevin Harter, kevin.harter@bloomingdales.com
View original content:
SOURCE Bloomingdale’s | https://www.whsv.com/prnewswire/2022/08/15/bloomingdales-unveils-celebration-like-no-other-its-150th-anniversary/ | 2022-08-15T14:17:44Z |
BOCA RATON, Fla., Aug. 15, 2022 /PRNewswire/ -- Castle Connolly Private Health Partners, LLC ("CCPHP"), a leading membership-based (or "concierge") medical practice conversion and support company, is pleased to announce its collaboration with Brian C. Moraes, DO, FASPC, and Deanna Weilbacher PA-C, to establish HMS CCPHP, a concierge medicine program in conjunction with their existing internal medicine practice Boca Raton, FL.
During Dr. Moraes and Deanna's tenure as internal medicine practitioners in Boca Raton, Florida, they have built enduring relationships with their patient base, many of whom have been loyal to them for many years. As their practice continued to grow, so did the administrative demands of operating and maintaining a private practice. They found themselves at a crossroads: either continue to practice high-volume medicine, seeing many patients a day, but spending a limited amount of time with each of them or let their practice evolve to deliver highly personalized, preventative care and a chance to empower their patients with greater education and information.
The concierge (membership-based) model continues to be a rewarding experience for providers and patients alike. The increased time and flexibility allow concierge providers, like Dr. Moraes and Deanna, to schedule patients for an hour appointment, if desired.
"I want to know my patients on a personal level, and having the extra time to do so allows me to provide them with better care," says Deanna Weilbacher.
Concierge patients of HMS CCPHP receive a host of added amenities as Members, including 24/7 connectivity to both Dr. Moraes and Deanna via a direct phone number and a customized telehealth app, same/next day appointments with limited to no wait times regardless of medical necessity, and the SENS Solution® Wellness Program powered by CCPHP.
"The most valuable thing I can give to my patients is my time," says Dr. Moraes. " This program enables me to spend significantly more time with them that I wouldn't have otherwise."
"CCPHP is pleased to add both Dr. Brian Moraes and Deanna Weilbacher to our roster of outstanding concierge physicians," says CCPHP CEO and President Dean McElwain. "Their practice philosophy aligns with CCPHP's mission to providing an exceptional healthcare experience for all Members."
Dr. Moraes' underlying guiding principle has always been that less medication equals better quality of life. Today, his practice has patients who travel from all over the country just for their medical care. Dr. Moraes was one of the first DOs in the country to be named a Fellow of The American College of Preventive Cardiology. He had a hand in the creation of Excel Medical Clinical Trials, one of the preeminent clinical trial sites in South Florida.
Deanna went to PA school at South University in Tampa, Florida, and has experience at a primary care office in Clearwater, FL. She later worked at a primary care clinic in Delray Beach, largely focusing on mental health and substance abuse. Deanna began working with Dr. Moraes soon after. Together they have put together protocols that combine traditional medicine, integrative medicine, nutrition, physical fitness, and a strong focus on quality of life.
Learn more about Dr. Moraes and Deanna's concierge program, HMS CCPHP:
- Visit: hmsccphp.com
- Call: (561) 235-3088
- Email: hmsmemberservices@ccphp.net
Castle Connolly Private Health Partners (CCPHP) works with exceptional physicians to create and support concierge (membership-based) healthcare programs that enable the optimal practice environment and the physician-patient relationship. Members (patients) pay an affordable fee to take advantage of a wide array of enhancements for a more convenient, comprehensive, collaborative, and personalized approach to support health and wellbeing. For more information, go to ccphp.net.
View original content to download multimedia:
SOURCE Castle Connolly Private Health Partners, LLC | https://www.whsv.com/prnewswire/2022/08/15/boca-raton-internist-dr-brian-c-moraes-internal-medicine-physician-assistant-deanna-weilbacher-collaborate-with-castle-connolly-private-health-partners-create-new-concierge-medical-program-offering-patients-more-personalized-approach-their-care/ | 2022-08-15T14:17:51Z |
MIAMI, Aug. 15, 2022 /PRNewswire/ -- Brand Institute's Vice President of Market Research and Commercial Strategy, Joe Bazerghi, who spearheaded the expansion of Brand Institute's market research panel of health care providers and patients across 180 countries, offers sage advice on the importance of market research panels in naming and brand development.
"As the need for focused market research in brand development increases, it is critical to access and survey the appropriate target audiences for specific projects," advises Bazerghi. "Building a high-quality research panel is critical in brand development - because market research data depends on it. With a sizable research panel, we can build detailed persona profiles of panel participants, which aids in ensuring that our reporting delivers meaningful, data-driven responses."
Bazerghi notes that quality research panels, such as those developed by Brand Institute, have the benefit of saving branding clients time and money due to easy access to research participants and reduced implementation time compared to using more time-intensive sample recruitment methodologies. Brand Institute developed its industry-leading market research panel internally and does not have to rely on external market research vendors. Direct market research panel access ensures a flexible, streamlined process and consistent customer experience.
About Joe Bazerghi
Mr. Joe Bazerghi has over 30 years of commercial experience in the field of pharmaceuticals. Before joining Brand Institute, Mr. Bazerghi worked in the US, Europe, Puerto Rico, and Canada for GSK, AbbVie, Gilead and Alkermes. Over his career, Mr. Bazerghi has held numerous leadership roles in sales, marketing, market research and new product planning.
About Brand Institute and its wholly owned subsidiary, Drug Safety Institute
Brand Institute is the global leader in brand name and identity development, providing a broad portfolio of branding and naming related services, including brand strategy, name development, trademark searches, market research, regulatory services, and visual identity solutions.
Drug Safety Institute (DSI) is a wholly owned subsidiary of Brand Institute that provides Brand Institute's healthcare clients with industry-leading guidance pertaining to drug name safety, packaging, and labeling. DSI is comprised of former naming regulatory officials from global government health agencies, including FDA, EMA, Health Canada, AMA, and the WHO.
Contact:
James Dettore
Chairman & C.E.O.
jdettore@brandinstitute.com
www.brandinstitute.com
View original content to download multimedia:
SOURCE Brand Institute, Inc. | https://www.whsv.com/prnewswire/2022/08/15/brand-institutes-vice-president-market-research-commercial-strategy-importance-market-research-panels-brand-development/ | 2022-08-15T14:17:58Z |
MySizeID supports Temperley London's commitment to sustainability while enhancing business economics and user experience
AIRPORT CITY, Israel, Aug. 15, 2022 /PRNewswire/ -- MySize, Inc. (NASDAQ: MYSZ) (TASE: MYSZ.TA) ("MySize" or the "Company"), an omnichannel e-commerce platform and provider of AI-driven measurement solutions to drive revenue growth and reduce costs for its business clients, today announced it has entered an agreement with Temperley London, a luxury British fashion brand, to license its MySizeID apparel sizing solution.
Founded by renowned British fashion designer Alice Temperley, the brand is available at luxury department stores worldwide, through https://www.temperleylondon.com/, and standalone Temperley London stores including its flagship store in Somerset, as well as stores in Chelsea, Fitzrovia, Marbella, and Dubai. Temperley London is famed for bohemian, feminine, and effortless styles that speak to British heritage, with each piece crafted to celebrate the wearer.
MySizeID will support Temperley London's customers generate highly accurate measurements of their body to select the optimal Termperley London size through an app on their mobile phone. MySizeID syncs the customer's measurement data to the brand's sizing chart and only presents items for purchase that match their measurements to ensure a correct fit.
Alice Temperley, Founder and Creative Director of Temperley London, commented, "We make timeless fashion designed to last, enveloping our customer in luxury with the principle of sustainability at its core. By implementing MySizeID, we are helping our customers optimize fit and reduce the potential for returns, resulting in associated financial and environmental benefits."
"Appropriate sizing for online fashion purchases is a critical component of any brand's user experience, and this is especially so for a luxury brand. We are very pleased to partner with Temperley London to support their customers in finding the right fit and to become a part of this unparalleled brand's environmental sustainability movement," stated Ronen Luzon, CEO, and Founder of MySize.
About MySize Inc.
MySize, Inc. (NASDAQ: MYSZ) (TASE: MYSZ.TA) is an omnichannel e-commerce platform and provider of AI-driven measurement solutions to drive revenue growth and reduce costs for its business clients. Orgad, its online retailer platform, has expertise in e-commerce, supply chain, and technology operating as a third-party seller on Amazon.com and other sites. MySize recently launched FirstLook Smart Mirror, a mirror-like touch display that provides in-store customers an enhanced shopping experience and contactless checkout. FirstLook Smart Mirror extends MySize's reach into physical stores and is expected to contribute to revenues through unit sales and recurring service fees.
MySize has developed a unique measurement technology based on sophisticated algorithms and cutting-edge technology with broad applications, including the apparel, e-commerce, DIY, shipping, and parcel delivery industries. This proprietary measurement technology is driven by several algorithms that are able to calculate and record measurements in a variety of novel ways. To learn more about MySize, please visit our website: www.mysizeid.com.
We routinely post information that may be important to investors in the Investor Relations section of our website. Follow us on Facebook, LinkedIn and Twitter.
Please click here for a demonstration of how MySizeID provides a full sizing solution for the retail industry.
Register here for a free plan of MySizeID solution for your online store.
Please click here to download MySizeID for iOS.
Please click here to download MySizeID for Android.
To learn more about MySize and for additional information, please visit: our website: www.mysizeid.com.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" and similar expressions that are intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections. Actual results to differ materially from those in the forward-looking statements and the trading price for our common stock may fluctuate significantly. Forward-looking statements also are affected by the risk factors described in the Company's filings with the U.S. Securities and Exchange Commission. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
Investor Contacts:
Or Kles, CFO
ir@mysizeid.com
Logo: https://mma.prnewswire.com/media/689689/MySize_Logo.jpg
View original content:
SOURCE My Size Inc. | https://www.whsv.com/prnewswire/2022/08/15/british-luxury-brand-temperley-london-implement-mysizes-mysizeid-apparel-sizing-tech/ | 2022-08-15T14:18:05Z |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.